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POST-DIAGNOSIS QUALITY OF LIFE AND MORTALITY IN NON-HISPANIC 
WHITE AND HISPANIC WOMEN DIAGNOSED WITH INVASIVE BREAST 
CANCER 
Delvon T. Mattingly 
August 7, 2018 
The prevalence of breast cancer is increasing, and the health-related quality of life 
(HRQOL) of breast cancer survivors may help to further understand survivorship. This 
study evaluated HRQOL as a potential prognostic factor for mortality among Non-
Hispanic White (NHW) and Hispanic women diagnosed with invasive breast cancer. 
Data were used from the Health, Eating, Activity, and Lifestyle (HEAL) Study. Data for 
351 participants were analyzed for associations between HRQOL scores (subscale, 
component) and mortality. Cox proportional hazards regression was conducted to assess 
the relationship between HRQOL and mortality outcomes (all-cause, breast cancer-
specific, non-cancer). Median follow-up time from HRQOL assessment (approximately 
36-months post-diagnosis) to the end of the study period was 11.2 years. There was a 
statistically significant association between the physical component summary score and 
all mortality outcome measures for all women and when stratified by race/ethnicity. 
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Breast cancer remains a leading cause of cancer-related diagnoses and deaths in 
women (1). The estimated number of breast cancer survivors is rising due to increasing 
rates of long-term survival, and improving survivorship (1, 2). Minority women, most 
notably African American and Hispanic women, in the United States tend to have poorer 
breast cancer prognosis and survival outcomes compared to their Non-Hispanic White 
(NHW) counterparts (3-7). However, recent studies have suggested that this is 
inconclusive when comparing NHW and Hispanic women (8-10). Measures of health-
related quality of life (HRQOL) encompass the overall well-being of individuals while 
assessing areas of interest that may be affected by illness or post-diagnosis treatments 
(11). While breast cancer survivors are living longer, they may require mental and 
physical adjustment in response to their diagnosis and treatment (12). Studies assessing 
HRQOL as a predictor of breast cancer prognosis, including studies evaluating the impact 
of HRQOL in long-term breast cancer survivor populations are limited (13, 14), as well 




Utilizing data from the New Mexico site of the Health Eating Activity and 
Lifestyle (HEAL) study, the objective of this study is to evaluate Health-Related Quality 
of Life (HRQOL) at 36-months post-diagnosis and determine its association with 
mortality among Hispanic and NHW women diagnosed with invasive breast cancer. 
 
Specific Aims 
1. To compute HRQOL subscale and MCS and PCS scores by all-cause, breast 
cancer-specific, and non-cancer mortality. 
2. To determine if survival probabilities differ by HRQOL MCS and PCS scores 
measured at 36-months post-diagnosis among all women and by ethnic groups. 
3. To evaluate the association of HRQOL subscale and MCS and PCS scores at 36-
months post-diagnosis with all-cause, breast cancer-specific, and non-cancer 




1. There will be differences in HRQOL subscale and MCS and PCS scores between 
women who are alive and women who died from all-cause, breast cancer-specific, 
and non-cancer mortality. 
2. Survival probabilities in women with poorer HRQOL will significantly differ 
from women with better HRQOL overall and by ethnic group. 
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3. Women with poorer HRQOL MCS and PCS scores will be at higher risks of 
dying by all-cause, breast cancer-specific, and non-cancer mortality, compared to 
their counterparts with better HRQOL. These associations will reflect similarly 























Breast Cancer Survivorship in the U.S. 
Breast cancer remains a leading cause of cancer-related diagnoses and deaths in 
women with an estimated incidence of 266,120 new diagnoses and 40,920 estimated 
deaths in 2018 (1). In breast cancer patients receiving treatment, long-term survival is 
common, with a 5-year survival rate of nearly 90% (1, 2), 83% for 10-year survival (2), 
and 78% for 15-year survival (2). Survivorship is defined simply as “Living with, 
through, and beyond cancer,” (17). Since long-term survival rates are increasing, breast 
cancer survivors face a multitude of convoluted barriers when dealing with the 
implications of their diagnoses and treatments, including pre-existing or developed 
comorbid conditions, during survivorship (18).  
As of January, 2016, the estimated number of breast cancer survivors in the 
United States is 3,560,570, and this is theorized to increase to 4,571,210 by January, 2026 
(2). Post-treatment, breast cancer survivors contend with life-changing responsibilities 
such as seeking follow-up medical care, developing a wellness plan—which includes 
ways to take care of physical, emotional, social, and spiritual needs—and staying in 
contact with a physician or cancer specialist (19). The American Cancer Society 
recommends a number of guidelines for survivorship care, including the evaluation and 
management of physical and mental/psychosocial effects of diagnosis and treatment (20).
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HRQOL and Breast Cancer Survivorship 
The burden of breast cancer at diagnosis and throughout survivorship may require 
mental/psychosocial and physical adjustment, which has often been described as self-
reported health-related quality of life (HRQOL) (12). While survivorship increases in 
breast cancer survivors, so will a variety of health problems, derived from breast cancer 
or its treatment over short- or long-term survivorship, which may require care. These 
health problems can exacerbate the well-being of survivors, and studies have suggested 
that HRQOL is a good indicator of detriments related to breast cancer survivorship (21, 
22). Considering the increasing survival rates for women diagnosed with breast cancer, 
limited research has evaluated the effects of HRQOL measured post-diagnosis on long-
term survival or mortality (14, 16, 22-24). By 2026, the population of breast cancer 
survivors is expected to increase by approximately 30% (25). Since HRQOL may have a 
direct impact on breast cancer outcomes, understanding the relationship between them is 
important to bolster survivorship research and improve specified developments of 
interventions and clinical care tactics, including guidelines recommended by the ACS 
(20). 
 
Breast Cancer Survival and Mortality in Hispanic Women 
The latest SEER cancer registry data estimates that in 2015 incidence of breast 
cancer in NHW women was 133.8 per 100,000 individuals, compared to 90.3 per 100,000 
in Hispanic women (1), a 38.8% difference between the two populations.  
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Although breast cancer incidence is higher in NHW women, Hispanic women 
tend to have poorer breast cancer prognosis, higher odds of being diagnosed with 
estrogen-receptor/progesterone-receptor negative (ER-/PR-) breast cancer subtypes, a 
greater number of positive lymph nodes, higher odds of being diagnosed with more 
advanced breast cancer, and poorer survival outcomes. These outcomes include a higher 
risk of breast-cancer specific mortality and a poorer HRQOL compared to NHW cases 
(3-7). However, recent studies suggest this is inconclusive (8-10). Recent Centers for 
Disease Control and Prevention (CDC) projections indicated that Hispanic women have a 
lower rate of breast cancer-related death per 100,000 women (13.6) compared to NHW 
women (19.8) (9). A 2017 report concluded that 5-year survival by tumor stage is 
relatively similar between Hispanic and NHW women. When Hispanic women were 
diagnosed with a distant or unknown tumor stage, their survival was higher than NHW 
women (10). 
Many established risk factors that impact breast cancer prognosis have been 
compared between NHW and Hispanic women (26-28). Despite growing evidence that 
breast cancer survival is improving in minorities, due to better cancer screening and 
treatment strategies, disparities in clinical characteristics and mortality persist and remain 
unexplained (29). A better understanding of prognosis following a breast cancer 
diagnosis in diverse populations is important, given that between 2016 and 2017, the 
Hispanic population accounted for over half of the U.S. population growth (30), and it is 
projected to almost double from 56 million to 119 million by 2060 (31). A research gap 
exists evaluating the relationship between HRQOL and breast cancer prognosis in 
minority populations, including Hispanic women (32). 
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Overall HRQOL 
HRQOL is an evolving concept that may have either positive or negative 
associations with cancer survival depending on the way it is defined. HRQOL is 
commonly defined in terms of physical and mental responses to illness, as measured from 
self-reported information on functional, psychological, social, spiritual, and sexual well-
being (33, 34). There are several validated instruments used to measure HRQOL in 
cancer patients. These include the 36-item Short Form Health Survey (SF-36) (35, 36); 
the Functional Assessment of Cancer Therapy, both the General (FACT-G) version and 
the Breast Cancer-specific (FACT-B) version (37, 38); and the European Organization 
for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 
(39, 40). Some studies use a combination of psychosocial scales to evaluate HRQOL 
among women diagnosed with breast cancer (41-43). 
The SF-36 instrument, which is used to evaluate physical and mental HRQOL 
across various chronic diseases and validated among diverse population groups (35), was 
chosen as the primary instrument used for this thesis study. Eight subscales can be 
derived from the 36 questions to measure physical and mental domains of HRQOL. 
Physical functioning, role limitations-physical (role physical), bodily pain, and general 
health subscales are used to calculate a physical health component summary score; and 
social functioning, role limitations-emotional (role emotional), vitality, and mental health 
subscales are used to calculate a mental health component summary score (44, 45). 
Measures of HRQOL summarize the overall well-being of individuals while assessing 
specific areas of interest that may be affected by an individual’s condition of disease as 
well as by treatment (11).  
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 Previous studies suggest that Hispanic women diagnosed with breast cancer 
frequently report lower overall HRQOL compared to NHW cases (32). Additionally, they 
report a lower socioeconomic status, and are usually diagnosed at a younger age and a 
later tumor stage (32) Some studies suggest that a disparity exists between NHW and 
Hispanic women for HRQOL, which may be related to differences in socioeconomic 
status, treatment, and cultural factors (32, 46). 
 
Mental/Psychosocial HRQOL 
Breast cancer survivors experience mental/psychosocial adjustment post-
diagnoses and pre- and post-treatment (47-49). Mental HRQOL in breast cancer survivors 
is primarily associated with age (28), stress (50), anxiety (41), depression (41, 51-53), 
social support (54, 55), coping (56), feelings of helplessness/hopelessness (57), and 
religiosity/spirituality (58); however, much of the extant research evaluate ethnically 
homogenous populations, or populations containing one predominant race/ethnicity. 
Among these factors, declines in mental/psychosocial HRQOL were associated with 
younger age at diagnosis (28), higher stress (50), higher anxiety (41), higher depression 
or more depressive symptoms (41, 51-53), social isolation (including low levels of social 
support) (54, 55), negative forms of coping (56), feeling helpless/hopeless (57), and 
lower levels of religiosity/spirituality (58). Some studies have suggested that components 
of mental HRQOL have been shown to improve over time in breast cancer patients 
shortly after diagnosis (59) and after short-term treatment (60), while other aspects have 
suggested some exacerbate HRQOL (61). Mental HRQOL is theorized to be lower in 
Hispanic women compared to NHW women for all cancers (61). Hispanics may also 
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report poorer psychological and emotional well-being compared to other ethnic groups 
(15, 62).  
 
Physical HRQOL 
A breast cancer diagnosis and the effects of breast cancer treatment influence 
physical HRQOL (59). Factors associated with physical HRQOL in breast cancer 
survivors include, but may not be limited to, age (28, 63), physical activity (64, 65), 
treatment type (60, 66) including mastectomy (52), psychological well-being (63), social 
support (54, 55), body mass index (BMI) (16, 67, 68), fatigue (53, 64, 69, 70), and pain 
(69, 71). Long-term breast cancer survivors usually report good HRQOL, yet these 
women may still experience some physical-related complications (72). Among these 
factors, declines in physical HRQOL were associated with younger age at diagnosis (28), 
yet conversely other studies revealed that younger age was predictive of higher HRQOL 
(63), lower physical activity (64, 65), not receiving treatment (60, 66), receiving a 
mastectomy (52), lower psychological well-being (63), lack of social support (54), 
obesity (16, 67, 68), present fatigue (53, 64, 69, 70), and present pain (69, 71) 
In minorities specifically, physical HRQOL is higher when patients are diagnosed 
with a lower stage of disease, fewer comorbidities, exercise more, and have healthier 
diets. (51). Compared to other ethnic groups, Hispanic breast cancer survivors report 
more physical symptoms during survivorship (73), and declines in physical and 
functional well-being are significantly associated with survival (50). Additional factors, 
such as sexual functioning, responses to treatments and therapies, pain, and fatigue, 
impact HRQOL post-breast cancer diagnosis (46, 49). In a multi-ethnic sample of breast 
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cancer survivors including Europeans, Africans, Latinas, and Asians, socio-ecological 
factors and health care varied by race/ethnicity, while psychological well-being showed 
consistency, suggesting a relationship driven by physical components of HRQOL one to 
five years post-diagnosis (63). In long-term breast cancer survivors, treatment type is 
predictive of HRQOL, specifically chemotherapy worsening physical-related HRQOL 
(74). 
Clarifying how differences in HRQOL influence mortality is necessary in 
understanding survival disparities in cancer patients. Studies assessing HRQOL as a 
predictor of short- and long-term breast cancer survival are limited, especially studies 
including underrepresented populations, such as Hispanic women (15, 16). 
 
HRQOL and Breast Cancer Prognosis 
 Previous epidemiologic studies have assessed indicators of poorer HRQOL in 
breast cancer survivors (23, 28, 41, 52, 58, 75-77) while other studies have evaluated 
levels of HRQOL in breast cancer survivors to understand health-related experiences of 
survivorship (24, 32, 46, 55, 59). Of the studies that have assessed HRQOL as a predictor 
of breast cancer prognosis (13, 14, 42, 43, 50, 78-82), few have focused on 
underrepresented populations (62, 83). A meta-analysis evaluating HRQOL as a 
prognostic predicator of cancer survival in patients, using studies assessing HRQOL via 
the EORTC QLQ-C30, found that HRQOL may be useful in distinguishing survival 
patterns (81). Research examines the HRQOL status of breast cancer survivors, with 
fewer studies utilizing HRQOL as a predictor of breast cancer prognosis, as well as 
longitudinal designs that can evaluate survival over a long-term (13, 14). Among these 
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longitudinal studies, a report suggested that changes in components of HRQOL may have 
an impact on survival (14).  
Though, the relationship between HRQOL and breast cancer prognosis isn’t fully 
understood, studies evaluating components of HRQOL show that factors are positively 
and negatively associated with the risk of breast cancer prognosis (84).  
 
HRQOL Factors 
Perceived social support, social networks, and marriage are positive indicators of 
a lower risk of breast cancer mortality (85, 86). A study examining the association 
between post-diagnosis HRQOL in breast cancer patients and breast cancer mortality and 
recurrence found that social well-being at baseline is a significant indicator of mortality 
(HR: 0.62, 95% CI: 0.46, 0.85) and recurrence (HR: 0.52, 95% CI: 0.38, 0.71) (83).  
In a study by Goodwin et al., better role functioning and better avoidance 
significantly (p<0.05) predicted a lower risk of overall survival (HR=0.56 and 0.48, 
respectively), while domestic environment was significantly associated with a 1.5-fold 
increased risk of death (42). Other studies have indicated that high scores for anxious 
preoccupation are associated with poorer distant disease-free survival and overall survival 
(78). Helplessness or hopelessness also has been reported as an indicator of poorer 
disease-free survival (HR: 1.53; 95% CI: 1.11, 2.11), with a significant effect maintained 
over ten years of follow-up (14). Findings from two studies suggested that better 
emotional functioning is associated with improved survival (HR: 0.81; 95% CI: 0.70, 
0.95) (13) and (HR: 0.49; 95% CI: 0.22, 1.09) (50). However, both studies used different 
HRQOL measurements and assessed HRQOL at different time points (13, 50). In a 
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systematic review of studies evaluating the impact of psychosocial factors on breast 
cancer prognosis, at least 80% found a significant protective or exacerbating association 
between one or more psychosocial factors and survival or recurrence (62). 
Several studies have shown a significant association between mental HRQOL 
components and breast cancer prognosis (13, 14, 42, 43, 50, 80, 83). Some reported that 
higher mental-related functioning predicted lower risk of dying from breast cancer in (83, 
87), with hazard ratios ranging from 0.56 to 0.66 (83, 87). However, one study reported 
that breast cancer survivors with higher cognitive functioning had decreased survival 
(HR: 1.76, p-value: 0.041) (42). Three studies showed significant associations between 
physical HRQOL components and breast cancer mortality (87-89). Women who reported 
higher levels of physical-related health or functioning had decreased risks of mortality, 
with hazard ratios ranging from 0.42-0.64 (87, 89), while women who reported lower 
levels of physical-related functioning had increased risks of all-cause mortality (HR: 
1.49, 95% CI: 1.17, 1.89) and breast cancer-specific mortality (HR: 1.39, 95% CI: 1.07, 
1.80) (88). 
 Studies evaluating physical HRQOL as a predictor of breast cancer outcomes (13, 
50, 79-82, 87-92) have suggested that better levels of physical and functional HRQOL 
were associated with decreased risk of all-cause mortality (HR: 0.24; 95% CI: 0.08, 0.70 
and HR: 0.35; 95% CI: 0.14, 0.87, respectively) (50). Physical functioning is also proven 
to be of significant prognostic value in survivors of multiple cancers (81). Components of 
physical HRQOL, such as mood, pain, and loss of appetite, were also found to be 
significant predictors of mortality in breast cancer patients (81, 82, 93). Nausea/vomiting 
has been reportedly associated with increased risk of breast cancer recurrence (79). One 
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study concluded that fatigue increased risk of recurrence-free mortality (13), and another 
suggested that severe fatigue led to shorter survival (HR: 1.48; 95% CI: 1.13, 1.93) (91). 
Three studies that utilized the SF-36 indicated that better physical health or 
physical functioning were predictive of lower risks of mortality (87-89). Saquib et al. 
found that higher levels of physical health predicted lower additional breast cancer events 
(p-trend: 0.005) and lower risk of all-cause mortality (p-trend: 0.004) (89). Marinac et al. 
reported that participants with low physical functioning were more likely to die by all-
causes (HR: 1.49, 95% CI: 1.17, 1.89) and breast cancer-specific causes (HR: 1.39, 95% 
CI: 1.07, 1.80). DuMontier et al. found that better levels of physical functioning were 
predictive of lower mortality (OR: 0.64, 95% CI: 0.44, 0.94). 
Taken together, the studies have evaluated HRQOL as an indicator of breast 
cancer prognosis (13, 14, 42, 43, 50, 78-81, 83, 87-95) are heterogeneous. Most studies 
are limited by their sample sizes (n < 1,000) (14, 42, 43, 78, 79, 87, 90-94), and they 
differed in the use of the specific HRQOL instrument. Out of the 19 studies evaluated, 
one used the Linear Analog Self-Assessment (LASA) (80), seven used the EORTC QLQ-
C30 (13, 42, 43, 91, 93-95), one used both the Functional Assessment of Cancer Therapy 
General (FACT-G) and/or the Functional Assessment of Cancer Therapy (FACT-B+4) 
(50), one used the IBCSG Quality of Life Core Questionnaire (79), one used the General 
Quality of Life Inventory-74 (83), three used the Medical Outcomes Study (MOS) Short-
Form Survey (SF-36) (87-89) and the remaining studies utilized a combination of 
physical or psychosocial scales to measure HRQOL (13, 14, 42, 43, 78). The majority of 
studies have been based predominantly on white populations (62, 83). Furthermore, the 
majority of the studies evaluated breast cancer survival as an outcome (13, 14, 42, 43, 50, 
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78, 80, 81, 83, 89-95), while four evaluated mortality (83, 87-89) and recurrence (79, 83, 
88, 89) 
The variance in breast cancer and all-cause mortality that HRQOL might explain 
could help improve efforts that focus on addressing HRQOL in breast cancer survivors as 
they deal with survivorship. Further research is necessary to analyze these associations in 




Recognized breast cancer prognostic factors include cancer metastasis, size of 
tumor, tumor grade, hormone receptor status, lymph node involvement, age at diagnosis, 
breast cancer recurrence (location of recurrence, time to recurrence), adjuvant therapy, 
comorbid conditions, family history of breast cancer, age, socioeconomic status (96-98). 
Many of these factors are associated with HRQOL including adjuvant therapy, cancer 
metastasis, tumor characteristics, lymph node involvement, comorbid conditions, age at 
diagnosis, and breast cancer recurrence (28, 60, 66, 72, 83, 99-101). Additional factors 
that may impact the relationship between HRQOL and risk of mortality include 
race/ethnicity, menopausal status, clinical characteristics, psychosocial factors, lifestyle 
and physical factors. 
Race/Ethnicity 
Breast cancer mortality and treatment differs by race/ethnicity (6, 29). Minority 
women are diagnosed with more advanced stage breast cancer (102) and usually report 
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worse HRQOL (51, 61, 103). A study has found that race/ethnicity modifies the 
association between tumor subtype and mortality (104).  
 
Menopausal Status 
Menopausal status can modify breast cancer risk and survival, and is usually 
associated with other factors. For example, post-menopausal breast cancer survivors who 
are not overweight or obese tend to have better survival rates (105, 106). The opposite 
trend appears to be true for premenopausal women who have better survival rates if they 
are overweight or obese compared to their normal-weight counterparts (106). A study 
found an association between high-cognitive fatigue and sever menopause, depressive 
symptoms, and worsened HRQOL (107). 
 
Clinical Characteristics 
Tumor size and lymph node status interact to modify the effect of survival (97). 
Tumor subtype predicts whether or not breast cancer patients require surgery and any 
other type of treatment, and tumor size influences the probability of metastasis occurring 
in breast cancer patients (97). Studies have shown that tumor characteristics impact 
HRQOL in breast cancer patients (68, 99). An increased number of axillary lymph nodes 
is predictive of breast cancer survival, metastasis, treatment failure, and recurrence (97). 
Women have reported higher HRQOL after surgical removal of affected lymph nodes 
(100). Types of adjuvant treatment prescribed are associated with breast cancer node 
type/tumor subtype. Although breast cancer patients have benefited from adjuvant 
therapy, regardless of tumor subtype (108), node-negative breast cancer patients do not 
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benefit significantly compared to node-positive breast cancer patients (97). HRQOL has 
been shown to worsen or improve in patients depending on the type of treatment they 
received (60, 100). 
 
Mental/Psychosocial Characteristics 
Depression is the most common of all psychiatric disorders (109), and a few 
studies have evaluated the effects of depression on HRQOL in breast cancer patients (41, 
51, 52), and in long-term breast cancer survivors (110). Lower HRQOL scores are 
associated with depressive symptoms in breast cancer survivors (41, 53). Evidence 
suggests that psychosocial stress plays an important role in the development of cancer 
growth and metastasis (62, 111) and impacts HRQOL (50). Additionally, stress events, 
anxiety, hopelessness, repressive defensiveness, and denial/avoidance are associated with 
decreased breast cancer survival, whereas factors such as perceived social support, 
minimizing adjustment, extroversion, religiosity/spirituality, and marriage are associated 
with increased survival (62). Generally, many mental/psychosocial factors are associated 
with HRQOL in breast cancer survivors (41, 50, 54, 57, 58). 
 
Lifestyle and Physical Factors: 
 An increase in physical activity has been shown to decrease breast cancer 
mortality overall (112) and in Hispanic women, specifically (113). Higher physical 
activity is predictive of better HRQOL in women diagnosed with breast cancer (64, 65). 
BMI and waist-hip ratio are associated with breast cancer survival and may differ by 
race/ethnicity (114, 115). Furthermore, other HRQOL and breast cancer survival studies 
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have indicated that obesity is associated with a decreased mental health among survivors 
(16). A study has found that higher BMI and waist-hip ratio were predictive of higher 
mortality in breast cancer survivors (116). 
 Lymphedema is a complication of lymph node dissection apart of breast cancer 
treatment (117). It is defined as the swelling of 100-200 cm3 or 2 cm by circumference of 
an affected area in comparison to an unaffected area (117, 118). The prevalence of 
lymphedema in breast cancer survivors rises every year (119). Breast cancer patients who 
experienced lymphedema had poorer HRQOL (118, 120).  
 The association between diet and breast cancer prognosis is inconclusive (121). 
Studies have shown that better diet predicts lower all-cause mortality in breast cancer 
survivors (122, 123), while fewer studies have found a similar association between diet 
and breast cancer-specific mortality (122). Diet quality is associated with mental and 
physical HRQOL in breast cancer survivors (124). Women who have better diets tend to 
have higher HRQOL scores (124). 
 A systematic review found that current smoking increased the risk of all-cause 
death in breast cancer survivors (125). In a study evaluating breast, colorectal, and 
endometrial female cancer survivors, persistent smoking predicted increased likelihoods 
of poorer mental/psychosocial and physical HRQOL (126). In breast cancer survivors, 
HRQOL is poorer in women who smoke versus women who don’t (127). 
 
Possible Biological Mechanisms 
 HRQOL measures the overall well-being of breast cancer survivors.  Lower 
scores or decreases in scores may reflect both acute and chronic stress responses to 
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cancer diagnosis, treatment, co-morbidity and various negative life changes (e.g. divorce 
or separation) (128). Evidence indicates that chronic stress is a nervous system response 
with signaling pathways that may directly impact cancer cells and promote cancer 
metastasis (111).  
 The human body responds to stress by activating body systems such as the 
hypothalamic-pituitary-adrenal (HPA) axis. Levels of norepinephrine and epinephrine are 
known to increase in people who experience acute or chronic stress (129), while 
dopamine levels may increase during episodes of acute stress but decrease in people who 
experience chronic stress (130, 131). Norepinephrine and epinephrine are known to 
induce a ‘fight or flight’ response from the sympathetic nervous system (SNS). These 
catecholamines also target β-adrenergic receptors that mediate their effects on cancer 
cells, including breast cancer cells (132).  
 Cortisol, a human glucocorticoid, regulates many cardiovascular, metabolic, 
immunologic, and homeostatic functions (133), and is secreted by the adrenal cortex in 
response to stress (134). Studies have shown that cortisol can disrupt neuroendocrine 
circadian rhythms to support tumor growth and metastasis (135). Chronic stress is 
involved in inhibiting immune responses, and increased levels of cortisol have been 
shown to be immunosuppressive (136). On the other hand, studies have shown that acute 
stress can amplify cellular immunity, increasing resistance to some cancer such as 
squamous cell carcinoma (137). 
 Stress also influences cancer metastasis (138). Norepinephrine has shown to 
stimulate VEGF, an angiogenic molecule that induces neovascularization of malignancy 
(138). Studies have linked positive and negative psychosocial factors to either an increase 
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or decrease of the regulation of VEGF in various cancer patients (139, 140). Additionally, 
the production of IL-6, another angiogenic molecule or cytokine, has been reported to 
increase or decrease based on the impact of psychosocial factors (141). Although there is 
limited evidence of the effects of stress on the proliferation of metastatic cancer cells, 
studies have suggested that the presence of catecholamines may suppress the production 
of normal or good cells, impacting an immune response to cancer cell proliferation. 
(142). 
 Other cytokines, such as IL-1 and TNF-α, may work synergistically with IL-6 to 
stimulate an inflammatory response in response to various stressors (109). The brain can 
also induce stress-inflammatory responses to perceived social-environmental hazards 
(109). Inflammation is partly regulated by cortisol, and when stress is high, inflammation 
can become chronic and promote diseases, such as cardiovascular, autoimmune disorders, 
and cancers (143). A study concluded that the association between HRQOL and mortality 
in breast cancer survivors may be contributed to inflammation as the core biological 
mechanism, where low levels of physical functioning predicts higher risk of mortality 
(88). 
 Chronic stress is associated with the pathogenesis of cancer and the development 
of tumor growth and metastasis (111). Cancers with improving survivorship, such as 
breast cancer, impact the overall well-being of survivors over short- and long-term 
periods following a diagnosis. The chronic relationship between stress-responses to what 
precedes and follows cancer, and the diagnoses of cancer itself, needs to be further 
evaluated in patients who are living longer with chronic diseases. Even though the 
association between HRQOL and mortality in breast cancer survivors, and the impact 
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stress may have on this association, is not completely understood, studies have found 
relationships between stress and HRQOL factors. One study found that socially isolated 
mice were more likely to develop stress via increased corticosterone levels (144), while 
another showed that exposure to inevitable foot-shock stress in rats reduced the innate 
activity of natural killer cells (145). Researchers have emphasized the importance of 
social support on breast cancer survivors, including its impact on reducing stress in these 








 The Health Eating, Activity, and Lifestyle (HEAL) Study is a multicenter 
prospective cohort of 1,183 enrolled multi-ethnic women diagnosed with first primary in-
situ or invasive (stages I to III-A) breast cancer between 1994 and 1999 (148). 
Participants were ascertained from the Surveillance, Epidemiology, and End Results 
(SEER) cancer registries in New Mexico, Los Angeles County (LA), and Western 
Washington. Women were initially followed to evaluate how lifestyle factors (physical 
activity, diet, weight history), hormones, and clinical characteristics had an impact on 
breast cancer outcomes and prognosis. Participants were evaluated over multiple time 
periods and each period differed by study site. For New Mexico, participants were 
evaluated at baseline, 2-year follow-up, 3-year follow-up, 5-year follow-up, and 10-year 
follow-up (149). Informed consent was obtained during each assessment. Institutional 
Review Board approvals were obtained at each participating center. Additional study 
design, recruitment processes, and aims have been previously described in detail (148). 





Eligibility and Recruitment 
 In the HEAL-New Mexico (HEAL-NM) site, women were eligible to be 
ascertained from SEER New Mexico Tumor Registry (NMTW) for the study if they were 
diagnosed with in situ to Stage IIIA breast carcinoma between July 1996 and March 
1999. Additional eligibility criteria for recruitment included: 1) participants identifying as 
≥ 18 years of age; 2) the ability to participate in an interview within 9-months post-
diagnosis; 3) residence in Bernalillo, Santa Fe, Sandoval, Valencia, or Taos Counties in 
New Mexico; and 4) self-reported Hispanic or NHW race/ethnicity. 
 
HEAL-NM Study Population 
 Figure 1 provides a description of subject recruitment, participation, and timing of 
data collection regarding the primary variables used in this thesis. 999 women were 
eligible. Out of these women, 616 of them completed the baseline survey, on average, six 
months post-diagnosis. Participants were asked to complete a follow-up assessment 
approximately 24 months after baseline. Out of the 616 women who participated in the 
baseline survey, 591 (95.9%) were eligible to participate in the follow-up assessment at 
24-months and 496 (80.5%) completed it. Reasons for non-participation in the 24-month 
follow-up assessment included: refusal to participate (n=64), unable to interview (n=17) 
or locate (n=8), and leaving the state (n=6). Of the 591 who participated in the 24-month 
follow-up, 567 (95.9%) were eligible to participate in the follow-up assessment at 36-
months, which included the HRQOL assessment, and 459 (77.7%) completed it. Reasons 
for non-participation in the 36-month follow up assessment included: no return (n=42), 
not chosen (n=33), refusal to participate (n=22), unable to interview (n=8), and unable
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Figure 1. Study Participation Flow—HEAL Study New Mexico Site 
 
Note: ‘never contact’ does not mean the women were ‘never’ contacted but rather somewhere 






















24-Month (post-baseline) Follow-Up Assessment 
 
Hispanics: 109 
Non-Hispanic White: 387 
 
Variables: Additional demographic characteristics, 
such as marital status, employment, income, weight, 
smoking, menopausal status, the Charlson 
Comorbidity Index, Tamoxifen use, and medical 
record abstraction. 
6-Month Baseline Assessment 
 
Hispanics: 150 
Non-Hispanic White: 465 
 
Variables: Demographic characteristics (e.g., age, 
education, ethnicity, height, menopausal status), 
Tamoxifen use, and medical record abstraction. 
Of the 999 participants who were eligible 
for the baseline survey, 615 participated in 
it. 
 
230 refusal, 53 unable to interview, 27 
physician refusal, 29 unable to locate, 20 left 
the state, 12 received late notice, 7 never 
contact, 3 left the county, 3 unreliable. 
Of the 615 who participated in the baseline 
survey, 590 were eligible for the 24-month 
follow-up, and 496 completed it. 
 
64 refusal, 25 deaths, 17 unable to interview, 
7 unable to locate, 6 left the state. 
HRQOL Assessment 
 
Conducted on average 36 months post-baseline 
 
Hispanics: 98 
Non-Hispanic White: 361 
 
Variables: Health-related Quality of Life (SF-36) (8 
sub-scales & 2 summary scores), pain, fatigue, 
general health, social support, fear of recurrence, 





Of the 590 who participated in the 24-
month follow-up, 566 were eligible for the 
36-month follow-up, and 459 completed it. 
 
49 deaths, 42 no returns, 33 not chosen 
(based on 24-month follow-up refusal), 22 




Analytic Sample Eligibility Criteria 
  
-Exclude women with in-situ breast cancer 
(n=85) 
-Exclude women with incomplete HRQOL 
data (n=23) 
-Exclude women with missing survival time 
(n=0) Analytic Sample: 
 
351 eligible participants 
 
Hispanics: 78 






to locate (n=3). (150). Participants were further contacted for 5-year and 10-year follow-
up post-diagnosis; however, data from these assessments are not used for this study. 
Passive follow-up on all cases occurred by updating survival and cancer diagnosis 
information regularly through the NMTR. Information on survival and new primaries was 
available through December 2012 for approximately 12.5 years from baseline 
assessment. 
 Participants were eligible for this analysis if they had completed HRQOL 
assessments and completed data on survival time. Among the 459 women who completed 
the 36-month HRQOL follow-up, 436 (94.9%) provided complete HRQOL information. 
Among these 436 participants, none were missing survival time. The analytic sample was 
restricted to participants who had invasive breast cancer only (Stage I to Stage IIIa). 
Thus, women who were diagnosed with in situ breast carcinoma were excluded (n=85). 
The final analytic sample size consisted of 351 participants, 78 Hispanic women and 273 
NHW women.  
 
Data Collection & Outcome Measures 
 Data used in this thesis originate from HEAL baseline, 24-month, and 36-month 
(HRQOL) assessments, medical record abstraction, and Surveillance Epidemiology and 
End Results (SEER) cancer registry records. Baseline interviews occurred, on average, at 
6-months post-diagnosis and were conducted at the University of New Mexico Aging and 
Genetic Epidemiology Program. Questionnaires measured demographics (age, 
race/ethnicity, education), lifestyle factors covering Tamoxifen use, smoking status, and 
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screening practices, as well as anthropometric measurements including BMI, and blood 
or saliva samples.  
At 24-month follow-up, questionnaires measured similar demographics, 
menstrual status, eating habits, additional breast disease and treatment, medical 
conditions, hormone replacement therapy, physical activity, smoking habits, and alcohol 
intake. 
At 36-month follow-up, questionnaires measured HRQOL characteristics such as 
support group experiences, information about breast cancer and surgery, pain, 
lymphedema, religiosity, optimism, the impact of cancer and changes after cancer, social 
support, fatigue, sexual activity, life events, fear about recurrence, health 
status/functioning, perceived stress, and Tamoxifen use. 
 
Demographic and Lifestyle Characteristics 
 Demographic data collected at baseline and 24-month follow-up and evaluated in 
this study include age, self-reported race/ethnicity, education, and marital status. Lifestyle 
factors evaluated include physical activity, smoking status, and Tamoxifen use. Physical 
activity was measured only at 24-month follow-up while smoking status and Tamoxifen 
use were measured at both baseline and 24-month follow-up. 
 
Clinical Characteristics 
 Data on breast cancer diagnoses and breast cancer stage were ascertained using 
SEER-NMTR, including additional data on tumor size, lymph node involvement, and 
tumor subtypes (Luminal A, Luminal B, HER2 Overexpressing, Triple Negative), which 
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were obtained via pathology reports. Information on co-morbid conditions and cancer 
treatment, such as adjuvant therapy, was abstracted from medical record and SEER-
NMTR registry records. This information includes: radiation and/or chemotherapy, types 
of surgery, and use of Tamoxifen (medically abstracted and self-reported during the 24-
month assessment). Participants were passively followed through the SEER NMTR and 




 The following instruments were used to collect HRQOL data at the 36-month 
follow-up: RAND 36-item Short Form Health Survey (SF-36) (35), Lymphedema Status 
(added by HEAL investigators), the Life Orientation Test (151), Social Support (152), the 
Piper Fatigue Scale (153), and Fear of Recurrence Scale (154). 
 Data from the SF-36 was used to measure eight health components (subscales) 
and two derived component summary scales (MCS/PCS). Response values from 36 items 
(questions) were recoded per the scoring key and items in the same scale were averaged 
to create a measure for each of the eight subscales (35, 155). When scoring occurs, items 
that are left blank are not included in calculating the scale scores, which are calculated by 
taking an average of only the completed answers (156). There are four 
mental/psychosocial subscales (Social Functioning, Role-Emotional, Vitality, and Mental 
Health) and four physical subscales (Physical Functioning, Role-Physical, Bodily Pain, 
and General Health). Raw subscale scores range from 0 to 100, higher scores indicating a 
better HRQOL. The MCS and PCS scores were calculated by using weighted Z-scores of 
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the eight subscales multiplied by a factor score coefficient and summed over their 
respective subscales (35, 157). Raw scores of the four psychosocial subscales and the 
four physical subscales as well as the two component summary scores were normalized 
to the general U.S. population on a T-score metric (mean = 50, SD ± 10) in order to 
compare across groups. A score change of ½ a SD had been used to determine the 
presence of a clinically meaningful difference (35, 157). The SF-36 has been proven 
reliable with Cronbach’s alpha estimates of 0.78 or higher in the MOS (155, 158). 
Lymphedema status was determined based on those who ever experienced 
lymphedema, received treatment for lymphedema, and who were experiencing 
lymphedema at the time of assessment. The Life Orientation Test provided information 
on perceived optimism, and conversely, perceived pessimism, both analyzed separately 
via a 6-item questionnaire (151). Information on the number of types of confidants was 
utilized from the Social Support aspect of the HRQOL assessment (152). One question 
pulled from the Piper Fatigue Scale determined current fatigue in participants four weeks 
prior to assessment (153), and one question about fear of breast cancer recurrence during 
time of assessment was chosen via the Fear of Recurrence Scale (154).  
 Optimism, derived from the Life Orientation test, was categorized into two 
components: perceived pessimism and perceived optimism, based on reverse coding for 
pessimism in contrast to optimism, and the inherent way the two new concepts differ.  
 Social support was based on a series of questions about types of confidants at 
diagnosis and at the time of the interview (i.e., spouse, children, other family members, 
friends, neighbors, nurses, treating physicians, psychiatrists, psychologists/therapists, 
priest/rabbis/ministers, support groups, or ‘other’). 
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 Current fatigue (yes/no) in the four weeks before HRQOL assessment was 
denoted by a preliminary question in the Piper Fatigue Scale (153). Fear of recurrence 
was defined by participants who indicated that they were afraid of their cancer returning 
at the time of HRQOL assessment. 
 
Mortality and Survival Periods 
 Figure 2 displays a graph of the entire follow-up and survival periods for the 
population. Mortality, including type of death, of participants was ascertained via the 
National Death Index. A survival period of one to 12.5 years was used, abstracted from 
consented passive follow-up through SEER and calculated based on the difference from 
HRQOL interview to censor date. For this analysis, survival time began at 3-years based 
on the average completed time for the HRQOL follow-up assessment post-diagnosis. The 
outcome of interest was mortality, specifically all-cause, breast cancer-specific, and non-
cancer mortality.  
 
 
Figure 2. HEAL New Mexico Site Follow-Up and Survival Time. 
July 1996 March 1999 Dec. 2012 
0 16 3
Baseline Assessment Period 
Survival Period, Total: ~12.5 years, Median: 11.2 years (range: 0.03-12.3 years) 
Average time for 24-month follow-up assessment 
Average time for 36-month follow-up assessment (HRQOL) 
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Statistical Analysis 
Eligible Analytic Sample Size 
 Among the 459 women who completed the 36-month follow-up, 23 were missing 
complete HRQOL data and 85 were excluded due to a diagnosis in situ disease (stage 0). 
The eligible analytic sample size subsequently consisted of 351 participants (78 Hispanic 
women and 273 NHW) with complete data on HRQOL assessments, vital status, and 




 For all-cause and non-cancer mortality, HRQOL subscale and component 
summary scores were categorized into tertiles with the highest tertile used as the referent 
group, based on the distribution of the cohort. Because breast cancer-specific mortality 
had a low number of events, the HRQOL subscale and component summary scores were 
dichotomized, based on the distribution of the cohort, to increase statistical power. 
 
Outcome Assessment 
 Outcomes for analyses included all-cause (death due to any cause), breast cancer-
specific, and non-cancer (death due to causes other than cancer) mortality as ascertained 
from death records. For this analysis, participants were passively followed from date of 
HRQOL interview (approximately 36-months post-diagnosis) to December 2012. 
International Classification of Diseases, 10th Revision (ICD-10) codes were used to sort 
causes of deaths (159, 160). For all-cause mortality, the time frame for follow-up was 
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initiated from HRQOL assessment to the date of death, and non-deceased participants 
were censored on December 2012. For breast cancer-specific mortality, women dying of 
breast cancer-related deaths were the outcome of interest and women dying from other 
causes were censored on December 2012. For non-cancer mortality, women dying of all-
causes with exception to cancer-related deaths were the outcome of interest and women 
dying from cancer were censored on December 2012. Furthermore, participants were 




Covariates were analyzed as either confounders or effect modifiers in the 
associations between HRQOL and mortality. Covariates analyzed from the baseline 
assessment included age, race/ethnicity, education, marital status, and BMI. Clinical 
characteristics considered included tumor stage, tumor size, tumor subtype, treatment 
type, lymph node involvement, and comorbidities. At 24-month follow-up, covariates 
selected were physical activity, smoking status, and Tamoxifen Use. Variables 
considered from the HRQOL assessment were: current lymphedema, perceived 
optimism, perceived pessimism, types of confidants, current fatigue, current pain, 
perceived general health, and fear of recurrence. 
 Among the self-reported baseline characteristics, age was continuous. 
Race/ethnicity were categorized as NHW or Hispanic. Education was classified into four 
categories: 1) high school or less; 2) some college; 3) college graduate; and 4) graduate 
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school. Participants reported whether they were single or married for marital status, and 
BMI (kg/m2) was categorized into 1) <25; 2) 25-29; and 3) ≥ 30. 
 Clinical characteristics were abstracted via medical records or SEER-NMTR. For 
this analysis, tumor stage was dichotomized into localized (Stage 1) and regional (Stages 
II-IIIA). Tumor size was dichotomized as <3 centimeters and ≥ 3 centimeters. Tumor 
subtype was initially classified as luminal A, luminal B, HER2 overexpressing, or triple 
negative. However, due to a low sample size (missing=51), the covariate was 
dichotomized as ER+ and ER-. For breast cancer treatment type, there were three 
categories: any chemotherapy, surgery only, and surgery and radiation. Lymph node 
involvement was dichotomized as none versus one or more lymph nodes involved, 
similar to comorbidities, which was categorized as zero versus one or more comorbidity. 
 For 24-month follow-up covariates, physical activity was categorized as none, 
light, and moderate or vigorous, and smoking status was classified as never, former 
smoker, or current smoker. Tamoxifen use was dichotomized as yes/no. 
 Some of the covariates considered from the HRQOL assessment were 
dichotomized as yes/no, including current lymphedema, current fatigue, current pain, and 
fear of recurrence. For perceived optimism/pessimism, identical scores were created 
based on participants’ responses to the three questions for optimism and the three 
questions for pessimism, categorized as ≤ 10 or > 10, or less versus greater perception. 
These cut points were chosen based on the distribution of the cohort to allow for adequate 
numbers of participants in each category. A social support variable, types of confidants, 
was created and categorized based on the distribution of coded responses, similar to the 
optimism and pessimism variables. In reference to the types of confidants previously 
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listed, participants were categorized as having less than four, four to five, or greater or 
equal to six types of different confidants. Perceived general health, SF-36 item, was 
dichotomized to include participants who rated their health as fair or poor compared to 
participants who rated their health as good, very good, or excellent. 
 
Descriptive Characteristics 
 Descriptive characteristics of participants who completed the HRQOL assessment 
were compared to those who did not, and by vital status (alive vs. deceased) at the end of 
the study period among those with complete HRQOL data. Frequencies and percentages 
were reported for categorical variables and means (SD), medians (min-max), and ranges 
were reported for continuous variables. Chi-square tests of independence for categorical 
variables and student t-tests for continuous variables were calculated to determine 
whether the distributions of the variables differed among the groups compared. 
Descriptive characteristics of the analytic sample were computed by vital status, and the 
same tests were computed to compare alive and deceased participants. 
 
Statistical Model Building 
 Cox proportional hazards regression models were used to examine the statistical 
associations of HRQOL component summary scores with mortality. Hazard Ratios (HR) 
and 95% Confidence Intervals (CI) were estimated for each outcome. A HR measures 
how much greater a death rate is in one group compared to another group, using survival 
times as a comparison between the two groups of participants (161). The time metric in 
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all analyses was survival years. The referent group for MCS and PCS scores was tertile 3 
(T3) and HR 95% CIs were estimated for tertile 1 (T1) and tertile 2 (T2). 
 Crude HRs between the exposure, MCS scores and PCS scores, and mortality 
outcomes were calculated. To determine potential confounders for consideration in the 
model building process, each variable was added to the crude model and a percent change 
was calculated between each adjusted model and crude model to determine the individual 
magnitude of effect by each covariate. 
 A base model (Model 1) was established to assess additional associations between 
the crude model and Model 1, the crude model and Model 1 plus each covariate, and 
Model 1 and Model 1 plus each covariate. The base model included age, marital status, 
and tumor stage, and was the same for both MCS scores and PCS scores. Age and marital 
status was chosen based on their magnitude of effect when added to the crude model for 
both MCS and PCS scores. Tumor stage was selected to include a clinical characteristic 
into the model, and this variable was the only one with no missing values.  
 Purposeful selection of covariates was employed to evaluate potential 
confounders yielding p-values less than 0.25 during the univariate analyses (162). This is 
utilized to identify variables that may not show significant associations between the 
exposure and outcome alone, but may make a relevant contribution alongside other 
variables (162). For MCS and PCS scores, respectively, covariates were added to the 
model one at a time to evaluate the change in association between the crude model and 
Model 1, the crude model and Model 1 plus a group of covariates, and Model 1 and 
Model 1 plus a group of covariates. For variables with missing data, data subsets were 
created to include only participants with complete data, and then the same previous 
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evaluations were repeated to assess relationships among each model. This step was 
repeated for each variable with missing data. Final models for associations between MCS 
scores and all-cause/non-cancer mortality and PCS scores and all-cause/non-cancer 
mortality were developed depending on the results from the multivariable modeling. 
These variables were already selected based on the purposeful selection algorithm, and 
then were further evaluated in conjunction to see their magnitude of effects. Since each 
variable with missing data (education, lymph node involvement, tumor size, physical 
activity, Tamoxifen use, smoking status, BMI, and tumor subtype), when considered, did 
not hold much effect on the associations between the exposures and outcomes, in 
conjunction with other considered variables, they were excluded. This enabled us to 
retain a parsimonious model while accounting for covariates that drive the confounding 
effects. MCS and PCS scores were adjusted for different variables based on their 
confounding effects in the model building process. Breast cancer-specific multivariable 
modeling building was not conducted to a low sample of events and no significant 
results. The final analytic sample size was (N = 351) (Figure 1). Tables detailing the 
statistical modeling process can be found in Appendices (B-O). 
 
Least Squares Means 
 Means (SD) and adjusted least-squares means (LSMs) for HRQOL subscales and 
MCS and PCS categories were calculated stratified by mortality outcome. For breast 
cancer-specific and non-cancer mortality, participants who died from causes other than 
breast-cancer specific or non-cancer, respectively, were excluded from the analyses. 
HRQOL subscales were adjusted for covariates associated with either MCS or PCS, and 
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these include age, race/ethnicity, tumor stage, education, BMI, treatment type, lymph 
node involvement, co-morbid conditions, physical activity, current lymphedema, 
perceived pessimism, number of types of confidants, and fear of recurrence. Tukey-
Kramer p-values were computed to compare HRQOL LSMs between participants who 
were deemed alive or dead during the study period. Frequencies (n%) and medians (min-
max) were reported for MCS and PCS by vital status and Kruskal-Wallis tests were 




Kaplan-Meier survival curves were generated to show the survival rates between 
MCS and all-cause/breast cancer-specific/non-cancer mortality, and PCS and all-
cause/breast cancer-specific/non-cancer mortality for all women, and by race/ethnicity. 
Survival curves between MCS/PCS tertiles and the three mortality outcomes were 
compared via log rank test p-values. The curves show survival times (time-to-event) by 
each tertile and with each death as the event, respectively. Censored participants, or 
participants who have the “event” or another censoring characteristics such as date of last 
contact or the end of the study, were displayed as ticks on each curve.  
 
Cox Proportional Hazards Regression 
 Associations from three models were reported: Model 1, the crude associations, 
Model 2 adjusted for demographic (age, race/ethnicity, marital status) and clinical 
characteristics (tumor stage, treatment type, co-morbid conditions), and Model 3, 
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adjusted for every covariate in Model 2, in addition to variables assessed during the 
HRQOL follow-up (current lymphedema, perceived optimism/pessimism, types of 
confidants, bodily pain, perceived general health, and fear of recurrence. P-trends were 
calculated to test the ordered relationship across the three MCS and PCS tertiles (163).  
 To evaluate effect modification, Cox Proportional hazard regression models 
investigated associations between MCS and mortality and PCS and mortality, stratified 
by race/ethnicity (NHW, Hispanic), and these associations were adjusted for every 
covariate (Model 3 only). Additional analyses evaluated the associations between 
individual HRQOL subscales scores and all-cause, breast cancer-specific, and non-cancer 
mortality, using the three step modeling procedure previously mentioned, adjusted for the 
same variables for MCS (mental/psychosocial-related) and PCS (physical-related), 
respectively. Models with breast cancer-specific mortality as the outcome variable were 
adjusted for the same covariates for all-cause mortality evaluations. 
 The proportional hazards assumption is that each covariate added to cox 
proportional hazard models do not vary with time (164). Violation of the proportional 
hazards assumption was evaluated using Schoenfeld Residuals testing (164, 165). Each 
variable was assessed using a time-dependent covariate method, adding interaction terms 
to test for their significance (164). P-values were generated for each covariate as well as 
one for the total model. P-values <0.05 were considered significant and as a violation of 
the proportional hazards assumption. 







Demographic and clinical characteristics of the entire HEAL-NM cohort by 
HRQOL assessment completion status are presented in Table 1. Of those that died prior 
to the HRQOL assessment, a majority died from breast cancer-specific mortality 
(n=47/100). Among the 615 participants who completed the baseline survey, 436 (70.9%) 
completed the HRQOL assessment while 179 (29.1%) did not. The 179 participants who 
did not complete the HRQOL assessment were either deceased or ineligible by the 
assessment date, or did not fully complete the HRQOL assessment. Of those who 
completed the assessment, many were younger (mean age: 58.5 ± 11.7) compared to their 
counterparts (mean age: 60.8 ± 14.6), p=0.0390. Additionally, cause of death 
significantly differed between the two groups (p=0.0019). People who completed the 
HRQOL assessment experienced more all-cause and non-cancer-related deaths but less 
breast cancer-specific deaths compared to people who did not fully complete the 
assessment. HRQOL status groups also differed by characteristics at both baseline, 
including race/ethnicity (p=0.0069), education (p=0.0005), marital status (p=<0.0001), 
lymph node involvement (p=0.0288); and 24-month follow-up, including Tamoxifen use 
(p=0.0206), significantly differed. 
Table 2 displays demographic, clinical, and HRQOL characteristics of the 
analytic sample (N=351) by vital status (all-cause mortality only) at the end of the study 
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Table 1. Demographic Characteristics of HEAL Participants Who Completed the 
HRQOL Assessment Compared to Non-respondents, The HEAL Study New Mexico 
Site (N = 615) 
    HRQOL Assessment    
 
Total 
Population Completed Not Completed 
 Characteristics N(%)a (N = 615) (n = 436) (n = 179) Pa 
Baseline 
       Age (years) 
   
0.0390 
      Mean ± (SD) 59.2 ± 12.6 58.5 ± 11.7 60.8 ± 14.6 
       Median (min-max) 58 (29-91) 57 (29-86) 61 (35-91) 
    Race/Ethnicity 
   
0.0069 
      Non-Hispanic White 461 (75.0) 340 (78.0) 121 (67.6) 
       Hispanic 154 (25.0) 96 (22.0) 58 (32.4) 
    Education 
   
0.0005 
      High school or less 184 (29.9) 109 (25.0) 75 (41.9) 
       Some college 197 (32.0) 146 (33.5) 51 (28.5) 
       College graduate 110 (17.9) 86 (19.7) 24 (13.4) 
       Graduate school 123 (20.0) 94 (21.6) 29 (16.2) 
       Missing 1 (0.2) 1 (0.2) 0 (0.0) 
    Marital status 
   
<0.0001 
      Single 321 (52.2) 190 (43.6) 131 (73.2) 
       Married 294 (47.8) 246 (56.4) 48 (26.8) 
    Body Mass Index (kg/m2) 
   
0.9708 
      < 25 268 (43.6) 194 (44.5) 74 (41.4) 
       25-29 185 (30.1) 132 (30.3) 53 (29.6) 
       ≥ 30 110 (17.9) 79 (18.1) 31 (17.3) 
       Missing 52 (8.4) 31 (7.1) 21 (11.7) 
    Tumor Stage 
   
0.2587 
      In-Situ (0) 118 (19.2) 85 (19.5) 33 (18.4) 
       Localized (I) 381 (61.9) 276 (63.3) 105 (58.7) 
       Regional (II-IIIa) 116 (18.9) 75 (17.2) 41 (22.9) 
    Tumor Size (cm) 
   
0.1005 
      <3 cm 503 (81.8) 364 (83.5) 139 (77.7) 
       ≥ 3 cm 64 (10.4) 40 (9.2) 24 (13.4) 
       Missing 48 (7.8) 32 (7.3) 16 (8.9) 
    Tumor Subtype 
   
0.4567 
      Luminal A 220 (35.8) 153 (35.1) 67 (37.4) 
       Luminal B 131 (21.3) 98 (22.5) 33 (18.4) 
       HER2 Overexpressing 34 (5.5) 21 (4.8) 13 (7.3) 
       Triple Negative 41 (6.7) 28 (6.4) 13 (7.3) 
       Missing 189 (30.7) 136 (31.2) 53 (29.6) 
    Breast Cancer Treatment Type 
  
0.4532 
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    HRQOL Assessment    
 
Total 
Population Completed Not Completed 
 Characteristics N(%)a (N = 615) (n = 436) (n = 179) Pa 
      Any chemotherapy 151 (24.6) 109 (25.0) 42 (23.5) 
       Surgery only 214 (34.8) 145 (33.3) 69 (38.5) 
       Surgery and radiation 250 (40.6) 182 (41.7) 68 (38.0) 
    Lymph Node Involvement 
   
0.0288 
      None 477 (77.6) 349 (80.0) 128 (71.5) 
       ≥ 1 Lymph Nodes Involved 122 (19.8) 77 (17.7) 45 (25.1) 
       Missing 16 (2.6) 10 (2.3) 6 (3.4) 
    Charlson Comorbidity Index 
  
0.0658 
      No co-morbid conditions 508 (82.6) 368 (84.4) 140 (78.2) 
       One or more conditions 107 (17.4) 68 (15.6) 39 (21.8) 
 
     24-month follow-up 
       Physical Activity 
   
0.3176 
      None 286 (46.5) 229 (52.5) 57 (31.8) 
       Light 88 (14.3) 74 (17.0) 14 (7.8) 
       Moderate 25 (4.1) 22 (5.0) 3 (1.7) 
       Vigorous 96 (15.6) 84 (19.3) 12 (6.7) 
       Missing 120 (19.5) 27 (6.2) 93 (52.0) 
    Smoking Status 
   
0.5858 
      Never 222 (36.1) 186 (42.7) 36 (20.1) 
       Former 212 (34.5) 171 (39.2) 41 (22.9) 
       Current 61 (9.9) 52 (11.9) 9 (5.0) 
       Missing 120 (19.5) 27 (6.2) 93 (52.0) 
    Tamoxifen Use 
   
0.0206 
      No 290 (47.2) 230 (52.7) 60 (33.5) 
       Yes 205 (33.3) 179 (41.1) 26 (14.5) 
       Missing 120 (19.5) 27 (6.2) 93 (52.0) 
 
     Vital Status 
   
0.0019 
   Alive 400 (65.0) 321 (73.6) 79 (44.1) 
    Death, Breast cancer-specific 74 (12.0) 27 (6.2) 47 (26.3) 
    Death, Non-cancer 123 (20.0) 78 (17.9) 47 (26.3) 
    Death, All-cause 215 (35.0) 115 (26.4) 100 (55.9)   
a. Chi-square p-value for categorical variables or t-test p-values for continuous variables comparing participants  
who have completed the HRQOL assessment and participants who have not, excluding missing values. An italicized  
p-value represents statistically significant differences between comparison groups. 
 Note: Reasons for not completing the HRQOL assessment were refusal and ineligibility (i.e. death).   
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period. Ninety-nine participants were deceased. 64 died from non-cancer causes, and 26 
died from breast cancer-specific causes. The median survival time was 11.2 years (range: 
0.03-12.3 years). Several baseline characteristics differed by vital status. Mean age for 
participants who were alive was significantly younger than those who died (56.1 ± 10.4 
vs. 65.2 ± 12.7, respectively). Of the total sample, 273 (75.4%) reported NHW race while 
78 (22.2%) reported Hispanic origin. The majority of the population indicated having 
completed some college (32.5%) and high school or less (26.2%), similar results were 
observed by vital status. The distribution of BMI was about the same by vital status. 
Almost half of the study population had a BMI of less than 25kg/m2 (45.9%). 
Marital status significantly differed by vital status (p=0.0004), the majority of 
deceased women were single (60.6%). Two hundred seventy six participants (78.6%) 
presented with localized (I) tumor stage, 75 (21.4%) were diagnosed with regional (II-
IIIa) stages. Most participants had a smaller tumor size <3cm (86.6%) compared to ≥3cm 
(10.5%). In terms of tumor subtypes, the majority was diagnosed with ER+ subtypes 
(71.5%) compared to ER- (14%); however, 14.5% were missing this information. Among 
all women in the study, most received surgery only (41.0%), followed by any 
chemotherapy (31.1%) and then surgery and radiation (27.9%). Furthermore, about 75% 
of the population had no lymph node involvement (75.2%). Tumor stage, size, and 
subtype, treatment type, and lymph node involvement did not significantly differ by vital 
status (p=-0.41, 0.63, 0.81, 0.24, 0.35, respectively). Approximately 85% of the cohort 
had zero comorbid conditions. The distribution of comorbidities significantly differed by 
vital status (p=0.0076), those who were deceased were more likely to have ≥1 comorbid 
condition compared to those who were alive (23.2% vs. 11.9%, respectively). Variables 
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ascertained from the 24-month follow-up assessment were physical activity, smoking 
status, and Tamoxifen use. Twenty one participants were missing these three variables. 
Levels of physical activity significantly differed between living and deceased participants 
 
Table 2. Demographic Characteristics of HEAL Participants with Invasive Breast 
Cancer by Vital Status (N = 351) 
    Vital Status   
 
Total 
Population Alive Deceased 
 Characteristics N(%)a (N = 351) (n = 252) (n = 99) Pa 
Baseline 
       Age (years) 
   
<0.0001 
      Mean ± (SD) 58.6 ± 11.8 56.1 ± 10.4 65.2 ± 12.7 
       Median (min-max) 58 (29-86) 55 (29-83) 68 (32-86) 
    Race/Ethnicity 
   
0.0869 
      Non-Hispanic White 273 (77.8) 190 (75.4) 83 (83.8) 
       Hispanic 78 (22.2) 62 (24.6) 16 (16.2) 
    Education 
   
0.0534 
      High school or less 92 (26.2) 61 (24.2) 31 (31.3) 
       Some college 114 (32.5) 76 (30.2) 38 (38.4) 
       College graduate 70 (19.9) 57 (22.6) 13 (13.1) 
       Graduate school 74 (21.1) 58 (23.0) 16 (16.2) 
       Missing 1 (0.3) 0 (0.0) 1 (1.0) 
    Marital status 
   
0.0004 
      Single 160 (45.6) 100 (39.7) 60 (60.6) 
       Married 191 (54.4) 152 (60.3) 39 (39.4) 
    Body Mass Index (kg/m2) 
   
0.2450 
      < 25 161 (45.9) 121 (48.0) 40 (40.4) 
       25-29 99 (28.2) 76 (30.2) 23 (23.2) 
       ≥ 30 64 (18.2) 42 (16.7) 22 (22.2) 
       Missing 27 (7.7) 13 (5.1) 14 (1.2) 
    Tumor Stage 
   
0.4102 
      Localized (I) 276 (78.6) 201 (79.8) 75 (75.8) 
       Regional (II-IIIa) 75 (21.4) 51 (20.2) 24 (24.2) 
    Tumor Size (cm) 
   
0.6294 
      <3 cm 304 (86.6) 217 (86.1) 87 (87.9) 
       ≥ 3 cm 37 (10.5) 25 (9.9) 12 (12.1) 
       Missing 10 (2.9) 10 (4.0) 0 (0.0) 
    Tumor Subtype 
   
0.8132 
      Luminal A 153 (43.6) 109 (43.3) 44 (44.4) 
       Luminal B 98 (27.9) 71 (28.2) 27 (27.3) 
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    Vital Status   
 
Total 
Population Alive Deceased 
 Characteristics N(%)a (N = 351) (n = 252) (n = 99) Pa 
      HER2 Overexpressing 21 (6.0) 13 (5.2) 8 (8.1) 
       Triple Negative 28 (8.0) 20 (7.9) 8 (8.1) 
       Missing 51 (14.5) 39 (15.5) 12 (12.1) 
    Breast Cancer Treatment Type 
  
0.2433 
      Any chemotherapy 109 (31.1) 81 (32.1) 28 (28.3) 
       Surgery only 144 (41.0) 107 (42.5) 37 (37.4) 
       Surgery and radiation 98 (27.9) 64 (25.4) 34 (34.3) 
    Lymph Node Involvement 
   
0.3466 
      None 264 (75.2) 196 (77.8) 68 (68.7) 
       ≥ 1  77 (21.9) 53 (21.0) 24 (24.2) 
       Missing 10 (2.9) 3 (1.2) 7 (7.1) 
    Charlson Comorbidity Index 
  
0.0076 
      No co-morbid conditions 298 (84.9) 222 (88.1) 76 (76.8) 
       One or more conditions 53 (15.1) 30 (11.9) 23 (23.2) 
 
     24-Month follow-up 
       Physical Activity 
   
0.0243 
      None 185 (52.7) 123 (48.8) 62 (62.6) 
       Light 59 (16.8) 47 (18.7) 12 (12.1) 
       Moderate/Vigorous 86 (24.5) 69 (27.4) 17 (17.2) 
       Missing 21 (6.0) 13 (5.1) 8 (8.1) 
    Smoking Status 
   
0.8182 
      Never 145 (41.3) 106 (42.1) 39 (39.4) 
       Former 144 (41.0) 105 (41.7) 39 (39.4) 
       Current 41 (11.7) 28 (11.1) 13 (13.1 
       Missing 21 (6.0) 13 (5.1) 8 (8.1) 
    Tamoxifen Use 
   
0.4780 
      No 160 (45.6) 113 (44.8) 47 (47.5) 
       Yes 170 (48.4) 126 (50.0) 44 (44.4) 
       Missing 21 (6.0) 13 (5.2) 8 (8.1) 
 
     HRQOL (36-month) follow-up 
      Current lymphedema 
   
0.2219 
      No 307 (87.5) 217 (86.1) 90 (90.9) 
       Yes 44 (12.5) 35 (13.9) 9 (9.1) 
    Perceived Optimism Score 
  
0.0341 
      ≤ 10 83 (23.7) 52 (20.6) 31 (31.3) 
       > 10 268 (76.3) 200 (79.4) 68 (68.7) 
    Perceived Pessimism Score 
  
0.0176 
      ≤ 10 255 (72.6) 192 (76.2) 63 (63.6) 
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    Vital Status   
 
Total 
Population Alive Deceased 
 Characteristics N(%)a (N = 351) (n = 252) (n = 99) Pa 
      > 10 96 (27.4) 60 (23.8) 36 (36.4) 
    Number of Types of Confidants 
  
0.1021 
      <4 people 66 (18.8) 41 (16.3) 25 (25.2) 
       4-5 people 172 (49.0) 124 (49.2) 48 (48.5) 
       ≥ 6 people 113 (32.2) 87 (34.5) 26 (26.3) 
    Current Fatigue 
   
0.9304 
      No 136 (38.8) 98 (38.9) 38 (38.4) 
       Yes 215 (61.2) 154 (61.1) 61 (61.6) 
    Current Pain 
   
0.0270 
      No 93 (26.5) 75 (29.8) 18 (18.2) 
       Yes 258 (73.5) 177 (70.2) 81 (81.8) 
    Perceived General Health 
   
<0.0001 
      Fair/Poor 54 (15.4) 26 (10.3) 28 (28.3) 
       Good/Very Good/Excellent 297 (84.6) 226 (89.7) 71 (71.7) 
    Fear of Recurrence 
   
0.0407 
      No 154 (43.9) 102 (40.5) 52 (52.5) 
       Yes 197 (56.1) 150 (59.5) 47 (47.5) 
 
     Cause of Death 
       Breast cancer-specific 
 
-- 26 (26.3) 
    Other-cancer 
 
-- 9 (9.1) 
    Non-cancer 
 
-- 64 (64.6) 
 a. Chi-square p-value for categorical variables or t-test p-values for continuous variables comparing participants  
who have completed the HRQOL assessment and participants who have not, excluding missing values. An   
italicized p-value represents statistically significant differences between comparison groups.   
 
(p=0.0243), where more women who were alive exercised in moderate or vigorous 
quantities (27.4%) compared to their deceased counterparts (17.2%). Forty-one percent of 
the population reported never smoked, 41% reported being a former smoker, 11.7% were 
current smokers, and 6% were missing data for smoking. Approximately half of the 
cohort reported never using Tamoxifen (48.4%). Among variables ascertained from 
HRQOL assessment, perceived optimism score (p=0.0341), perceived pessimism score 
(p=0.0176), current pain (p=0.0270), perceived general health (p=<0.0001), and fear of 
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recurrence (p=0.0407) significantly differed by vital status. Deceased women had higher 
proportions of reporting worse aspects of HRQOL variables. 
 
HRQOL Subscale and Component Summary Scores 
 Comparisons of HRQOL subscale and component summary scores by vital status 
by mortality outcomes are presented in Table 3. When stratified by all-cause mortality, 
one mental/psychosocial subscale and three physical subscales differed by vital status. 
The mean ± SD (adjusted least square means (LSM)) for the mental subscale, social 
functioning, was among those who were alive and was higher 50.16 ± 9.48 (47.83) 
compared to those who died 45.68 ± 11.21 (43.89), p=0.0030. MCS did not differ by vital 
status and mortality outcomes. 
 Of the physical subscales that differed by vital status, those who were alive also 
had significantly higher adjusted LSM compared to those who died: physical functioning 
(39.27 vs. 35.38, respectively), role physical (40.55 vs. 37.32, respectively), and bodily 
pain (45.89 vs. 42.43, respectively). The PCS significantly differed by vital status (41.97 
vs. 38.31, respectively, p=0.0037), but the MCS did not (p=0.2093).  
 For breast cancer-specific mortality, 73 participants were excluded from the 
analyses due to dying by other causes. Among participants who were alive and 
participants who died by breast cancer specific mortality, no significant associations were 
found. Similarly, 35 participants were excluded from analyses comparing HRQOL 
subscale and component summary scores by non-cancer mortality. Of the  
 Table 3. Comparisons of HRQOL SF-36 Subscale and Component Summary Scores by Vital Status (N = 351) 















HRQOL SF-36 (N = 351) (n = 252) (n = 99) Pd (n = 252) (n = 26) Pd (n = 252) (n = 64) Pd 
SF-36 Subscales 
             Social Functioning 






      Mean ± SD 48.89 ± 10.18 50.16 ± 9.48 45.68 ± 11.21 
 
50.16 ± 9.48 49.20 ± 9.37 
 
50.16 ± 9.48 44.24 ± 11.50 














      Mean ± SD 45.26 ± 11.76 46.19 ± 11.64 42.89 ± 11.79 
 
46.19 ± 11.64 44.40 ± 11.72 
 
46.19 ± 11.64 42.17 ± 12.02 







    Vitality 






      Mean ± SD 48.74 ± 10.22 49.61 ± 10.33 46.52 ± 9.64 
 
49.61 ± 10.33 49.51 ± 8.65 
 
49.61 ± 10.33 45.39 ± 10.13 







    Mental Health 






      Mean ± SD 48.93 ± 9.73 49.44 ± 9.81 47.62 ± 9.46 
 
49.44 ± 9.81 48.43 ± 9.67 
 
49.44 ± 9.81 47.28 ± 9.65 







    Physical Functioning 






      Mean ± SD 45.82 ± 11.27 48.17 ± 9.66 39.82 ± 12.80 
 
48.17 ± 9.66 46.66 ± 10.47 
 
48.17 ± 9.66 37.34 ± 13.17 







     Role Physical 






      Mean ± SD 45.36 ± 11.35 47.09 ± 10.79 40.96 ± 11.60 
 
47.09 ± 10.79 46.72 ± 9.58 
 
47.09 ± 10.79 38.78 ± 11.95 







    Bodily Pain 






      Mean ± SD 50.57 ± 10.49 51.83 ± 10.17 47.39 ± 10.66 
 
51.83 ± 10.17 51.09 ± 9.45 
 
51.83 ± 10.17 46.18 ± 11.08 






























HRQOL SF-36 (N = 351) (n = 252) (n = 99) Pd (n = 252) (n = 26) Pd (n = 252) (n = 64) Pd 
      Mean ± SD 49.51 ± 10.45 50.58 ± 9.86 46.79 ± 11.41 
 
50.58 ± 9.86 50.31 ± 10.92 
 
50.58 ± 9.86 45.34 ± 11.15 








           Component Summary Scores 







      Mean ± SD 48.31 ± 10.25 48.62 ± 10.54 47.54 ± 9.46 
 
48.62 ± 10.54 47.54 ± 10.24 
 
48.62 ± 10.54 47.39 ± 9.31 














      Mean ± SD 47.78 ± 10.50 49.77 ± 9.43 42.70 ± 11.39 
 
49.77 ± 9.43 49.27 ± 10.44 
 
49.77 ± 9.43 40.33 ± 10.93 
       LSMc   41.97 38.31   43.64 46.05   44.10 38.47   
a. Data collected at 36-month HRQOL follow-up assessment. 
b. Seventy-three participants were excluded from breast cancer-specific analyses and 35 participants were excluded from non-cancer analyses, both due to death by other causes. 
c. Least square means adjusted for covariates associated with either MCS or PCS (excluding characteristics involved in the creation of the summary scores). These include baseline (age,  
race/ethnicity, tumor stage, education, BMI, treatment type, lymph node involvement and comorbidities), 24-month follow-up (physical activity), and 36-month follow-up (current  
lymphedema, perceived pessimism, number of types of confidants, and fear of recurrence) characteristics. LSMs for breast cancer-specific mortality were adjusted for the same covariates  
as all-cause mortality due to a low sample size and inability to discern true confounding effects. For Non-cancer mortality perceived pessimism to perceived optimism were added.     







mental/psychosocial subscales that differed by non-cancer mortality, participants who 
were alive had significantly higher adjusted LSM compared to those who died: social 
functioning (49.62 vs. 43.32, respectively), vitality (45.55 vs. 40.94, respectively), and 
mental health (44.80 vs. 41.34, respectively). 
All of the physical subscales and the PCS significantly differed by non-cancer 
mortality. Participants who were alive had higher adjusted LSM compared to those who 
died: physical functioning (41.26 vs. 35.78, respectively), role physical (43.14 vs. 37.90, 
respectively), bodily pain (48.38 vs. 43.24, respectively), general health (45.07 vs. 41.03, 
respectively), and PCS (44.10 vs. 38.47, respectively, p=0.0002). The MCS did not 
significantly differ by non-cancer mortality (p=0.0504). 
 
Associations between HRQOL and All-Cause Mortality 
MCS/PCS and All-Cause Mortality 
 Results from multivariable Cox Proportional Hazard regression models assessing 
the association between PCS and MCS tertiles and the likelihood of dying of any cause 
can be found in Table 5. For all regression analyses, three models were analyzed. (See 
Methods Section, Statistical Analysis, Cox Proportional Hazards Regression for 
covariates included.) Compared to PCS T3, cases in PCS T1 had an almost four-fold 
increased risk of dying (HR: 3.80, 95% CI: 2.20, 6.54; p-trend=<0.0001) of any cause. 
After adjustment for baseline lifestyle and clinical characteristics, this association 
attenuated towards the null but remained significant (HR: 2.12, 95% CI: 1.18, 3.81; p-
trend=0.0053). Furthermore, when adjusted for HRQOL characteristics, the risk of dying 
of any causes did not change (HR: 2.17, 95% CI; 1.20, 3.90; p-trend=0.0061). No 
 Table 4. Comparisons of HRQOL SF-36 Component Summary Score Tertiles by Vital Status (N = 351) 
    Mortality Outcomes   
  
All-Cause    Breast Cancer-Specificb, e   Non-Cancerb 
 
 






Component Summary Scoresa (N = 351) (n = 252) (n = 99) Pd (n = 252) (n = 26) Pd (n = 252) (n = 64) Pd 
Mental Component Summary (MCS) 
            T1 






      n(%) 117 (33.3) 81 (32.2) 36 (36.4) 
 
120 (47.6) 14 (53.8) 
 
81 (32.2) 23 (35.9) 









(12.8-45.1)  (21.9-44.0) 
    T2 






      n(%) 117 (33.3) 82 (32.5) 35 (35.3) 
 
132 (52.4) 12 (46.2) 
 
82 (32.5) 24 (37.5) 





       (min-max)c  (45.2-54.4) (45.2-54.4) (45.2-54.4) 
 
(50.7-68.6)  (50.7-59.5) 
 
 (45.2-54.4) (45.2-54.4) 
    T3 










89 (35.3) 17 (26.6) 





       (min-max)c (54.4-68.6) (54.8-68.6)  (54.4-64.9) 
    
 (54.8-68.6) (54.4-64.9) 
 
           Physical Component Summary (PCS) 
            T1 






      n(%) 117 (33.3) 62 (24.6) 55 (55.5) 
 
109 (43.3) 13 (50.0) 
 
62 (24.6) 43 (67.2) 










    T2 






      n(%) 117 (33.3) 90 (35.7) 27 (27.3) 
 
143 (56.7) 13 (50.0) 
 
90 (35.7) 12 (18.8) 





       (min-max)c  (44.8-54.4) (44.8-54.4)  (44.8-54.1) 
 
(50.3-66.8)   (50.3-71.4) 
 
(44.8-54.4) (48.4-54.1) 
    T3 







    Mortality Outcomes   
  
All-Cause    Breast Cancer-Specificb, e   Non-Cancerb 
 
 






Component Summary Scoresa (N = 351) (n = 252) (n = 99) Pd (n = 252) (n = 26) Pd (n = 252) (n = 64) Pd 




100 (39.7) 9 (14.0) 





       (min-max)c (54.5-71.4) (54.6-66.8) (54.5-71.4) 
    
(54.6-66.8) (54.5-61.5) 
 a. Data collected at 36-month HRQOL follow-up assessment. 
b. Seventy-three participants were excluded from breast cancer-specific analyses and 35 participants were excluded from non-cancer analyses, both due to death by other causes. 
c. Min-max values may overlap due to rounding. 
d. Kruskal-Wallis tests comparing median values between alive and deceased. 










significant associations between MCS T1 vs. T3 and MCS T2 vs. T3 were observed; 
however all models were suggestive of an increased risk of dying of any cause. 
 
Table 5. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and All-Cause Mortality (N = 351) 
  Model 1c 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  36 (117) 1.36   (0.83, 2.23) 
    T2 (>45.12 & ≤54.40)    35 (117) 1.25   (0.76, 2.06) 
    T3 (>54.40) 28 (117) 1.00 (ref) 
 
    PCS 
  
<0.0001 
   T1 (≤ 44.75)  55 (117) 3.80   (2.20, 6.54) 
    T2 (>44.75 & ≤54.39)    27 (117) 1.67   (0.91, 3.07) 
    T3 (>54.39) 17 (117) 1.00 (ref) 
 




# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  36 (117) 1.51   (0.90, 2.53) 
    T2 (>45.12 & ≤54.40)    35 (117) 1.27   (0.77, 2.10) 
    T3 (>54.40) 28 (117) 1.00 (ref) 
 
    PCS 
  
0.0053 
   T1 (≤ 44.75)  55 (117) 2.12   (1.18, 3.81) 
    T2 (>44.75 & ≤54.39)    27 (117) 1.26   (0.68, 2.35) 
    T3 (>54.39) 17 (117) 1.00 (ref) 
 




# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  36 (117) 1.24   (0.72, 2.15) 
    T2 (>45.12 & ≤54.40)    35 (117) 1.26   (0.76, 2.10) 






# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 44.75)  55 (117) 2.17   (1.20, 3.90) 
    T2 (>44.75 & ≤54.39)    27 (117) 1.37   (0.74, 2.56) 
    T3 (>54.39) 17 (117) 1.00 (ref) 
 a. Data collected at 36-month HRQOL follow-up assessment.    
b. Frequency of # of events and total number within the category.      
  
c. Model 1, crude. 
   
d. Model 2 adjusted for baseline lifestyle and clinical characteristics. MCS: age, race/ethnicity, marital status, tumor stage,  
treatment type, and comorbidities; PCS: age, race/ethnicity, marital status, tumor stage, treatment type, and comorbidities. 
e. Model 3 adjusted for additional HRQOL characteristics in addition to Model 1. MCS: current lymphedema, perceived 
pessimism, number of types of confidants, bodily pain, and  perceived general health. PCS: current lymphedema,  
 
perceived pessimism, number of types of confidants, fear of recurrence. 
  
Abbreviations: HRQOL, Healthy-Related Quality of Life; HR, hazard ratio; CI, confidence interval; MCS, Mental Component  
Summary Score; PCS, Physical Component Summary Score.     
 
MCS/PCS and All-Cause Mortality by Race/Ethnicity 
Associations between MCS and PCS and all-cause mortality stratified by ethnicity is 
shown in Table 6. Among NHW women, compared to cases in PCS T3, those in PCS T1 
were twice as likely to die from any cause (HR: 2.13, 95% CI: 1.10, 4.12). The number of 
events was low in the Hispanic population, hence 95% CI were wide. Hispanics in PCS 
T1 had a four-fold increased risk of dying due to any cause compared to Hispanics in 
PCS T3 (HR: 4.05, 95% CI: 0.82, 20.05, but this association was not statistically 
significant. All associations between MCS and all-cause mortality we close to the null 
value and not significant when stratified by race/ethnicity. 
 
HRQOL Subscales and All-Cause Mortality 
Table 7 displays results from associations between HRQOL subscales and all-cause 
mortality. Compared to cases in T3, cases in T1 or T2 had an increased risk of death
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Table 6. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and All-Cause Mortality by Race/Ethnicity (N = 351) 
  Non-Hispanic White (n = 273) 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  28 (85) 1.06   (0.58, 1.92) 
    T2 (>45.12 & ≤54.40)    29 (90) 1.12   (0.64, 1.95) 
    T3 (>54.40) 26 (98) 1.00 (ref) 
 
    PCSd 
  
0.0151 
   T1 (≤ 44.75)  47 (90) 2.13   (1.10, 4.12) 
    T2 (>44.75 & ≤54.39)    22 (90) 1.29   (0.64, 2.58) 
    T3 (>54.39) 14 (93) 1.00 (ref) 
 
    
 
Hispanic (n = 78) 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  8 (32) 0.89   (0.12, 6.76) 
    T2 (>45.12 & ≤54.40)    6 (27) 0.47   (0.05, 4.42) 
    T3 (>54.40) 2 (19) 1.00 (ref) 
 
    PCSd 
  
0.0661 
   T1 (≤ 44.75)  8 (27) 4.05  (0.82, 20.05) 
    T2 (>44.75 & ≤54.39)    5 (27) 1.06   (0.21, 5.41) 
    T3 (>54.39) 3 (24) 1.00 (ref) 
 a. Data collected at 36-month HRQOL follow-up assessment.   
b. Frequency of # of events and total number within the category. 
  c. MCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
pessimism, number of types of confidants, fear of recurrence, bodily pain, and perceived general health. 
 d. PCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
pessimism, number of types of confidants, and fear of recurrence. 
Abbreviations: HRQOL, Health-Related Quality of Life; HR, hazard ratio; CI, confidence interval; MCS, Mental Component  
Summary Score; PCS, Physical Component Summary Score. 
 
due to any cause for the following MSC subscales: social functioning (T1, HR: 2.36, 95% 
CI: 1.51, 3.69), role emotional (T1, HR: 1.94, 95% CI: 1.25, 3.00), role emotional (T1, 
HR: 1.94, 95% CI: 1.25, 3.00), and vitality (T1, HR: 2.16, 95% CI: 1.25, 3.72; T2, HR: 
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2.11, 95% CI: 1.22, 3.65). Similarly, risk was increased among the following PCS 
subscales: physical functioning (T1, HR: 4.55, 95% CI: 2.52, 8.19; T2, HR: 2.11, 95% 
CI: 1.12, 3.96), role physical (T1, HR: 2.87, 95% CI: 1.75, 4.69; T2, HR: 2.34, 95% CI: 
1.36, 4.04), bodily pain (T1, HR: 2.18, 95% CI: 1.39, 3.43), and general health (T1, HR: 
1.63, 95% CI: 1.03, 2.59), compared to cases in T3. Additional adjustments in Model 2 
attenuated results for social functioning (T1, HR: 1.96, 95% CI: 1.23, 3.11), vitality (T1, 
HR: 2.00, 95% CI: 1.15, 3.49; T2, HR: 1.92, 95% CI: 1.10, 3.36), physical functioning 
(T1, HR: 2.65, 95% CI: 1.43, 4.92), role physical (T1, HR: 1.95, 95% CI: 1.17, 3.26; T2, 
HR: 1.97, 95% CI: 1.13, 3.44), and bodily pain (T1, HR: 1.74, 95% CI: 1.09, 2.77), 
compared to cases in T3. When adjusted for additional HRQOL characteristics (Model 
3), the increased risk of dying from any cause remained significant for the following 
subscales: vitality (T2, HR: 1.98, 95% CI: 1.12, 3.50) physical functioning (T1, HR: 2.58, 
95% CI: 1.38, 4.81), role physical (T1, HR: 1.94, 95% CI: 1.15, 3.25; T2, HR: 1.87, 95% 
CI: 1.06, 3.30) , and bodily pain (T1, HR: 1.87, 95% CI: 1.15, 3.05). 
 
Associations between HRQOL and Breast Cancer-Specific Mortality 
MCS/PCS and Breast Cancer-Specific Mortality 
 Associations between MCS/PCS and breast cancer-specific mortality are 
presented in Table 8. Compared to cases with high MCS or PCS scores, crude 
associations among cases with low MCS scores (HR: 1.40, 95% CI: 0.94, 2.09) or low 
PCS (HR: 1.09, 95% CI: 0.51, 2.36), were not statistically significant when comparing 
cases with high MCS or PCS scores, respectively. However, when adjusted for baseline 
lifestyle and clinical characteristics, associations between PCS and breast cancer-specific 
 Table 7. Associations between HRQOL SF-36 Subscale Scores and All-Cause Mortality (N = 351) 
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  




   
0.0046 
   
0.0593 
   T1 (≤ 40.86)  43 (98) 2.36   (1.51, 3.69) 
  
43 (98) 1.96   (1.23, 3.11) 
  
43 (98) 1.65   (0.98, 2.79) 
 
   T2 (>40.86 & ≤51.71)    21 (87) 1.18   (0.69, 2.03) 
  
21 (87) 1.35   (0.77, 2.35) 
  
21 (87) 1.32   (0.75, 2.31) 
 
   T3 (>51.71) 35 (166) 1.00 (ref) 
  
35 (166) 1.00 (ref) 
  





   
0.0567 
   
0.3318 
   T1 (≤ 34.28)  42 (113) 1.94   (1.25, 3.00) 
  
42 (113) 1.55   (0.99, 2.44) 
  
42 (113) 1.27   (0.78, 2.08) 
 
   T2 (>34.28 & ≤44.81)    18 (61) 1.40   (0.80, 2.44) 
  
18 (61) 1.28   (0.73, 2.25) 
  
18 (61) 1.18   (0.67, 2.11) 
 
   T3 (>44.81) 39 (177) 1.00 (ref) 
  
39 (177) 1.00 (ref) 
  





   
0.0201 
   
0.1627 
   T1 (≤ 44.33)  41 (121) 2.16   (1.25, 3.72) 
  
41 (121) 2.00   (1.15, 3.49) 
  
41 (121) 1.61   (0.88, 2.96) 
 
   T2 (>44.33 & ≤53.79)    39 (121) 2.11   (1.22, 3.65) 
  
39 (121) 1.92   (1.10, 3.36) 
  
39 (121) 1.98   (1.12, 3.50) 
 
   T3 (>53.79) 19 (109) 1.00 (ref) 
  
19 (109) 1.00 (ref) 
  





   
0.0543 
   
0.2250 
   T1 (≤ 43.63)  35 (108) 1.51   (0.93, 2.46) 
  
35 (108) 1.64   (0.99, 2.71) 
  
35 (108) 1.41   (0.81, 2.47) 
 
   T2 (>43.63 & ≤52.72)    34 (114) 1.32   (0.81, 2.16) 
  
34 (114) 1.37   (0.83, 2.25) 
  
34 (114) 1.34   (0.80, 2.25) 
 
   T3 (>52.72) 30 (129) 1.00 (ref) 
  
30 (129) 1.00 (ref) 
  





   
0.0012 
   
0.0023 
   T1 (≤ 43.17)  54 (118) 4.55   (2.52, 8.19) 
  
54 (118) 2.65   (1.43, 4.92) 
  
54 (118) 2.58   (1.38, 4.81) 
 
   T2 (>43.17 & ≤52.49)    31 (123) 2.11   (1.12, 3.96) 
  
31 (123) 1.73   (0.91, 3.28) 
  
31 (123) 1.82   (0.96, 3.46) 
 
   T3 (>52.49) 14 (110) 1.00 (ref) 
  
14 (110) 1.00 (ref) 
  





   
0.0131 
   
0.0146 
   T1 (≤ 35.03)  47 (116) 2.87   (1.75, 4.69) 
  
47 (116) 1.95   (1.17, 3.26) 
  
47 (116) 1.94   (1.15, 3.25) 
 
   T2 (>35.03 & ≤49.18)    28 (88) 2.34   (1.36, 4.04) 
  
28 (88) 1.97   (1.13, 3.44) 
  
28 (88) 1.87   (1.06, 3.30) 
 
   T3 (>49.18) 24 (147) 1.00 (ref) 
  
24 (147) 1.00 (ref) 
  
24 (147) 1.00 (ref) 
 
   
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  




   
0.0199 
   
0.0122 
   T1 (≤ 46.05)  44 (106) 2.18   (1.39, 3.43) 
  
44 (106) 1.74   (1.09, 2.77) 
  
44 (106) 1.87   (1.15, 3.05) 
 
   T2 (>46.05 & ≤54.19)    22 (81) 1.38   (0.80, 2.36) 
  
22 (81) 1.16   (0.68, 2.01) 
  
22 (81) 1.10   (0.63, 1.91) 
 
   T3 (>54.19) 33 (164) 1.00 (ref) 
  
33 (164) 1.00 (ref) 
  





   
0.1959 
   
0.3072 
   T1 (≤ 46.28)  45 (123) 1.63   (1.03, 2.59) 
  
45 (123) 1.33   (0.82, 2.16) 
  
45 (123) 1.25   (0.76, 2.05) 
 
   T2 (>46.28 & ≤54.64)    24 (104) 0.95   (0.55, 1.62) 
  
24 (104) 0.84   (0.48, 1.45) 
  
24 (104) 0.79   (0.45, 1.38) 
 
   T3 (>54.64) 30 (124) 1.00 (ref) 
  
30 (124) 1.00 (ref) 
  
30 (124) 1.00 (ref) 
 
a. Data collected at 36-month HRQOL follow-up assessment.    
b. Frequency of # of events and total number within the category.  
         
c. Model 1: crude. 
           
d. Model 2: adjusted for baseline lifestyle and clinical characteristics. Mental-related: age, race/ethnicity, marital status, tumor stage, treatment type, and comorbidities; Physical-related: age, race/ethnicity, 
 
marital status, tumor stage, treatment type, and comorbidities. 
         
e. Model 3: adjusted for additional HRQOL characteristics in addition to Model 1. Mental-related: current lymphedema, perceived pessimism, number of types of confidants, bodily pain, and perceived general health.  








Mortality were significantly increased (HR: 1.71, 95% CI: 1.10, 2.63), as well as the 
association adjusted for additional HRQOL characteristics (HR: 1.65, 95% CI: 1.06, 
2.58). 
 
Table 8. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and Breast Cancer-Specific Mortality (N = 351) 
  Model 1c 
 
# of Deaths 
  HRQOL Component Summary 




   Low (≤ 50.70)  14 (176) 1.40   (0.94, 2.09) 
    High (>50.70) 12 (175) 1.00 (ref) 
 
    PCS 
  
0.8239 
   Low (≤ 50.28)  13 (176) 1.09   (0.51, 2.36) 
    High (>50.28) 13 (175) 1.00 (ref) 
 




# of Deaths 
  HRQOL Component Summary 




   Low (≤ 50.70)  14 (176) 1.39   (0.93, 2.09) 
    High (>50.70) 12 (175) 1.00 (ref) 
 
    PCS 
  
0.0161 
   Low (≤ 50.28)  13 (176) 1.71   (1.10, 2.63) 
    High (>50.28) 13 (175) 1.00 (ref) 
 




# of Deaths 
  HRQOL Component Summary 




   Low (≤ 50.70)  14 (176) 1.24   (0.81, 1.91) 
    High (>50.70) 12 (175) 1.00 (ref) 
 
    PCS 
  
0.0283 
   Low (≤ 50.28)  13 (176) 1.65   (1.06, 2.58) 
    High (>50.28) 13 (175) 1.00 (ref) 
 a: Data collected at 36-month HRQOL follow-up assessment.    
b: frequency of # of events and total number within the category. 
  Model 1: crude. 
Model 2: adjusted for baseline lifestyle and clinical characteristics. MCS: age, race/ethnicity, marital status, tumor stage,  
treatment type; PCS: age, race/ethnicity, marital status, tumor stage, treatment type, and comorbidities. 
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Model 3: adjusted for additional HRQOL characteristics in addition to Model 1. MCS: current lymphedema, perceived 
pessimism, number of types of confidants, bodily pain, and  perceived general health. PCS: current lymphedema perceived   
pessimism, number of types of confidants, fear of recurrence; 
  Abbreviations: HRQOL, Health-Related Quality of Life; HR, hazard ratio; CI, confidence interval; MCS, Mental Component  
Summary Score; PCS, Physical Component Summary Score.     
 
 
MCS/PCS and Breast Cancer-Specific Mortality by Race/Ethnicity 
 The previous associations were stratified by ethnicity and is presented in Table 9. 
Among NHW women, cases in PCS T1 had a two-fold increased risk of dying of breast 
cancer compared to cases in PCS T3 (HR: 1.93, 95% CI: 1.16, 3.23). Hispanic women 
with low MCS scores had a four-fold increased risk of breast cancer-specific mortality 
compared to Hispanic women with high MCS scores (HR: 4.11, 95% CI: 0.80, 21.04), 
though the association was not statistically significant due to the small number of events. 
 
Table 9. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and Breast Cancer-Specific Mortality by Race/Ethnicity (N 
= 351) 
  Non-Hispanic White (n = 273) 
 
# of Deaths 
  HRQOL Component Summary 




   Low (≤ 50.70)  11 (131) 1.11   (0.70, 1.77) 
    High (>50.70) 10 (142) 1.00 (ref) 
 
    PCSd 
  
0.0115 
   Low (≤ 50.28)  11 (137) 1.93   (1.16, 3.23) 
    High (>50.28) 10 (136) 1.00 (ref) 
 
    
 
Hispanic (n = 78) 
 
# of Deaths 
  HRQOL Component Summary 
Scoresa  (Total)b HR (95% CI) P-value 
 
 
Hispanic (n = 78) 
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# of Deaths 
  HRQOL Component Summary 




   Low (≤ 50.70)  3 (45) 4.11  (0.80, 21.04) 
    High (>50.70) 2 (33) 1.00 (ref) 
 
    PCSd 
  
0.5070 
   Low (≤ 50.28)  2 (39) 1.51   (0.45, 5.05) 
    High (>50.28) 3 (39) 1.00 (ref) 
 a. Data collected at 36-month HRQOL follow-up assessment.    
b. Frequency of # of events and total number within the category. 
  c. MCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
pessimism, number of types of confidants, fear of recurrence, bodily pain, and perceived general health. 
d. PCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
pessimism, number of types of confidants, and fear of recurrence. 
Abbreviations: HRQOL, Health-Related Quality of Life; HR, hazard ratio; CI, confidence interval;  
MCS, Mental Component Summary Score; PCS, Physical Component Summary Score.   
 
HRQOL Subscales and Breast Cancer-Specific Mortality 
  Associations between each subscale and breast cancer-specific mortality are 
portrayed in Table 10. There were no significant associations. However, the crude risk of 
dying was somewhat stronger for certain physical subscales, such as cases with low 
physical functioning scores (HR: 1.56, 95% CI: 0.70, 3.51) compared to cases with high 
physical functioning scores. 
 
Associations between HRQOL and Non-Cancer Mortality 
MCS/PCS and Non-cancer Mortality 
 Table 11 presents associations between MCS and PCS component summary 
scores and risk of death due to non-cancer causes. Similar associations between HRQOL 
component summary scores and all-cause mortality, there were significant increased risks  
  
Table 10. Associations between HRQOL SF-36 Subscale Scores and Breast Cancer-Specific Mortality (N = 351) 
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  




   
0.9530 
   
0.7044 
   Low (≤ 57.13)  14 (185) 1.12   (0.52, 2.42) 
  
14 (185) 1.03   (0.46, 2.31) 
  
14 (185) 0.84   (0.35, 2.04) 
 
   High (>57.13) 12 (166) 1.00 (ref) 
  
12 (166) 1.00 (ref) 
  





   
0.7636 
   
0.9997 
   Low (≤ 55.34)  14 (174) 1.30   (0.60, 2.80) 
  
14 (174) 1.13   (0.51, 2.48) 
  
14 (174) 1.00   (0.43, 2.32) 
 
   High (>55.34) 12 (177) 1.00 (ref) 
  
12 (177) 1.00 (ref) 
  





   
0.8143 
   
0.9683 
   Low (≤ 51.42)  14 (183) 1.12   (0.52, 2.43) 
  
14 (183) 1.10   (0.49, 2.47) 
  
14 (183) 0.98   (0.39, 2.45) 
 
   High (>51.42) 12 (168) 1.00 (ref) 
  
12 (168) 1.00 (ref) 
  





   
0.5060 
   
0.7049 
   Low (≤ 52.71)  14 (177) 1.18   (0.55, 2.55) 
  
14 (177) 1.31   (0.59, 2.90) 
  
14 (177) 1.18   (0.50, 2.79) 
 
   High (>52.71) 12 (174) 1.00 (ref) 
  
12 (174) 1.00 (ref) 
  





   
0.6906 
   
0.7223 
   Low (≤ 50.15)  12 (166) 1.13   (0.52, 2.44) 
  
12 (166) 1.18   (0.52, 2.66) 
  
12 (166) 1.16   (0.51, 2.63) 
 
   High (>50.15) 14 (185) 1.00 (ref) 
  
14 (185) 1.00 (ref) 
  





   
0.5935 
   
0.6681 
   Low (≤ 56.24)  17 (204) 1.56   (0.70, 3.51) 
  
17 (204) 1.26   (0.54, 2.93) 
  
17 (204) 1.21   (0.51, 2.88) 
 
   High (>56.24) 9 (147) 1.00 (ref) 
  
9 (147) 1.00 (ref) 
  





   
0.9850 
   
0.9208 
   Low (≤ 54.18)  14 (184) 1.12   (0.52, 2.42) 
  
14 (184) 1.01   (0.46, 2.23) 
  
14 (184) 0.96   (0.43, 2.15) 
 
   High (>54.18) 12 (167) 1.00 (ref) 
  
12 (167) 1.00 (ref) 
  





   
0.9954 
   
0.6920 
   Low (≤ 52.29)  13 (188) 0.94   (0.43, 2.02) 
  
13 (188) 1.00   (0.45, 2.23) 
  
13 (188) 0.84   (0.25, 2.01) 
 
   High (>52.29) 13 (163) 1.00 (ref) 
  
13 (163) 1.00 (ref) 
  
13 (163) 1.00 (ref) 
 
   
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  
Subscale Scoresa (Total)b HR (95% CI) P   (Total)b HR (95% CI) P   (Total)b HR (95% CI) P 
a. Data collected at 36-month HRQOL follow-up assessment.    
b. Frequency of # of events and total number within the category.  
         
c. Model 1: crude. 
           
d. Model 2: adjusted for baseline lifestyle and clinical characteristics. Mental-related: age, race/ethnicity, marital status, tumor stage, treatment type, and comorbidities; Physical-related: age, race/ethnicity,  
 
marital status, tumor stage, treatment type, and comorbidities. 
         
e. Model 3: adjusted for additional HRQOL characteristics in addition to Model 1. Mental-related: current lymphedema, perceived pessimism, number of types of confidants, bodily pain, and perceived general health.  












of cases in PCS T1 compared to cases in PCS T3. Participants had a nearly six-fold 
increased risk of dying from non-cancer causes if they were in PCS T1 compared to PCS 
T3 (HR: 5.63, 95% CI: 2.74, 11.55; p-trend=<0.0001). This association was attenuated by 
56.48% when adjusted for baseline and clinical characteristics (Model 2) (HR: 2.45, 95% 
CI: 1.14, 5.26; p-trend=0.0025), and similar (percent change: 54.35%) when adjusted for 
additional HRQOL characteristics (HR: 2.57, 95% CI: 1.18, 5.61; p-trend=0.0023). No 
significant associations were discerned for MCS scores and non-cancer mortality. 
 
Table 11. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and Non-Cancer Mortality (N = 351) 
  Model 1c 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  23 (117) 1.45   (0.78, 2.72) 
    T2 (>45.12 & ≤54.40)    24 (117) 1.41   (0.76, 2.64) 
    T3 (>54.40) 17 (117) 1.00 (ref) 
 
    PCS 
  
<0.0001 
   T1 (≤ 44.75)  43 (117) 5.63   (2.74, 11.55) 
    T2 (>44.75 & ≤54.39)    12 (117) 1.41   (0.59, 3.35) 
    T3 (>54.39) 9 (117) 1.00 (ref) 
 




# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  23 (117) 1.63   (0.84, 3.14) 
    T2 (>45.12 & ≤54.40)    24 (117) 1.40   (0.74, 2.64) 
    T3 (>54.40) 17 (117) 1.00 (ref) 
 
    PCS 
  
0.0025 
   T1 (≤ 44.75)  43 (117) 2.45   (1.14, 5.27) 
    T2 (>44.75 & ≤54.39)    12 (117) 0.86   (0.35, 2.08) 
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# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  23 (117) 1.42   (0.70, 2.87) 
    T2 (>45.12 & ≤54.40)    24 (117) 1.49   (0.77, 2.87) 
    T3 (>54.40) 17 (117) 1.00 (ref) 
 
    PCS 
  
0.0023 
   T1 (≤ 44.75)  43 (117) 2.57   (1.18, 5.61) 
    T2 (>44.75 & ≤54.39)    12 (117) 0.94   (0.38, 2.32) 
    T3 (>54.39) 9 (117) 1.00 (ref) 
 a. Data collected at 36-month HRQOL follow-up assessment.  
b. frequency of # of events and total number within the category. 
  c. Model 1: crude. 
d. Model 2: adjusted for baseline lifestyle and clinical characteristics. MCS: age, race/ethnicity, marital status, tumor stage,  
treatment type; PCS: age, race/ethnicity, marital status, tumor stage, treatment type, and comorbidities. 
e. Model 3: adjusted for additional HRQOL characteristics in addition to Model 1. MCS: current lymphedema, perceived  
pessimism, number of types of confidants, bodily pain, and  perceived general health. PCS: current lymphedema, perceived  
pessimism, number of types of confidants, fear of recurrence; 
Abbreviations: HRQOL, Health-Related Quality of Life; HR, hazard ratio; CI, confidence interval; MCS, Mental Component  
Summary Score; PCS, Physical Component Summary Score. 
 
MCS/PCS and Non-Cancer Mortality by Race/Ethnicity 
 Stratification of the previous associations by race/ethnicity is presented in Table 
12. There were no significant associations, partly due to a low number of events in NHW 
and Hispanic women. Even though they were not significant, results were suggestive of 
increased risk of dying due to non-cancer causes for both NHW (HR: 2.08, 95% CI: 0.84, 
5.16) and Hispanic (HR: 2.62, 95% CI: 0.38, 18.30) women in PCS T1 vs. PCS T3. 
 
HRQOL Subscales and Non-Cancer Mortality 
 Associations between HRQOL subscale scores and non-cancer mortality is 
presented in Table 13. A significant increased risk of death due to non-cancer causes
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Table 12. Associations between HRQOL SF-36 Mental & Physical Component 
Summary Score Tertiles and Non-Cancer Mortality by Race/Ethnicity (N = 351) 
  Non-Hispanic White (n = 273) 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  18 (85) 1.20   (0.56, 2.54) 
    T2 (>45.12 & ≤54.40)    21 (90) 1.31   (0.64, 2.65) 
    T3 (>54.40) 16 (98) 1.00 (ref) 
 
    PCSd 
  
0.0116 
   T1 (≤ 44.75)  38 (90) 2.08   (0.84, 5.16) 
    T2 (>44.75 & ≤54.39)    10 (90) 0.69   (0.24, 1.96) 
    T3 (>54.39) 7 (93) 1.00 (ref) 
 
    
 
Hispanic (n = 78) 
 
# of Deaths 
  HRQOL Component Summary 




   T1 (≤ 45.12)  5 (32) 1.19  (0.07, 19.20) 
    T2 (>45.12 & ≤54.40)    3 (27) 1.33  (0.08, 22.14) 
    T3 (>54.40) 1 (19) 1.00 (ref) 
 
    PCSd 
  
0.2988 
   T1 (≤ 44.75)  5 (27) 2.62  (0.38, 18.30) 
    T2 (>44.75 & ≤54.39)    2 (27) 0.45   (0.04, 4.59) 
    T3 (>54.39) 2 (24) 1.00 (ref) 
 a. Data collected at 36-month HRQOL follow-up assessment.    
b. frequency of # of events and total number within the category. 
  c. MCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
optimism, number of types of confidants, fear of recurrence, bodily pain, and perceived general health. 
d. PCS Model adjusted for age, marital status, tumor stage, treatment type, comorbidities, current lymphedema, perceived  
optimism, number of types of confidants, and fear of recurrence. 
Abbreviations: HRQOL, Health-Related Quality of Life; HR, hazard ratio; CI, confidence interval; MCS, Mental Component  
Summary Score; PCS, Physical Component Summary Score.     
 
was observed for seven subscales. Specifically, cases in the physical functioning T1, had 
a 9-fold increased risk (T1, HR: 9.11, 95% CI: 3.58, 23.15) compared to cases in T3. 
Cases in T1 for social functioning (T1, HR: 3.27, 95% CI: 1.85, 5.77),  
  
Table 13. Associations between HRQOL SF-36 Subscale Scores and Non-Cancer Mortality (N = 351) 
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  




   
0.0010 
   
0.0037 
   T1 (≤ 40.86)  32 (98) 3.27   (1.85, 5.77) 
  
32 (98) 2.66   (1.48, 4.79) 
  
32 (98) 2.62   (1.36, 5.05) 
 
   T2 (>40.86 & ≤51.71)    13 (87) 1.35   (0.67, 2.74) 
  
13 (87) 1.64   (0.79, 3.38) 
  
13 (87) 1.84   (0.88, 3.85) 
 
   T3 (>51.71) 19 (166) 1.00 (ref) 
  
19 (166) 1.00 (ref) 
  





   
0.0802 
   
0.1935 
   T1 (≤ 34.28)  29 (113) 2.20   (1.28, 3.78) 
  
29 (113) 1.67   (0.94, 2.95) 
  
29 (113) 1.50   (0.81, 2.78) 
 
   T2 (>34.28 & ≤44.81)    11 (61) 1.39   (0.68, 2.84) 
  
11 (61) 1.32   (0.64, 2.72) 
  
11 (61) 1.31   (0.62, 2.74) 
 
   T3 (>44.81) 24 (177) 1.00 (ref) 
  
24 (177) 1.00 (ref) 
  





   
0.0098 
   
0.0427 
   T1 (≤ 44.33)  31 (121) 2.61   (1.34, 5.09) 
  
31 (121) 2.41   (1.22, 4.77) 
  
31 (121) 2.18   (1.04, 4.58) 
 
   T2 (>44.33 & ≤53.79)    21 (121) 1.84   (0.90, 3.74) 
  
21 (121) 1.70   (0.82, 3.49) 
  
21 (121) 1.81   (0.86, 3.80) 
 
   T3 (>53.79) 12 (109) 1.00 (ref) 
  
12 (109) 1.00 (ref) 
  





   
0.0631 
   
0.1205 
   T1 (≤ 43.63)  24 (108) 1.66   (0.91, 3.03) 
  
24 (108) 1.81   (0.97, 3.38) 
  
24 (108) 1.73   (0.86, 3.46) 
 
   T2 (>43.63 & ≤52.72)    21 (114) 1.30   (0.70, 2.43) 
  
21 (114) 1.29   (0.69, 2.42) 
  
21 (114) 1.41   (0.73, 2.74) 
 
   T3 (>52.72) 19 (129) 1.00 (ref) 
  
19 (129) 1.00 (ref) 
  





   
0.0019 
   
0.0019 
   T1 (≤ 43.17)  38 (118) 9.11   (3.58, 23.2) 
  
38 (118) 4.36  (1.68, 11.34) 
  
38 (118) 4.43   (1.69, 11.7) 
 
   T2 (>43.17 & ≤52.49)    21 (123) 3.98   (1.50, 10.6) 
  
21 (123) 3.16   (1.19, 8.43) 
  
21 (123) 3.17   (1.17, 8.60) 
 
   T3 (>52.49) 5 (110) 1.00 (ref) 
  
5 (110) 1.00 (ref) 
  





   
0.0031 
   
0.0033 
   T1 (≤ 35.03)  37 (116) 3.64   (2.00, 6.64) 
  
37 (116) 2.47   (1.33, 4.58) 
  
37 (116) 2.51   (1.34, 4.71) 
 
   T2 (>35.03 & ≤49.18)    12 (88) 1.64   (0.77, 3.50) 
  
12 (88) 1.48   (0.68, 3.23) 
  
12 (88) 1.49   (0.67, 3.29) 
 
   T3 (>49.18) 15 (147) 1.00 (ref) 
  
15 (147) 1.00 (ref) 
  
15 (147) 1.00 (ref) 
 
  
  Model 1c   Model 2d   Model 3e 
 
Deaths 
   
Deaths 
   
Deaths 
  




   
0.0026 
   
0.0014 
   T1 (≤ 46.05)  34 (106) 2.91   (1.66, 5.10) 
  
34 (106) 2.33   (1.32, 4.12) 
  
34 (106) 2.71   (1.46, 5.03) 
 
   T2 (>46.05 & ≤54.19)    11 (81) 1.18   (0.56, 2.49) 
  
11 (81) 0.94   (0.44, 1.99) 
  
11 (81) 0.94   (0.44, 2.00) 
 
   T3 (>54.19) 19 (164) 1.00 (ref) 
  
19 (164) 1.00 (ref) 
  





   
0.0125 
   
0.0146 
   T1 (≤ 46.28)  34 (123) 2.31   (1.27, 4.18) 
  
34 (123) 2.01   (1.11, 3.66) 
  
34 (123) 2.04   (1.11, 3.76) 
 
   T2 (>46.28 & ≤54.64)    14 (104) 1.03   (0.50, 2.11) 
  
14 (104) 0.92   (0.45, 1.89) 
  
14 (104) 0.97   (0.47, 2.01) 
 
   T3 (>54.64) 16 (124) 1.00 (ref) 
  
16 (124) 1.00 (ref) 
  
16 (124) 1.00 (ref) 
 
a. Data collected at 36-month HRQOL follow-up assessment.       
b. Frequency of # of events and total number within the category. 
         
c. Model 1: crude. 
d. Model 2: adjusted for baseline lifestyle and clinical characteristics. Mental-related: age, race/ethnicity, marital status, tumor stage, treatment type, and age, race/ethnicity, comorbidities; Physical-related:  
marital status, tumor stage, and treatment type. 
e. Model 3: adjusted for additional HRQOL characteristics in addition to Model 1. Mental-related: current lymphedema, perceived optimism number of types of confidants, bodily pain, and perceived general health.  








role emotional (T1, HR: 2.20, 95% CI: 1.28, 3.78), vitality (T1, HR: 2.61, 95% CI: 1.34, 
3.78), role physical (T1, HR: 3.64, 95% CI: 2.00, 6.64), bodily pain (T1, HR: 2.91, 95% 
CI: 1.66, 5.10), and general health (T1, HR: 2.31, 95% CI: 1.27, 4.18) were at 
significantly increased risk of dying due to non-cancer causes compared to cases in T3. 
 When adjusted for baseline lifestyle and clinical characteristics, all of the 
associations were attenuated for social functioning (T1, HR: 2.66, 95% CI: 1.48, 4.79), 
vitality (T1, HR: 2.41, 95% CI: 1.22, 4.77), physical functioning (T1, HR: 4.36, 95% CI: 
1.68, 11.34), role physical (T1, HR: 2.47, 95% CI: 1.33, 4.58), bodily pain (T1, HR: 2.33, 
95% CI: 1.32, 4.12), and general health (T1, HR: 2.01, 95% CI: 1.11, 3.66). 
 When further adjusted for additional HRQOL characteristics, subscales 
significant in Model 2 were also significant in Model 3. Specifically, cases in T1 or T2 
compared to T3 for physical functioning had nearly 4.5 times the increased risk of dying 
(T1, HR: 4.43, 95% CI: 1.69, 11.65; T2, HR: 3.17, 95% CI: 1.17, 8.60). Cases in the T1 
of all physical subscales (physical functioning, role physical, bodily pain, and general 
health) had at least a two-fold increased risk of dying compared to cases in T3. 
 
Kaplan-Meier Curves and Survival Rates 
 Seventeen survival curves were constructed to plot the distribution of survival 
rates by all-cause, breast cancer-specific, and non-cancer mortality for the entire study 
population. Additional curves were constructed stratified by race/ethnicity for all-cause 
and non-cancer mortality only because of sample size concerns. In the total population, 
the five-year survival rate was 89.4%, and 77.7% for 10-year survival, when considering 
death due to any cause. 
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For all-cause mortality, survival curves significantly differed by PCS tertiles 
(p=<0.0001); however, survival curves did not by MCS tertiles (p=0.4643). The five-year 
survival rate for PCS and all participants was higher than 75%. When approaching ten 
years, cases in T1 had approximately a 60% survival rate compared to approximately 
90% for cases in T3. Rates continued to decrease for T1 cases, yet remained constant for 
T2 and T3. Survival rates depicting PCS and non-cancer mortality told a similar story. 
However, participants in T1 had a much worse survival rate compared to participants in 
T2 and T3. Curves displaying rates for breast cancer-specific mortality did not reveal any 
significant differences. Figures 3 and 4 display survival curves for all-cause mortality and 
MCS/PCS. 
When stratifying PCS for all-cause and non-cancer by race/ethnicity, the pattern 
for differences in PCS by tertiles was weighted by the higher number of NHW cases in 
relation to Hispanic cases. These curves are displayed in Figures 5, 6, 7, and 8. For all-
cause mortality by race/ethnicity, the survival curves significantly differed by PCS 
tertiles (p=<0.0001), and the same association can be found for non-cancer mortality 
(p=<0.0001). However, this was not true for Hispanic cases for PCS tertiles and all-cause 
mortality (p=0.2415) and PCS tertiles and non-cancer mortality (p=0.3032).At about 11 
years post-diagnosis, NHW cases in T1 had a 50% survival rate compared to NHW cases 
in T3 (~90%). For non-cancer outcomes, the survival rates were similar by tertile. The 
remaining survival curves are presented in the Appendices section (P-Z). 
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Figure 3. Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for PCS 
Tertiles. 
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Figure 4. Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for MCS 
Tertiles. 
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Figure 5. Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for PCS 
Tertiles by Race/Ethnicity (NHW Women). 
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Figure 6. Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for PCS 
Tertiles by Race/Ethnicity (Hispanic Women). 
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Figure 7. Kaplan-Meier Curves: (Non-Cancer) Survival Probability Estimates for PCS 
Tertiles by Race/Ethnicity (NHW Women). 
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Figure 8. Kaplan-Meier Curves: (Non-Cancer) Survival Probability Estimates for PCS 






















To our knowledge, this is the first study to evaluate physical (PCS) and mental 
(MCS) component summary scores from the SF-36 instrument as a predictor of breast 
cancer mortality among NHW and Hispanic women. A few other studies evaluating 
HRQOL via the SF-36 as a predictor of breast cancer prognosis will be discussed later 
(87-89). 
Results from the present study indicate that the physical-related items of HRQOL 
among women with invasive breast cancer approximately 3-years post-diagnosis were 
statistically significantly associated with a decreased risk of all-cause, breast cancer-
specific, and non-cancer mortality. Furthermore, these associations were demonstrated in 
NHW women for all-cause and breast cancer-specific mortality when stratifying the 
association by ethnicity; however, the association was not observed for non-cancer 
mortality. There were no significant associations between MCS and mortality outcomes. 
This finding is in accordance with other studies that have reported no association between 
overall mental/psychosocial HRQOL and breast cancer prognosis (42, 50, 78, 89-92, 94). 
Although our results did not indicate evidence of an association between the MCS 
summary score and mortality there were associations present for two subscales (social 
functioning and vitality). 
A comparison between these study findings and those reported in the literature is 
hindered due to differences in study design, subject characteristics, and the HRQOL 
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measures. This study controlled for demographic, clinical, and HRQOL prognostic 
factors that were found to influence the measure of effect by 10% or more. 
Distinguishing the impact of specific variables based on when they were evaluated is 
vital to consider. The 36-month follow-up consisted of many of the self-reported 
variables pertaining to mental/psychosocial or physical HRQOL, in addition to SF-36-
related assessments. Ultimately, this study found that women who reported their HRQOL 
negatively had an increased risk of death.  
 
Mental/Psychosocial HRQOL 
Studies have evaluated some form of mental/psychosocial HRQOL as a predictor 
of survival or mortality in women diagnosed with breast cancer. This analysis found no 
evidence of association for overall mental/psychosocial HRQOL with mortality, which is 
consistent with findings reported by previous studies (42, 78-81, 89-92). However, in 
keeping with several studies (13, 14, 42, 43, 83, 87, 95) there was evidence of an 
association between eight mental/psychosocial-related subscales and mortality. In 
contrast to the finding of this study, Dumontier et al. reported that better mental health 
was associated with lower mortality in a study testing HRQOL in a predictive model for 
mortality, utilizing the Mental Health Index (MHI-5) from the SF-36 and 10-year follow-
up data for women diagnosed with breast cancer (87). These results were strengthened 
with the addition of other HRQOL measures (physical health, mental health, social 
support) (87). These results suggest prognostic relevancy between HRQOL measures and 
breast cancer outcomes. Saquib et al. discovered that the mental health summary score in 
their sample was marginally associated with breast cancer recurrence and all-cause 
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mortality when alone, but the associations attenuated towards the null when evaluated via 
a multivariable model, similar to our study (89). 
Seven studies reported significant associations between aspects of 
mental/psychosocial HRQOL and breast cancer survival or mortality (13, 14, 42, 43, 83, 
87, 95). Goodwin et al. was similar in study size (N=397) and measured HRQOL post-
diagnosis via the European Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire-Core 30 (EORTC QLQ-C30), as well as other measures of 
HRQOL factors, with a median of 5.8 years of follow-up. Even though four significant 
associations were found between mental/psychosocial HRQOL and distant disease-free 
survival (DDFS) or overall survival, the researchers reported that seven significant 
associations would’ve been generated due to chance. They found that women with higher 
cognitive functioning had lower DDFS; opposite of what was hypothesized, perhaps 
bolstering their suggestion of deeming the associations inconclusive due to random error. 
Similarly, although Phillips et al., a quite larger study (N=708), discovered a connection 
between anxious preoccupation and worse DDFS and OS, there were no significant 
associations in the adjusted models, and the aforementioned report was driven more by 
the confounding of poor prognostic factors rather than a direct relationship (78). The two 
studies used some of the same surveys to assess mental/psychosocial health (42, 78). 
Many studies found that out of a variety of evaluated mental/psychosocial 
prognostic factors, a couple showed significant relationships with breast cancer 
outcomes. Watson et al. reported that women with higher scores of 
helplessness/hopelessness were at risk of lower disease-free survival (14). Participants 
were evaluated via the Mental Adjustment to Cancer Scale (MAC) and for depression 
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(HADS) within 4-12 weeks post-diagnosis. Unlike our analysis, these 
mental/psychosocial factors were assessed immediately after diagnoses, potentially 
impacting the emotional response to cancer diagnoses, especially in a study evaluating 
early emotional response on survival. Conversely, participants in our study, who might 
have undergone treatment, could have reported emotional responses to their health 
differently if HRQOL evaluations were administered at baseline. De Aguiar et al. used 
the EORTC QLQ-C30 in a similar sized sample (N=549) and reported lower survival in 
participants who had worse future perspective (95). Though, helplessness/hopelessness 
and future perspective are unrelated, they share commonalities, and further research 
should explore the idea of the prognostic relevancy behind perceptions of disease burden.  
Groenvold et al. reported associations between greater emotional functioning and 
better recurrence-free survival and overall survival, using the EORTC QLQ-C30 for 
HRQOL measures (13). The researchers claimed that their study is one of the first to find 
significant relationships between self-rated psychological factors and breast cancer 
recurrence and death, contrasting a handful of other studies previously cited (13). 
Conversely, this study found no associations between role emotional of the SF-36 and 
mortality. Even then, it’s tough to speculate whether the two findings are in any way 
analogous, given that HRQOL was measured contrarily and distributed at different 
survivorship periods. 
Among the aspects of mental/psychosocial HRQOL, social-related paradigms 
seemed to have significant relationships with breast cancer prognosis. Lehto et al. 
suggested that shorter survival was predicted by perceived support, though their 
classification of support as a covariate was created on the basis of hypothetical support 
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rather than support actually received by participants (43). Utilizing the General Quality of 
Life Inventory-74, Epplein et al. found that women with higher levels of social well-
being had lower risks of mortality and breast cancer recurrence (83). This association is 
similar to ours when comparing it to the effects of levels of social functioning and all-
cause and non-cancer mortality. In our study, participants in  T1 of social functioning 
subscale had a 2.6 times increased likelihood of dying of non-cancer causes in the fully-
adjusted model. Similar associations were found for all-cause mortality, but significance 
was lost when the relationship was adjusted for additional HRQOL-related 
characteristics. Another support-related variable, numbers of types of confidants, was 
adjusted for in the final models to control for social support mainly in associations 
between component summary scores and mortality. The social functioning subscale isn’t 
built to include this specific concept, so controlling for it is appropriate. 
The effects seen in the Epplein et al. study and ours share similarities in 
methodology and sample. Although the Epplein et al. study was far larger (N=2,230) 
(83), the sample contained in-situ cases and a predominant amount of Chinese women, 
whereas ours was composed of a mix of NHW and Hispanic women. They also 
categorized their HRQOL predictor variables into tertiles based on the distribution of 
their population sample (83). Epplein et al. evaluated HRQOL at baseline and 36-month 
follow-up, contrasting our study only assessing HRQOL-related variables during a 
follow-up around the same period post-diagnosis. However, Epplein et al. found no 
significant results between any HRQOL predictors and breast cancer survival or 
recurrence at 36-month follow-up (83). Additionally, as stated before, the validity of 
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comparisons of the two studies originates from how social support and social functioning 
is classified, defined, and measured. 
A variety of factors play a role in the relationship between mental/psychosocial 
HRQOL and breast cancer prognosis. Among studies evaluating many of these factors, a 
large proportion of them find at least one significant association between a 
mental/psychosocial-related predictor and a breast cancer outcome (83). Although, as 
discussed above, some of these associations were calculated by chance (42), posing a 
problem with analyses evaluating many variables at once. However, the nature of 
HRQOL evolves from paradigms of multiple factors influencing health. Considering 
many aspects of health is essential but can result in analysis containing an oversaturated 
amount of variables when validated instruments encapsulating HRQOL may be more 
efficient. The relationship between overall PCS) and mortality remained consistent for all 
three mortality outcomes. When evaluating similar relationships between each physical-
related subscale and mortality, several remained significant in fully-adjusted models.  
 
Physical HRQOL 
It has been suggested that poorer physical HRQOL is predictive of poorer breast 
cancer-related outcomes (50, 79-81, 87-94). In this study, the relationship between 
physical-related HRQOL and all-cause, breast cancer-specific, and non-cancer mortality 
were significant in fully-adjusted models. In fact, the association slightly strengthened for 
all-cause and non-cancer outcomes, and slightly attenuated for breast cancer-specific 
mortality. 
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Some researchers evaluated the prognostic value of physical-related factors, such 
as fatigue and pain (13, 91), inflammation (94), nausea/vomiting (79), and appetite loss 
(93) after a diagnosis of breast cancer. Instead of evaluating these factors as separate 
predictors, they were evaluated all as potential confounders and retained some in the final 
models (e.g., fatigue and pain) to account for their magnitudes of effects. Some of these 
factors may serve a proxy of reporting lower physical HRQOL.  
 Three studies have used SF-36 as the primary HRQOL measurement in breast 
cancer survivor populations (87-89). Saquib et al. and Marinac et al. both analyzed data 
from the Women’s Healthy Eating and Living (WHEL) Study; both studies reporting 
analytic sample sizes near 3,000 participants (88, 89), majority NHW women, with a 
mean survival time of 7.3 years) (105). However, the two studies that utilized data from 
WHEL did adjust their regression models for race/ethnicity. (88, 89). 
Saquib et al. reported that higher PCS had protective effects against recurrence 
and all-cause mortality (89). The researchers categorized physical health into quintiles by 
overall score (0-100), the higher the score, the better HRQOL (89). Even though the 
categorization of HRQOL differed, the takeaway message remained the same. Our 
findings parallel their study by comparing higher levels (healthier) of HRQOL to lower 
levels. Marinac et al. found that lower self-reported physical functioning was 
significantly associated with all-cause and breast cancer-specific mortality (88).  
 
The Role of Chronic Stress and Inflammation 
Marinac et al. suggested that inflammation might be partly responsible for the 
increased risk of mortality in women who report lower physical functioning 
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characteristics. In their study, BMI, physical activity, and C-reactive protein were all 
related to physical functioning. Extant research has suggested that stress and the social 
environment can exacerbate inflammatory responses to diseases (109), and inflammation 
is partly regulated by cortisol levels, specifically when stress is high, causing erratic 
increases in inflammation that may promote chronic disease (109, 143). Consequently, 
chronic stress is directly associated with cancer pathogenesis (111).  
Stress and inflammation are full-body responses to internal and external factors. 
When evaluating self-reported data on HRQOL, it is important to consider stress and 
chronic inflammation as factors that can influence response bias to health-related 
questions as well as mediate associations between health-related predictors and disease 
outcomes. Additionally, weighing stress responses may be helpful, especially if they are 
associated with higher levels of inflammation. In a future study similar to ours where 
mental/psychosocial and physical HRQOL are evaluated, it would be interesting to see 
the effects of HRQOL as a whole (e.g., mental/psychosocial & physical combined) on 
breast cancer prognosis. Theoretically, since inflammation is associated with poorer 
HRQOL (94) and stress (143), then psychosocial factors that influence stress may be 
indicative of inflammatory responses that may worsen physical well-being as well. 
However, our measure of HRQOL does not account for an overall health status.. 
Nevertheless, the idea stands that levels of mental/psychosocial and physical HRQOL 
may be related via biological pathways. 
Understanding why participants are answering HRQOL-related parameters as 
poor compared to healthy is important. Cancer diagnoses can elicit stress responses 
(111); therefore, it is essential to consider timing of HRQOL assessment during the post-
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diagnosis period and whether assessment occurs pre- or post-treatment. Lower levels of 
HRQOL are indicative of lower overall well-being and worse survivorship in women 
previously diagnosed with breast cancer. Research surrounding these domains is vital in 
improving survivorship and understanding what may be responsible for low HRQOL and 
poorer prognosis. 
 
HRQOL Evaluated in Other HEAL Studies 
HRQOL has been evaluated in this study population previously; however, none of 
the previous studies have assessed HRQOL as a predictor of mortality (124, 149, 150, 
166-173). The HEAL study was originally designed to examine the relationship between 
anthropometrics, body composition, lifestyle factors, hormone measurements, clinical 
characteristics, and other prognostic factors with early stage breast cancer (148).  
Although the majority of previous HEAL HRQOL-related analyses have utilized 
data from all three study sites (New Mexico, Los Angeles County, Western Washington) 
(124, 149, 150, 167, 168, 170-173), this analysis is based on New Mexico site data only, 
which accounts for the majority of Hispanic subjects (148). 
In one study, Meeske et al. found that correlates of fatigue were pain, cognitive 
problems, physical inactivity, weight gain, and antidepressant use (150). Additionally, 
fatigue and poorer HRQOL were associated (150). In our study, fatigue was analyzed as a 
confounder. In the univariate models to assess individual effects of covariates on the 
effect of HRQOL on mortality, fatigue was not significantly associated with MCS (had 
no effective change between the crude model and additional models) and for all-cause, 
breast cancer-specific, and non-cancer mortality, and thus was not retained in the 
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multivariable models. For PCS, fatigue was not evaluated since questions that compose 
the PCS contain aspects of fatigue. 
Wayne et al. discovered that diet quality was associated with HRQOL, 
specifically for 3 of the 4 mental subscales and 2 of the 4 physical subscales (124). 
Though, our study didn’t include diet quality, the results of the aforementioned study 
suggested that factors impacting HRQOL may also effect breast cancer prognosis through 
mediation. Another HEAL study concluded that better physical activity was associated 
with better physical HRQOL (166). Additionally, in another HEAL analysis, lack of 
physical activity and weight gain was associated with risk for pain (149). Unlike fatigue, 
bodily pain was included in multivariable analyses for MCS and all-cause and non-cancer 
mortality, attenuating the crude associations. When evaluating MCS and all-cause 
mortality, pain altered the effects by 38.2% (T1) and 24.0% (T2). This may suggest that 
self-reported pain plays a significant role in the relationship between mental/psychosocial 
HRQOL and mortality. An issue with self-reported pain falls in its subjectivity—
participants with low mental HRQOL may be more likely to report higher levels of pain 
related to mental/psychosocial factors rather than physical ones (or vice versa)—and this 
phenomena is damaging if pain-related assessments presume to be homologous with 
physiological experiences. 
Studies utilizing the HEAL data have found significant prognostic differences 
between ethnicities (167, 168, 173, 174). Although differences in ethnicity (NHW vs. 
Hispanic) weren’t of main focus in this study, the analyses between HRQOL and 
mortality were stratified by ethnicity to see if a single group could explain some of the 
survival disparity. Since the sample size of Hispanics in the present analysis is low 
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(n=78), including only five deaths, it is difficult to determine whether the present findings 
are due to chance.  
Moreover, when stratifying associations between MCS/PCS and mortality by 
ethnicity, NHW women with poorer physical HRQOL were twice as likely to die  
compared to NHW women with better physical HRQOL. While a similar relationship 
was observed for NHW and breast cancer-specific and non-cancer mortality, these 
associations were not significant. A similar phenomenon was discerned for Hispanic 
women in the all-cause mortality model. Hispanic women with worse PCS were four 
times as likely to die by all-causes compared to Hispanics with better PCS, though this 
association wasn’t significant (HR: 4.05, 95% CI: 0.82, 20.05).  
 
Strengths and Limitations 
This study has several strengths. It utilized a variety of validated and standardized 
measures for HRQOL and collected data on a number of self-reported HRQOL-related 
covariates, which allowed for an evaluation of potential confounders (35). Additionally, 
clinical data were abstracted from medical records and from the SEER registry and used 
for further evaluation of confounding. Deaths were confirmed via the National Death 
Index, a reliable approach to validating consistent death counts and survival time.  
Results were based on a median of 11 years of survival time, which permitted an 
assessment of long-term survival in relation to HRQOL.  
This study has another strength. Since three assessments were of interest, I was 
able to utilize variables from three time points (baseline, 24-month follow-up, HRQOL 
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assessment). Some of these variables, such as demographics, were consistently available 
at each point of assessment. 
Another strength includes the model building process. Accounting for the joint 
effects of significant covariates created the most parsimonious models. This study also 
utilized additional HRQOL-related variables that were not included in the construction of 
the SF-36. If variables were included in the construction of the MCS, and they held 
relevancy as a confounder in the model building process, then they were adjusted for in 
the PCS model, and vice versa. For example, bodily pain was controlled for in 
associations between MCS and mortality, but not PCS and mortality. This was calculated 
to consider how much of the effect is impacted by physical-related factors in 
mental/psychosocial models and vice versa. 
Utilizing cases with only invasive breast cancer is another strength. Women with 
in-situ breast cancer experience an approximate 95% survival rate after five years (1). 
Thus, it is suggested that these women may undergo different survivorship experiences 
compared to women diagnosed with higher stages of disease.  
Our analysis has several limitations that require thorough consideration. HRQOL 
was evaluated 36-months post-diagnosis, and cases who died prior to the assessment may 
or may not of had a poorer HRQOL. Associations between HRQOL and breast cancer 
mortality may be underestimated in comparison to findings derived from utilizing a 
HRQOL assessment at baseline. Additionally, one reason why the data has limited breast 
cancer-specific mortality events is because 63.5% (n=47) of women who died of breast 
cancer died before the HRQOL assessment was conducted, and this can create a survival 
bias.  
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Furthermore, data was lacking for of multiple HRQOL measures over time. 
Measuring HRQOL at baseline and 24-month assessment, in addition to 36-months post-
diagnosis, would have presented opportunities to clarify uncertainty behind causal 
pathways, such as unveiling what factors are correlated with poorer HRQOL during each 
follow-up. More opportunities to evaluate changes of HRQOL and its impact on breast 
cancer prognosis would be valuable. Also, I would have had the ability to measure these 
associations directly after diagnosis in comparison to 36-months post-diagnosis, 
considering factors such as treatment and the effects of HRQOL on short-term breast 
cancer survival.  
It was difficult to detect the presence of an effect due to small sample size and too 
few deaths. However, the evaluation of this underrepresented population has added 
relevant data to the overall literature. Another limitation includes the fact that I may have 
missed residual confounding by unmeasured measures (e.g., inflammation, stress). 
Nevertheless, this research question needs to be tested on other populations, especially 
ones with ethnic demographics.  
This study may not indicate a direct causal relationship between HRQOL 
predictors and breast cancer mortality, but as suggested, the current associations may be 
representative of additional unmeasured prognostic factors. Physical HRQOL was 
predictive of all mortality outcomes, and NHW women drove the effect. However, 
associations with MCS were inconsistent and only remained significant in relationships 
between few individual subscales and mortality outcomes. Conversely, these findings 
may elucidate specific relationships between aspects of mental/psychosocial HRQOL and 
breast cancer prognosis, since a majority of studies evaluating similar associations find at 
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least one association between a mental/psychosocial factor and breast cancer prognosis 




 In summary, this analysis has demonstrated a significant prognostic value 
between items include in a validated HRQOL instrument (mental/psychosocial, physical), 
and breast cancer-specific mortality in a unique population of women diagnosed with 
invasive breast cancer. This study also revealed significant associations between HRQOL 
and mortality in breast cancer survivors by ethnicity. This study appears to be the first to 
evaluate HRQOL as a predictor of mortality in a population of ethnically diverse breast 
cancer survivors. Although based on a small sample, study findings suggest that the 
association between HRQOL and mortality should be addressed in future research, 
specifically among Hispanic women with breast cancer. Additional research in a larger 
sample of minority populations will bolster a better understanding of HRQOL as a 
predictor of breast cancer prognosis (survival, mortality, recurrence). Such research may 
provide important data for interventions designed to improve overall well-being among  
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 Appendix A. Studies Evaluating Health-Related Quality of Life (HRQOL) as a Predictor of Breast Cancer Prognosis 
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 





VI (n=1,262) and 
Trial VII (n=1,008) 
at baseline; (n=869) 
of Trial VI and 
(n=742) of Trial VII 
at 18 months. At 1 
month after relapse: 
(n=203) Trial VI 
and (n=149) Trial 
VII. At 6 months 
after relapse: 
(n=219) Trial VI 





for 6 years after 
randomization or 







survival Not provided 
Six months after relapse: 
Better physical well-being in 
premenopausal women (HR: 
0.91, p-value: 0.03) and 
postmenopausal women (HR: 
0.85, p-value: <0.0001) 
predicted longer survival. 
Mood (HR: 0.88, p-value: 
0.002) and coping (HR: 0.85, 
p-value: 0.0001) predicted 




et al., 2000 (n=19)  
















Physical elements of quality of 
life predicted survival, but 
psychosocial elements did not. 
3 
Luoma et 









6 days to 29 
months for 
both) 
More severe fatigue (HR: 1.48, 
95% CI: 1.13-1.93, p-value: 
0.0044) and pain (HR: 1.46, 
95% CI: 1.10-1.94, p-value: 
0.008) were associated with 
shorter overall survival. 
  
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 









before treatment) Overall survival Not provided 
Inflammatory breast cancer 
was significantly associated 
with worse survival (HR: 1.38, 




al., 2004 (n=397)  
EORTC QLQ-C30; 
Profile of Mood 
States (POMS); Total 
Mood Disturbance 
(TMD) score; Impact 
of Events Scale (IES); 
Mental Adjustment to 












(mean: 57.4, SD: 






(OS) Not provided 
Cognitive functioning (HR: 
1.76, p-value: 0.04) of distant 
recurrence (or reduced distant 
disease-free survival); 
Domestic environment (HR: 
1.48, p-value: 0.049) of overall 
survival; Avoidance (HR: 0.48, 




al., 2005 (n=578) 
Hospital Anxiety and 
Depression Scale 
(HADS); Mental 










overall survival Not provided 
After 10-years, women with 
higher 
helplessness/hopelessness 
scores had increased risk of 
breast cancer death or relapse 
(HR: 1.53; 95% CI: 1.11-2.11) 
   
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 
Measures Survival Time Findings 
7 
Lehto et al., 
2006 (n=102) 
Chronic Strains 







diagnosis Overall survival Not provided 
High education and distancing 
predicted better overall 
survival (HR: 0.08, p-value: 
0.003); (HR: 0.78; p-value: 
0.034). Behavioral escape-
avoidance (HR: 1.38, p-value: 
0.008), emotional 
defensiveness (HR: 1.31, p-
value: 0.007) and perceived 
support (HR: 5.19; p-value: 




et al., 2007 (n=1,588) 
EORTC QLQ-C30; 









survival (OS) Not provided 
Higher levels of emotional 
functioning predicted better 
recurrence-free survival (RFS) 
(RR: 0.80; 95% CI: 0.69-0.93) 
and overall survival (OS) (RR: 
0.81; 95% CI: 0.70-0.95). 
Higher levels of fatigue 
predicted worse RFS (RR: 
1.32; 95% CI: 1.13-1.54) and 




al., 2007 (n=251) 
Ferrans and Powers 
quality of life index 
(QLI) 
At time of 
diagnosis Overall survival Not provided 
Higher scores in the health and 
physical subscale (RR: 0.91, 
95% CI: 0.86-0.96, p-value: 
<0.001) and overall HRQOL 
(RR: 0.90, 95% CI: 0.85-0.95, 
p-value: <0.001) were 
associated with better survival. 
  
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 
Measures Survival Time Findings 
10 
Phillips et 
al., 2008 (n=708) 
Hospital Anxiety and 
Depression Scale 
(HADS), Mental 


















(OS) Not provided 




variables and DDFS and OS 













Physical functioning (HR: 
0.94; 95% CI: 0.92, 0.96), pain 
(HR: 1.04; 95% CI: 1.02-1.06), 
and appetite loss (HR: 1.05; 
95% CI: 1.03-1.06) were 
significant prognostic factors 
of overall cancer survival. 
12 
Sarenmalm 
et al., 2009 
(n=67) Trial 12-93, 
(n=74) Trial 14-93  




during the trials 
at 
randomization, 
and at 3, 6, 9, 12, 
and 18 months, 
followed by 
annual follow-




recurrence Not provided 
Nausea/vomiting (β: -0.006, p-
value: 0.013) and physical 
well-being (β: 0.004, p-value: 
0.047) predict breast cancer 
recurrence. 
   
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 
Measures Survival Time Findings 
13 
Bredal et 
al., 2011 (n=195)  
EORTC QLQ-C30; 
Hospital Anxiety and 
Depression Scale 
(HADS) 









Appetite loss was significantly 
associated with worse survival 




al., 2011 (n=287) 
Functional 
Assessment of Cancer 
Therapy, General 
(FACT-G) & Breast 
(FACT-B+4) 
HRQOL 















Physical well-being, emotional 
well-being, functional well-
being, breast cancer concerns, 
FACT-G, and FACT-B+4 all 
showed significant changes 
over time (6 to 12 to 18 
months post-diagnosis). 
Women who reported 
stable/improving physical 
well-being had better survival 
than women who reported 
declining physical well-being 
(HR: 0.24; 95% CI: 0.08-0.70). 
The same applied to functional 
well-being (HR: 0.35; 95% CI: 
0.14-0.87). 
  
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 








General Quality of 
Life Inventory-74 
















up: 2.4 years 
for women 
who lived and 
1.2 years for 
women who 
died. 
At baseline, a higher 
psychological well-being and a 
higher social well-being were 
associated with better mortality 
(HR: 0.66; 95% CI: 0.49-0.88); 
(HR: 0.52; 95% CI: 0.38-0.71). 
There were no significant 
associations at follow-up. 
16 
Saquib et 




(included the Medical 
Outcomes Study 
(MOS) Short-Form 
Survey (SF-36)) Baseline 
Additional breast 
cancer events and 
all-cause mortality Not provided 
Higher levels of physical 
health predicted lower 
additional breast cancer events 
(p-trend: 0.005) and lower risk 




et al., 2014 
(n=1,002) beginning 





and the BR23 module 
About 4 years 




Worse future perspective was 
associated with a higher 
likelihood of death (HR: 3.46, 
95% CI: 1.36-8.79, p-value: 
0.009). 
  
# Authors Study Sample Study Measures Date(s) Assessed 
Outcome 
Measures Survival Time Findings 
18 
Marinac et 
al., 2014 (n=2,892) 
10-item physical 
function subscale (PF-
10) of the Medical 
Outcomes Study 





specific mortality Not provided 
Compared to adequate and 
high physical functioning, 
participants with low physical 
functioning were more likely 
to die by all-causes (HR: 1.49, 
95% CI: 1.17-1.89) and breast 
cancer-specific-causes (HR: 
1.39, 95% CI: 1.07-1.80) 
19 
DuMontier 
et al., 2018 (n=660) 
Medical Outcomes 
Study (MOS) 36-item 
Short-Form Survey 
(SF-36) and MOS 
Social Support Survey 
(mMOS-SSS) 




In the fully adjusted model, 
better levels of mental health 
(OR: 0.56, 95% CI: 0.37-0.83) 
and physical functioning (OR: 
0.64, 95% CI: 0.44-0.94) were 





 Appendix B. Physical Component Summary Score Univariate HR Analysis and Percent Change for All-Cause Mortality when 
Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (PCS) 
0: ≤ 44.75                                      
1: > 44.75 & ≤ 54.39                       
2: > 54.39 (REF) 
0: 117                
1: 117            
2: 117  
n=351                    
d=99 
0 
0: HR=3.80 (2.20-6.54)                
1: HR=1.67 (0.91-3.07) 
p=<0.0001 
0: HR=3.80 (2.20-6.54)             
p(PCS)=<0.0001                                
1: HR=1.67 (0.91-3.07)           
p(PCS)=0.0963 
-- 
1 Age Continuous -- 
n=351                    
d=99 
0 HR=1.06 (1.04-1.08) p=<0.0001 
0: HR=2.37 (1.34-4.19)           
p(PCS)=0.0030                              
1: HR=1.29 (0.69-2.39)           
p(PCS)=0.4138                              
p(Age)=<0.0001 




White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=99 
0 
0: HR=1.00                                    
1: HR=0.66 (0.38-1.12) 
p=0.1231 
0: HR=3.80 (2.21-6.56)           
p(PCS)=<0.0001                              
1: HR=1.68 (0.92-3.08)           
p(PCS)=0.0944                             
p(Ethnicity)=0.1231 
0: 0.00%           
1: 0.60% 
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=99 
0 
0: HR=1.75 (1.17-2.64)                                    
1: HR=1.00 
p=0.0067 
0: HR=3.52 (2.04-6.09)           
p(PCS)=<0.0001                              
1: HR=1.66 (0.91-3.05)           
p(PCS)=0.1003                              
p(Marital)=0.0067 
0: 7.37%           
1: 0.60% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=1.25 (0.79-1.98)         
p=0.3405 
0: HR=3.84 (2.23-6.63)           
p(PCS)=<0.0001                              
1: HR=1.69 (0.92-3.10)           
p(PCS)=0.0904                            
p(Stage)=0.3405                                          
0: 1.05%           
1: 1.20% 
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=99 
0 
0: HR=1.00                                  
1: HR=0.80 (0.48-1.32)                                  
2: HR=0.73 (0.46-1.16)                    
p=0.3937 
0: HR=3.73 (2.16-6.44)           
p(PCS)=<0.0001                             
1: HR=1.66 (0.90-3.04)           
p(PCS)=0.1023                             
p(Treatment1)=0.3827              
p(Treatment2)=0.1795                
0: 1.84%           
1: 0.60% 
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=99 
0 
0: HR=1.00                                    
1: HR=1.52 (0.94-2.45) 
p=0.0864 
0: HR=3.50 (2.01-6.09)           
p(PCS)=<0.0001                              
1: HR=1.61 (0.87-2.96)           
p(PCS)=0.1266                             
p(Comorbidities)=0.0864 
0: 7.89%           
1: 3.59% 
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307           
1: 44             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=0.55 (0.28-1.09) 
p=0.0524 
0: HR=4.08 (2.36-7.05)           
p(PCS)=<0.0001                              
1: HR=1.74 (0.95-3.20)           
p(PCS)=0.0731                             
p(Lymphedema)=0.0524 
0: 7.37%           
1: 4.19% 
   










Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                     
1: 268            
n=351                    
d=99 
0 
0: HR=1.25 (0.81-1.93)                                    
1: HR=1.00 
p=0.3160 
0: HR=3.61 (2.07-6.28)           
p(PCS)=<0.0001                              
1: HR=1.64 (0.90-3.02)           
p(PCS)=0.1093                           
p(Optimism)=0.3160 
0: 5.00%           
1: 1.80% 
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255                    
1: 96             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=1.42 (0.93-2.15) 
p=0.1009 
0: HR=3.54 (2.04-6.14)           
p(PCS)=<0.0001                              
1: HR=1.64 (0.89-3.01)           
p(PCS)=0.1114                             
p(Pessimism)=0.1009 
0: 6.84%           
1: 1.80% 
10 
Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                  
1: 172            
2: 113                 
n=351                    
d=99 
0 
0: HR=1.78 (1.02-3.08)                                     
1: HR=1.28 (0.79-2.06)                                  
2: HR=1.00 
p=0.1226 
0: HR=3.84 (2.23-6.62)           
p(PCS)=<0.0001                             
1: HR=1.73 (0.94-3.18)           
p(PCS)=0.0761                            
p(Confidant0)=0.0412            
p(Confidant1)=0.3118                
0: 1.05%           
1: 3.59% 
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154           
1: 197             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=0.69 (0.47-1.03) 
p=0.0674 
0: HR=3.78 (2.19-6.52)           
p(PCS)=<0.0001                            
1: HR=1.68 (0.92-3.09)           
p(PCS)=0.0935                      
p(Fear)=0.0674 
0: 0.53%           
1: 0.60% 
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with education) 
  
0: 116                 
1: 117                
2: 117  
n=350                    
d=98 
  
0: HR=3.74 (2.17-6.45)                
1: HR=1.67 (0.91-3.07) 
p=<0.0001 
0: HR=3.74 (2.17-6.45)           
p(PCS)=<0.0001                                




0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=98 
1 
0: HR=1.65 (0.90-3.02)                                     
1: HR=1.28 (0.71-2.32)                   
2: HR=0.92 (0.44-1.91)                   
3: HR=1.00 
p=0.2352 
0: HR=3.43 (1.97-5.98)           
p(PCS)=<0.0001                             
1: HR=1.55 (0.84-2.86)           
p(PCS)=0.1587                              
p(Education0)=0.1087              
p(Education1)=0.4054               
p(Education2)=0.8174 
0: 8.29%           
1: 7.19% 
Crude 
PCS (restricted to those 
with tumor size) 
  
0: 116                 
1: 114                
2: 111  
n=341                    
d=99 
  
0: HR=3.66 (2.12-6.30)                
1: HR=1.65 (0.90-3.02) 
p=<0.0001 
0: HR=3.66 (2.12-6.30)            
p(PCS)=<0.0001                                
1: HR=1.65 (0.90-3.02)           
p(PCS)=0.1069 
-- 
13 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=99 
10 
0: HR=1.00                                     
1: HR=1.25 (0.68-2.29) 
p=0.4712 
0: HR=3.66 (2.12-6.30)           
p(PCS)=<0.0001                              
1: HR=1.63 (0.89-3.00)           
p(PCS)=0.1142                             
p(Size)=0.4712 
0: 0.00%           
1: 1.21% 
   










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with lymph node 
involvement) 
  
0: 113                 
1: 112                
2: 116  
n=341                    
d=92 
  
0: HR=3.96 (2.26-6.94)                
1: HR=1.63 (0.87-3.07) 
p=<0.0001 
0: HR=3.96 (2.26-6.94)            
p(PCS)=<0.0001                                 






0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=92 
10 
0: HR=1.00                                 
1: HR=1.32 (0.83-2.10) 
p=0.2435 
0: HR=4.02 (2.29-7.05)           
p(PCS)=<0.0001                              
1: HR=1.64 (0.87-3.10)           
p(PCS)=0.1239                             
p(Lymph node)=0.6706 
0: 1.52%           
1: 0.61% 
Crude 
PCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 107                 
1: 110                
2: 113  
n=330                    
d=91 
  
0: HR=3.55 (2.04-6.17)                
1: HR=1.56 (0.84-2.90) 
p=<0.0001 
0: HR=3.55 (2.04-6.17)           
p(PCS)=<0.0001                                
1: HR=1.56 (0.84-2.90)           
p(PCS)=0.1556 
-- 
15 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=91 
21 
0: HR=1.18 (0.78-1.79)                                    
1: HR=1.00 
p=0.4226 
0: HR=3.56 (2.05-6.19)           
p(PCS)=<0.0001                              
1: HR=1.55 (0.84-2.87)           
p(PCS)=0.1659                             
p(Tamoxifen)=0.4226 
0: 0.28%           
1: 0.64% 
   










Missing Univariate-Cox HR (95% CI) p-values* 





16 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=91 
21 
0: HR=1.00                                     
1: HR=1.02 (0.66-1.60)                                  
2: HR=1.25 (0.66-2.34)                    
p=0.7825 
0: HR=3.51 (2.02-6.11)           
p(PCS)=<0.0001                             
1: HR=1.55 (0.83-2.87)           
p(PCS)=0.1671                              
p(Smoker1)=0.9169              
p(Smoker2)=0.4933                
0: 1.13%           
1: 0.64% 
17 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=91 
21 
0: HR=1.48 (0.86-2.56)                                    
1: HR=0.80 (0.38-1.68)                                 
2: HR=1.00     
p=0.0842 
0: HR=3.35 (1.90-5.88)           
p(PCS)=<0.0001                             
1: HR=1.49 (0.80-2.77)           
p(PCS)=0.2065                              
p(PA0)=0.1621             
p(PA1)=0.5513            
0: 5.63%           
1: 4.49% 
Crude 
PCS (restricted to those 
with BMI) 
  
0: 106                 
1: 110                
2: 108  
n=324                    
d=85 
  
0: HR=3.48 (1.94-6.24)                
1: HR=1.71 (0.90-3.24) 
p=<0.0001 
0: HR=3.48 (1.94-6.24)             
p(PCS)=<0.0001                                 
1: HR=1.71 (0.90-3.24)          
p(PCS)=0.1011 
-- 
   










Missing Univariate-Cox HR (95% CI) p-values* 





18 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=85 
27 
0: HR=1.00                                     
1: HR=0.80 (0.48-1.34)                   
2: HR=1.15 (0.68-1.95)                    
p=0.4604 
0: HR=3.43 (1.89-6.23)           
p(PCS)=<0.0001                             
1: HR=1.71 (0.90-3.25)           
p(PCS)=0.1028                              
p(BMI1)=0.3879              
p(BMI2)=0.6073                
0: 1.44%           
1: 0.00% 
Crude 
PCS (restricted to those 
tumor subtype) 
  
0: 102                 
1: 101                
2: 97  
n=300                    
d=87 
  
0: HR=3.37 (1.88-6.04)                
1: HR=1.79 (0.95-3.38) 
p=<0.0001 
0: HR=3.37 (1.88-6.04)             
p(PCS)=<0.0001                                 
1: HR=1.79 (0.95-3.38)         
p(PCS)=0.0733 
-- 
19 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=87
51 
0: HR=1.00                                     
1: HR=1.29 (0.75-2.23)      
p=0.3553 
0: HR=3.43 (1.91-6.15)           
p(PCS)=<0.0001                             
1: HR=1.78 (0.94-3.37)           
p(PCS)=0.0745                              
p(Subtype)=0.3553                           
0: 1.78%           
1: 0.56% 





Appendix C. Percent Change from Crude Model and Model 1 with Each Potential Confounder (PCS & All-Cause Mortality) 
(N = 351) 
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Dataset restricted to those diagnosed with invasive breast cancer who have HRQOL and baseline covariates data 
Crude Physical Component Summary Score (PCS) 
0: HR=3.80 (2.20-6.54)                
1: HR=1.67 (0.91-3.07)                            
2: HR=1.00 (REF)                     
p=<0.0001 
0 
n=351                    
d=99 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.32 (1.30-4.11)               
1: HR=1.34 (0.72-2.47)                            
2: HR=1.00 (REF)                       
p=0.0052 
0 
n=351                    
d=99 
0: 38.95%                      
1: 19.76% 
-- 
2 Model 1 + Race/Ethnicity 
0: HR=2.34 (1.32-4.15)               
1: HR=1.34 (0.72-2.48)                            
2: HR=1.00 (REF)                       
p=0.0048 
0 
n=351                    
d=99 
0: 38.42%                      
1: 19.76% 
0: 0.86%           
1: 0.00% 
3 Model 1 + Treatment Type 
0: HR=2.25 (1.27-3.98)               
1: HR=1.29 (0.69-2.40)                            
2: HR=1.00 (REF)                       
p=0.0065 
0 
n=351                    
d=99 
0: 40.79%                      
1: 22.75% 
0: 3.02%           
1: 3.73% 
  
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
4 Model 1 + Comorbidities 
0: HR=2.21 (1.24-3.95)               
1: HR=1.31 (0.71-2.43)                            
2: HR=1.00 (REF)                       
p=0.0109 
0 
n=351                    
d=99 
0: 41.84%                      
1: 21.56% 
0: 4.74%           
1: 2.24% 
5 Model 1 + Current Lymphedema 
0: HR=2.45 (1.37-4.37)               
1: HR=1.37 (0.74-2.55)                            
2: HR=1.00 (REF)                       
p=0.0033 
0 
n=351                    
d=99 
0: 35.53%                      
1: 17.76% 
0: 5.60%           
1: 2.24% 
6 Model 1 + Optimism 
0: HR=2.23 (1.25-3.97)               
1: HR=1.32 (0.71-2.44)                            
2: HR=1.00 (REF)                       
p=0.0099 
0 
n=351                    
d=99 
0: 41.32%                      
1: 20.96% 
0: 3.88%           
1: 1.49% 
7 Model 1 + Pessimism 
0: HR=2.17 (1.23-3.83)               
1: HR=1.36 (0.74-2.51)                            
2: HR=1.00 (REF)                       
p=0.0156 
0 
n=351                    
d=99 
0: 42.89%                      
1: 18.56% 
0: 6.47%           
1: 1.49% 
8 Model 1 + Number of Types of Confidants 
0: HR=2.34 (1.32-4.15)               
1: HR=1.36 (0.73-2.51)                            
2: HR=1.00 (REF)                       
p=0.0051 
0 
n=351                    
d=99 
0: 38.42%                      
1: 18.56% 
0: 0.86%           
1: 1.49% 
  
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
9 Model 1 + Fear of Recurrence 
0: HR=2.34 (1.32-4.16)               
1: HR=1.34 (0.72-2.49)                            
2: HR=1.00 (REF)                       
p=0.0047 
0 
n=351                    
d=99 
0: 38.42%                      
1: 19.76% 
0: 0.86%           
1: 0.00% 
Subset--Restricted to participants with Education variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.74 (2.17-6.45)                
1: HR=1.67 (0.91-3.07)                             
2: HR=1.00 (REF)                       
p=<0.0001 
1 
n=350                    
d=98 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.29 (1.29-4.07)               
1: HR=1.33 (0.72-2.47)                            
2: HR=1.00 (REF)                       
p=0.0063 
1 
n=350                    
d=98 
0: 38.77%                      
1: 20.36% 
-- 
10 Model 1 + Education 
0: HR=2.26 (1.28-4.02)               
1: HR=1.31 (0.71-2.43)                             
2: HR=1.00 (REF)                      
p=0.0076 
1 
n=350                    
d=98 
0: 39.57%                      
1: 21.56% 
0: 1.31%           
1: 1.50% 
Subset--Restricted to participants with the Tumor Size variable 
   
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Crude Physical Component Summary Score (PCS) 
0: HR=3.66 (2.12-6.30)                
1: HR=1.65 (0.90-3.02)                            
2: HR=1.00 (REF)                        
p=<0.0001 
10 
n=341                  
d=99 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.30 (1.30-4.07)               
1: HR=1.34 (0.73-2.49)                            
2: HR=1.00 (REF)                       
p=0.0059 
10 
n=341                  
d=99 
0: 37.16%                      
1: 18.79% 
-- 
11 Model 1 + Tumor Size 
0: HR=2.25 (1.28-3.98)               
1: HR=1.30 (0.70-2.41)                            
2: HR=1.00 (REF)                       
p=0.0064 
10 
n=341                  
d=99 
0: 38.52%                      
1: 21.21% 
0: 2.17%           
1: 2.99% 
Subset--Restricted to participants with Lymph Node Involvement variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.96 (2.26-6.94)                
1: HR=1.63 (0.87-3.07)                            
2: HR=1.00 (REF)                        
p=<0.0001 
10 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.36 (1.30-4.25)               
1: HR=1.35 (0.71-2.56)                             
2: HR=1.00 (REF)                      
p=0.0071 
10 
n=341                    
d=92 
0: 40.40%                      
1: 17.18% 
-- 
12 Model 1 + Lymph Node Involvement 
0: HR=2.34 (1.30-4.24)               
1: HR=1.34 (0.71-2.55)                             
2: HR=1.00 (REF)                      
p=0.0076 
10 
n=341                    
d=92 
0: 40.91%                      
1: 17.79% 
0: 0.85%           
1: 0.74% 
Subset--Restricted to participants with Tamoxifen Use, Smoking Status, & Physical Activity variables (24-month follow-up) 
Crude Physical Component Summary Score (PCS) 
0: HR=3.55 (2.04-6.17)                
1: HR=1.56 (0.84-2.90)                             
2: HR=1.00 (REF)                       
p=<0.0001 
21 
n=330                    
d=91 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.18 (1.22-3.91)               
1: HR=1.24 (0.66-2.34)                              
2: HR=1.00 (REF)                     
p=0.0107 
21 
n=330                    
d=91 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
13 Model 1 + Tamoxifen Use 
0: HR=2.21 (1.24-3.95)               
1: HR=1.23 (0.66-2.29)                              
2: HR=1.00 (REF)                     
p=0.0079 
21 
n=330                    
d=91 
0: 37.75%                      
1: 21.15% 
0: 1.38%           
1: 0.81% 
14 Model 1 + Smoking Status 
0: HR=2.13 (1.20-3.81)               
1: HR=1.22 (0.65-2.29)                              
2: HR=1.00 (REF)                     
p=0.0128 
21 
n=330                    
d=91 
0: 40.00%                      
1: 21.79% 
0: 2.29%           
1: 1.61% 
15 Model 1 + Physical Activity 
0: HR=2.13 (1.18-3.82)               
1: HR=1.22 (0.65-2.28)                              
2: HR=1.00 (REF)                     
p=0.0143 
21 
n=330                    
d=91 
0: 40.00%                      
1: 21.79% 
0: 2.29%           
1: 1.61% 
Subset--Restricted to participants with BMI variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.48 (1.94-6.24)                
1: HR=1.71 (0.90-3.24)                             
2: HR=1.00 (REF)                       
p=<0.0001 
27 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.19 (1.19-4.04)               
1: HR=1.44 (0.75-2.76)                              
2: HR=1.00 (REF)                     
p=0.0300 
27 
n=324                    
d=85 
0: 37.07%                      
1:15.79% 
-- 
16 Model 1 + BMI 
0: HR=2.17 (1.16-4.07)               
1: HR=1.45 (0.75-2.78)                              
2: HR=1.00 (REF)                     
p=0.0402 
27 
n=324                    
d=85 
0: 37.64%                      
1: 15.20% 
0: 0.91%           
1: 0.69% 
Subset--Restricted to participants with Tumor Subtype variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.37 (1.88-6.04)                
1: HR=1.79 (0.95-3.38)                             
2: HR=1.00 (REF)                       
p=<0.0001 
51 
n=300                    
d=87 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.11 (1.15-3.89)               
1: HR=1.46 (0.76-2.77)                              
2: HR=1.00 (REF)                     
p=0.0435 
51 
n=300                    
d=87 
0: 37.39%                      
1: 18.44% 
-- 
   
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
17 Model 1 + Tumor Subtype 
0: HR=2.14 (1.16-3.95)               
1: HR=1.45 (0.76-2.77)                              
2: HR=1.00 (REF)                     
p=0.0371 
51 
n=300                    
d=87 
0: 36.50%                      
1: 18.99% 
0: 1.42%           
1: 0.68% 












 Appendix D. Multivariable Modeling with Physical Component Summary Score as the Predictor and All-Cause Mortality as 
the Outcome (N = 351) 
Model Variable(s) in model 
Physical Component 




Total in model 











Crude Physical Component Summary Score (PCS) 
0: HR=3.80 (2.20-6.54)                
1: HR=1.67 (0.91-3.07)                             
2: HR=1.00 (REF)                       
p=<0.0001 
0 
n=351                    
d=99 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.32 (1.29-4.11)               
1: HR=1.34 (0.72-2.47)                             
2: HR=1.00 (REF)                      
p=0.0052 
0 
n=351                    
d=99 
0: 38.95%                      
1: 19.76% 
-- -- 
2 Model 1 + Race/Ethnicity 
0: HR=2.34 (1.32-4.15)               
1: HR=1.34 (0.72-2.48)                             
2: HR=1.00 (REF)                      
p=0.0048 
0 
n=351                    
d=99 
0: 38.42%                      
1: 19.76% 
0: 0.86%           
1: 0.00% 
-- 
3 Model 1 + Race/Ethnicity + Treatment Type 
0: HR=2.26 (1.27-4.00)               
1: HR=1.29 (0.70-2.40)                            
2: HR=1.00 (REF)                       
p=0.0062 
0 
n=351                    
d=99 
0: 40.53%                      
1: 22.75% 
0: 2.59%           
1: 3.73% 
0: 3.42%           
1: 3.73% 
4 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities 
0: HR=2.12 (1.18-3.81)               
1: HR=1.26 (0.68-2.35)                            
2: HR=1.00 (REF)                       
p=0.0152 
0 
n=351                    
d=99 
0: 44.21%                      
1: 24.55% 
0: 8.62%           
1: 5.97% 
0: 6.19%           
1: 2.33% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema 
0: HR=2.26 (1.26-4.06)               
1: HR=1.31 (0.70-2.44)                            
2: HR=1.00 (REF)                       
p=0.0086 
0 
n=351                    
d=99 
0: 40.53%                      
1: 21.56% 
0: 2.59%           
1: 2.24% 
0: 6.60%           
1: 3.97% 
6 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism 
0: HR=2.14 (1.19-3.85)               
1: HR=1.34 (0.72-2.48)                            
2: HR=1.00 (REF)                       
p=0.0205 
0 
n=351                    
d=99 
0: 43.68%                      
1: 19.76% 
0: 7.76%           
1: 0.00% 
0: 5.31%           
1: 2.29% 
7 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Number of Types of Confidants (Confide) 
0: HR=2.17 (1.21-3.90)               
1: HR=1.36 (0.73-2.54)                            
2: HR=1.00 (REF)                       
p=0.0201 
0 
n=351                    
d=99 
0: 42.89%                      
1: 18.56% 
0: 6.47%           
1: 1.49% 
0: 1.40%           
1: 1.49% 
8 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Confide + Fear of Recurrence 
0: HR=2.17 (1.20-3.90)               
1: HR=1.37 (0.74-2.56)                              
2: HR=1.00 (REF)                     
p=0.0209 
0 
n=351                    
d=99 
0: 17.96%                      
1: 21.56% 
0: 6.47%           
1: 2.24% 
0: 0.00%           
1: 0.74% 
Subset--Restricted to participants with Education variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.74 (2.17-6.45)                
1: HR=1.67 (0.91-3.07)                             
2: HR=1.00 (REF)                       
p=<0.0001 
1 
n=350                  
d=98 
-- -- -- 
  
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.30 (1.29-4.07)               
1: HR=1.33 (0.72-2.47)                              
2: HR=1.00 (REF)                     
p=0.0063 
1 
n=350                  
d=98 
0: 38.50%                      
1: 20.36% 
-- -- 
9 Model 1 + Education 
0: HR=2.26 (1.28-4.02)               
1: HR=1.31 (0.71-2.43)                              
2: HR=1.00 (REF)                     
p=0.0076 
1 
n=350                  
d=98 
0: 39.57%                      
1: 21.56% 
0: 1.74%           
1: 1.50% 
-- 
10 Model 1 + Education + Race/Ethnicity 
0: HR=2.27 (1.28-4.04)               
1: HR=1.31 (0.71-2.43)                              
2: HR=1.00 (REF)                     
p=0.0071 
1 
n=350                  
d=98 
0: 39.30%                      
1: 21.56% 
0: 1.30%           
1: 1.50% 
0: 0.44%           
1: 0.00% 
11 Model 1 + Education + Race/Ethnicity + Treatment Type 
0: HR=2.18 (1.23-3.87)               
1: HR=1.28 (0.69-2.37)                              
2: HR=1.00 (REF)                     
p=0.0100 
1 
n=350                  
d=98 
0: 41.71%                      
1: 23.35% 
0: 5.22%           
1: 3.76% 
0: 3.96%           
1: 2.29% 
12 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities 
0: HR=2.08 (1.16-3.72)               
1: HR=1.25 (0.67-2.32)                              
2: HR=1.00 (REF)                     
p=0.0204 
1 
n=350                  
d=98 
0: 44.39%                      
1: 25.15% 
0: 9.57%           
1: 6.02% 
0: 4.59%           
1: 2.34% 
   
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema 
0: HR=2.21 (1.23-3.97)               
1: HR=1.30 (0.70-2.42)                              
2: HR=1.00 (REF)                     
p=0.0119 
1 
n=350                  
d=98 
0: 40.91%                      
1: 22.16% 
0: 3.91%           
1: 2.26% 
0: 6.25%           
1: 4.00% 
14 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism 
0: HR=2.09 (1.16-3.75)               
1: HR=1.34 (0.72-2.49)                              
2: HR=1.00 (REF)                     
p=0.0296 
1 
n=350                  
d=98 
0: 44.12%                      
1: 19.76% 
0: 9.13%           
1: 0.75% 
0: 5.43%           
1: 3.08% 
15 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Confide 
0: HR=2.11 (1.17-3.80)               
1: HR=1.37 (0.73-2.54)                              
2: HR=1.00 (REF)                     
p=0.0289 
1 
n=350                  
d=98 
0: 43.58%                      
1: 17.96% 
0: 8.26%           
1: 3.01% 
0: 0.96%           
1: 2.24% 
16 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Confide + Fear of Recurrence 
0: HR=2.11 (1.18-3.80)               
1: HR=1.38 (0.74-2.57)                              
2: HR=1.00 (REF)                     
p=0.0293 
1 
n=350                  
d=98 
0: 43.58%                      
1: 17.37% 
0: 8.26%           
1: 3.76% 
0: 0.00%           
1: 0.73% 
Subset--Restricted to participants with Lymph Node Involvement variable 
Crude Physical Component Summary Score (PCS) 
0: HR=3.96 (2.26-6.94)                
1: HR=1.63 (0.87-3.07)                              
2: HR=1.00 (REF)                       
p=<0.0001 
10 
n=341                
d=92 
-- -- -- 
   
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.36 (1.30-4.25)               
1: HR=1.35 (0.71-2.56)                              
2: HR=1.00 (REF)                     
p=0.0071 
10 
n=341                
d=92 
0: 40.40%                      
1: 17.18% 
-- -- 
17 Model 1 + Lymph Node Involvement (LNI) 
0: HR=2.34 (1.30-4.24)               
1: HR=1.34 (0.71-2.55)                              
2: HR=1.00 (REF)                     
p=0.0076 
10 
n=341                
d=92 
0: 40.91%                      
1: 17.79% 
0: 0.85%           
1: 0.74% 
-- 
18 Model 1 + LNI + Race/Ethnicity 
0: HR=2.36 (1.31-4.28)               
1: HR=1.35 (0.71-2.56)                              
2: HR=1.00 (REF)                     
p=0.0070 
10 
n=341                
d=92 
0: 40.40%                      
1: 17.18% 
0: 0.00%           
1: 0.00% 
0: 0.85%           
1: 0.75% 
19 Model 1 + LNI + Race/Ethnicity + Treatment Type 
0: HR=2.28 (1.26-4.13)               
1: HR=1.33 (0.70-2.52)                              
2: HR=1.00 (REF)                     
p=0.0102 
10 
n=341                
d=92 
0: 42.42%                      
1: 18.40% 
0: 3.39%           
1: 1.48% 
0: 3.39%           
1: 1.48% 
20 
Model 1 + LNI + Race/Ethnicity + Treatment Type + 
Comorbidities 
0: HR=2.19 (1.20-4.01)               
1: HR=1.30 (0.68-2.48)                              
2: HR=1.00 (REF)                     
p=0.0174 
10 
n=341                
d=92 
0: 44.70%                      
1: 20.25% 
0: 7.20%           
1: 3.70% 
0: 3.95%           
1: 2.26% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + LNI + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema 
0: HR=2.32 (1.27-4.26)               
1: HR=1.35 (0.71-2.58)                              
2: HR=1.00 (REF)                     
p=0.0109 
10 
n=341                
d=92 
0: 41.41%                      
1: 17.18% 
0: 1.69%           
1: 0.00% 
0: 5.94%           
1: 3.85% 
22 
Model 1 + LNI + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism 
0: HR=2.20 (1.20-4.04)               
1: HR=1.37 (0.72-2.61)                              
2: HR=1.00 (REF)                     
p=0.0222 
10 
n=341                
d=92 
0: 44.44%                      
1: 15.95% 
0: 6.78%           
1: 1.48% 
0: 5.17%           
1: 1.48% 
23 
Model 1 + LNI + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Confide 
0: HR=2.24 (1.22-4.11)               
1: HR=1.40 (0.74-2.68)                              
2: HR=1.00 (REF)                     
p=0.0206 
10 
n=341                
d=92 
0: 43.43%                      
1: 14.11% 
0: 5.08%           
1: 3.70% 
0: 1.82%           
1: 2.19% 
24 
Model 1 + LNI + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Confide + Fear of Recurrence 
0: HR=2.25 (1.23-4.11)               
1: HR=1.42 (0.74-2.70)                              
2: HR=1.00 (REF)                     
p=0.0207 
10 
n=341                
d=92 
0: 43.18%                      
1: 12.88% 
0: 4.66%           
1: 5.19% 
0: 0.45%           
1: 1.43% 
Subset--Restricted to participants with Education and LNI variables (24-month follow-up) 
Crude Physical Component Summary Score (PCS) 
0: HR=3.90 (2.22-6.84)                
1: HR=1.63 (0.87-3.07)                             
2: HR=1.00 (REF)                       
p=<0.0001 
11 
n=340               
d=91 
-- -- -- 
   
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.33 (1.29-4.21)               
1: HR=1.35 (0.71-2.56)                              
2: HR=1.00 (REF)                     
p=0.0085 
11 
n=340               
d=91 
0: 40.26%                      
1: 17.18% 
-- -- 
25 Model 1 + Education + LNI 
0: HR=2.31 (1.27-4.18)               
1: HR=1.31 (0.69-2.49)                              
2: HR=1.00 (REF)                     
p=0.0093 
11 
n=340               
d=91 
0: 40.77%                      
1: 19.63% 
0: 0.86%           
1: 2.96% 
-- 
26 Model 1 Education + LNI + Race/Ethnicity 
0: HR=2.32 (1.28-4.20)               
1: HR=1.32 (0.69-2.50)                              
2: HR=1.00 (REF)                     
p=0.0086 
11 
n=340               
d=91 
0: 40.51%                      
1: 19.02% 
0: 0.43%           
1: 2.22% 
0: 0.43%           
1: 0.76% 
27 
Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type 
0: HR=2.23 (1.23-4.04)               
1: HR=1.30 (0.69-2.47)                              
2: HR=1.00 (REF)                     
p=0.0129 
11 
n=340               
d=91 
0: 42.82%                      
1: 20.25% 
0: 4.29%           
1: 3.70% 
0: 3.88%           
1: 1.52% 
28 
Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type + Comorbidities 
0: HR=2.16 (1.18-3.95)               
1: HR=1.28 (0.67-2.43)                              
2: HR=1.00 (REF)                     
p=0.0202 
11 
n=340               
d=91 
0: 44.62%                      
1: 21.47% 
0: 7.30%           
1: 5.19% 
0: 7.30%           
1: 1.54% 
   
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema 
0: HR=2.29 (1.25-4.20)               
1: HR=1.34 (0.70-2.55)                              
2: HR=1.00 (REF)                     
p=0.0128 
11 
n=340               
d=91 
0: 41.28%                      
1: 17.79% 
0: 1.72%           
1: 0.74% 
0: 6.02%           
1: 4.69% 
30 
Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism 
0: HR=2.16 (1.18-3.95)               
1: HR=1.37 (0.72-2.61)                              
2: HR=1.00 (REF)                     
p=0.0298 
11 
n=340               
d=91 
0: 44.62%                      
1: 15.95% 
0: 7.30%           
1: 1.48% 
0: 5.68%           
1: 2.24% 
31 
Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Confide 
0: HR=2.19 (1.20-4.02)               
1: HR=1.40 (0.74-2.68)                              
2: HR=1.00 (REF)                     
p=0.0274 
11 
n=340               
d=91 
0: 43.85%                      
1: 14.11% 
0: 6.01%           
1: 3.70% 
0: 0.44%           
1: 2.19% 
32 
Model 1 + Education + LNI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Confide + Fear of Recurrence 
0: HR=2.21 (1.20-4.05)               
1: HR=1.42 (0.74-2.72)                              
2: HR=1.00 (REF)                     
p=0.0268 
11 
n=340               
d=91 
0: 43.33%                      
1: 12.88% 
0: 5.15%           
1: 5.19% 
0: 0.91%           
1: 1.43% 
Subset--Restricted to participants with Physical Activity variable (24-month follow-up) 
Crude Physical Component Summary Score (PCS) 
0: HR=3.55 (2.04-6.17)                
1: HR=1.56 (0.84-2.90)                             
2: HR=1.00 (REF)                       
p=<0.0001 
21 
n=330                    
d=91 
-- -- -- 
   
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.18 (1.22-3.91)               
1: HR=1.24 (0.66-2.33)                              
2: HR=1.00 (REF)                     
p=0.0107 
21 
n=330                    
d=91 
0: 38.59%                      
1: 20.51% 
-- -- 
33 Model 1 + Physical Activity 
0: HR=2.13 (1.18-3.82)               
1: HR=1.22 (0.65-2.28)                              
2: HR=1.00 (REF)                     
p=0.0143 
21 
n=330                    
d=91 
0: 40.00%                      
1: 21.79% 
0: 2.29%           
1: 1.61% 
-- 
34 Model 1 + Physical Activity + Race/Ethnicity 
0: HR=2.14 (1.19-3.85)               
1: HR=1.21 (0.65-2.27)                              
2: HR=1.00 (REF)                     
p=0.0130 
21 
n=330                    
d=91 
0: 39.72%                      
1: 22.44% 
0: 1.83%           
1: 2.42% 
0: 0.47%           
1: 0.82% 
35 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type 
0: HR=2.03 (1.13-3.64)               
1: HR=1.19 (0.63-2.22)                              
2: HR=1.00 (REF)                     
p=0.0224 
21 
n=330                    
d=91 
0: 42.82%                      
1: 23.72% 
0: 6.88%           
1: 4.03% 
0: 5.14%           
1: 1.65% 
36 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities 
0: HR=1.90 (1.04-3.45)               
1: HR=1.17 (0.62-2.20)                              
2: HR=1.00 (REF)                     
p=0.0549 
21 
n=330                    
d=91 
0: 46.48%                      
1: 25.00% 
0: 12.84%           
1: 5.65% 
0: 6.40%           
1: 1.68% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema 
0: HR=2.00 (1.09-3.64)               
1: HR=1.21 (0.65-2.28)                              
2: HR=1.00 (REF)                     
p=0.0386 
21 
n=330                    
d=91 
0: 43.66%                      
1: 22.44% 
0: 8.26%           
1: 2.42% 
0: 5.26%           
1: 3.42% 
38 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism 
0: HR=1.96 (1.08-3.57)               
1: HR=1.24 (0.66-2.32)                              
2: HR=1.00 (REF)                     
p=0.0523 
21 
n=330                    
d=91 
0: 44.79%                      
1: 20.51% 
0: 10.09%           
1: 0.00% 
0: 2.00%           
1: 2.48% 
39 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Confide 
0: HR=1.98 (1.08-4.08)               
1: HR=1.26 (0.67-2.36)                              
2: HR=1.00 (REF)                     
p=0.0521 
21 
n=330                    
d=91 
0: 44.23%                      
1: 19.23% 
0: 9.17%           
1: 1.61% 
0: 1.02%           
1: 1.61% 
40 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Confide + Fear of Recurrence 
0: HR=1.98 (1.08-3.63)               
1: HR=1.26 (0.67-2.36)                              
2: HR=1.00 (REF)                     
p=0.0521 
21 
n=330                    
d=91 
0: 44.23%                      
1: 19.23% 
0: 9.17%           
1: 1.61% 
0: 0.00%           
1: 0.00% 
Subset--Restricted to participants with Education, LNI, and Physical Activity variables  
Crude Physical Component Summary Score (PCS) 
0: HR=3.62 (2.05-6.41)                
1: HR=1.51 (0.79-2.87)                             
2: HR=1.00 (REF)                       
p=<0.0001 
32 
n=319                 
d=83 
-- -- -- 
  
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.17 (1.19-3.98)               
1: HR=1.25 (0.65-2.40)                              
2: HR=1.00 (REF)                     
p=0.0186 
32 
n=319                 
d=83 
0: 40.06%                      
1: 17.22% 
-- -- 
41 Model 1 + Education + LNI + Physical Activity 
0: HR=2.13 (1.15-3.93)               
1: HR=1.23 (0.64-2.36)                              
2: HR=1.00 (REF)                     
p=0.0258 
32 
n=319                 
d=83 
0: 41.16%                      
1: 18.54% 




Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity 
0: HR=2.14 (1.16-3.95)               
1: HR=1.23 (0.64-2.35)                              
2: HR=1.00 (REF)                     
p=0.0241 
32 
n=319                 
d=83 
0: 40.88%                      
1: 18.54% 
0: 1.38%           
1: 1.60% 
0: 0.47%           
1: 0.00% 
43 
Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type 
0: HR=2.01 (1.09-3.71)               
1: HR=1.22 (0.64-2.34)                              
2: HR=1.00 (REF)                     
p=0.0444 
32 
n=319                 
d=83 
0: 44.48%                      
1: 19.21% 
0: 7.37%           
1: 2.40% 
0: 6.07%           
1: 0.81% 
44 
Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities 
0: HR=1.93 (1.04-3.61)               
1: HR=1.21 (0.63-2.32)                              
2: HR=1.00 (REF)                     
p=0.0707 
32 
n=319                 
d=83 
0: 46.69%                      
1: 19.87% 
0: 11.06%           
1: 3.20% 
0: 3.98%           
1: 0.82% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema 
0: HR=2.05 (1.09-3.83)               
1: HR=1.26 (0.65-2.42)                              
2: HR=1.00 (REF)                     
p=0.0504 
32 
n=319                 
d=83 
0: 43.37%                      
1: 16.56% 
0: 5.53%           
1: 0.80% 
0: 6.22%           
1: 4.13% 
46 
Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism 
0: HR=2.00 (1.07-3.74)               
1: HR=1.29 (0.67-2.48)                              
2: HR=1.00 (REF)                     
p=0.0666 
32 
n=319                 
d=83 
0: 44.75%                      
1: 14.57% 
0: 7.83%           
1: 3.20% 
0: 2.44%           
1: 2.38% 
47 
Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Confide 
0: HR=2.05 (1.09-3.85)               
1: HR=1.31 (0.68-2.54)                              
2: HR=1.00 (REF)                     
p=0.0617 
32 
n=319                 
d=83 
0: 43.37%                      
1: 13.25% 
0: 5.53%           
1: 4.80% 
0: 2.50%           
1: 1.55% 
48 
Model 1 + Education + LNI + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Confide + Fear of 
Recurrence 
0: HR=2.05 (1.09-3.86)               
1: HR=1.32 (0.68-2.56)                              
2: HR=1.00 (REF)                     
p=0.0622 
32 
n=319                 
d=83 
0: 43.37%                      
1: 12.58% 
0: 5.53%           
1: 5.60% 





 Appendix E. Mental Component Summary Score Univariate HR Analysis and Percent Change for All-Cause Mortality when 
Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (MCS) 
0: ≤ 45.12                                      
1: > 45.12 & ≤ 54.40                       
2: > 54.40 (REF) 
0: 117                 
1: 117            
2: 117  
n=351                    
d=99 
0 
0: HR=1.36 (0.83-2.23)                
1: HR=1.25 (0.76-2.06) 
p=0.4590 
0: HR=1.36 (0.83-2.23)            
p(MCS)=0.4590                               
1: HR=1.25 (0.76-2.06)           
p(MCS)=0.3760 
-- 
1 Age Continuous -- 
n=351                    
d=99 
0 HR=1.07 (1.05-1.09) p=<0.0001 
0: HR=1.66 (1.01-2.72)           
p(MCS)=0.0461                              
1: HR=1.34 (0.81-2.20)           
p(MCS)=0.2496                              
p(Age)=<0.0001 




White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=99 
0 
0: HR=1.00                                    
1: HR=0.64 (0.37-1.09) 
p=0.1015 
0: HR=1.41 (0.86-2.32)           
p(MCS)=0.1720                              
1: HR=1.28 (0.78-2.11)           
p(MCS)=0.3275                             
p(Ethnicity)=0.1015 
0: 3.68%           
1: 2.40% 
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=99 
0 
0: HR=1.99 (1.33-2.98)                                    
1: HR=1.00 
p=0.0008 
0: HR=1.35 (0.83-2.22)           
p(MCS)=0.2290                              
1: HR=1.29 (0.78-2.12)           
p(MCS)=0.3201                              
p(Marital)=0.0008 
0: 0.74%           
1: 3.20% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=1.20 (0.76-1.90)         
p=0.4442 
0: HR=1.38 (0.84-2.26)           
p(MCS)=0.2050                              
1: HR=1.26 (0.76-2.07)           
p(MCS)=0.3682                            
p(Stage)=0.4442                                          
0: 1.47%           
1: 0.80% 
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=99 
0 
0: HR=1.00                                  
1: HR=0.69 (0.42-1.14)                                  
2: HR=0.69 (0.43-1.10)                    
p=0.2202 
0: HR=1.37 (0.84-2.25)           
p(MCS)=0.2111                             
1: HR=1.25 (0.76-2.06)           
p(MCS)=0.3777                             
p(Treatment1)=0.1492              
p(Treatment2)=0.1211                
0: 0.74%           
1: 0.00% 
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=99 
0 
0: HR=1.00                                    
1: HR=1.96 (1.22-3.14) 
p=0.0056 
0: HR=1.25 (0.76-2.05)           
p(MCS)=0.3898                              
1: HR=1.23 (0.75-2.03)           
p(MCS)=0.4095                             
p(Comorbidities)=0.0056 
0: 8.09%           
1: 1.60% 
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307           
1: 44             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=0.61 (0.31-1.21) 
p=0.1586 
0: HR=1.43 (0.87-2.35)           
p(MCS)=0.1612                             
1: HR=1.27 (0.77-2.09)           
p(MCS)=0.3417                             
p(Lymphedema)=0.0524 
0: 5.15%           
1: 1.57% 










Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                     
1: 268            
n=351                    
d=99 
0 
0: HR=1.51 (0.99-2.41)                                    
1: HR=1.00 
p=0.0519 
0: HR=1.20 (0.72-2.00)           
p(MCS)=0.4913                              
1: HR=1.17 (0.71-1.94)           
p(MCS)=0.5348                           
p(Optimism)=0.0519 
0: 11.76%           
1: 6.40% 
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255                    
1: 96             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=1.69 (1.10-2.58) 
p=0.0146 
0: HR=1.19 (0.71-1.97)           
p(MCS)=0.5096                              
1: HR=1.17 (0.71-1.94)           
p(MCS)=0.5330                             
p(Pessimism)=0.0146 
0: 12.50%           
1: 6.40% 
10 Current Fatigue 
0: No (REF)                                           
1: Yes  
0: 136           
1: 215             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=0.86 (0.55-1.35) 
p=0.5080 
0: HR=1.47 (0.85-2.54)           
p(MCS)=0.1664                             
1: HR=1.29 (0.78-2.14)           
p(MCS)=0.3237                      
p(Fatigue)=0.5080 
0: 8.09%           
1: 3.20% 
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154           
1: 197             
n=351                    
d=99 
0 
0: HR=1.00                                     
1: HR=0.64 (0.43-0.96) 
p=0.0313 
0: HR=1.49 (0.90-2.46)           
p(MCS)=0.1177                           
1: HR=1.34 (0.81-2.21)           
p(MCS)=0.2528                     
p(Fear)=0.0313 
0: 9.56%           
1: 7.20% 
   










Missing Univariate-Cox HR (95% CI) p-values* 






Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                  
1: 172            
2: 113                 
n=351                    
d=99 
0 
0: HR=1.76 (1.01-3.04)                                     
1: HR=1.23 (0.76-1.98)                                  
2: HR=1.00 
p=0.1241 
0: HR=1.35 (0.82-2.22)           
p(MCS)=0.2328                             
1: HR=1.26 (0.76-2.06)           
p(MCS)=0.3710                           
p(Confidant0)=0.0444            
p(Confidant1)=0.4031                
0: 0.74%           
1: 0.80% 
13 Bodily Pain 
0: No Pain                                      
1: Experienced Pain 
(REF) 
0: 180                        
1: 171             
n=351                   
d=99 
0 
0: HR=1.00                                   
1: HR=1.60 (0.96-2.67) 
p=0.0746 
0: HR=0.84 (0.36-1.96)           
p(MCS)=0.6864                          
1: HR=0.95 (0.49-1.84)           
p(MCS)=0.8795                     
p(Pain)=0.0746 





0: "Poor" & "Fair"                                          
1: "Good", "Very 
Good", & "Excellent" 
(REF) 
0: 54                   
1: 297            
n=351                    
d=99 
0 
0: HR=2.43 (1.53-3.85)                                     
1: HR=1.00 
p=0.0002 
0: HR=1.08 (0.64-1.80)              
p(MCS)=0.7809                          
1: HR=1.21 (0.73-1.98)                   
p(MCS)=0.4627                           
p(Health)=0.0797               
0: 20.59%           
1: 3.20% 
Crude 
MCS (restricted to those 
with education) 
  
0: 117                 
1: 116                
2: 117  
n=350                    
d=98 
  
0: HR=1.36 (0.83-2.23)                
1: HR=1.22 (0.74-2.01) 
p=0.4697 
0: HR=1.36 (0.83-2.23)           
p(MCS)=0.2210                                














Missing Univariate-Cox HR (95% CI) p-values* 






0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=98 
1 
0: HR=1.88 (1.03-3.45)                                     
1: HR=1.55 (0.86-2.78)                   
2: HR=0.87 (0.42-1.81)                   
3: HR=1.00 
p=0.0504 
0: HR=1.33 (0.81-2.19)           
p(MCS)=0.2554                             
1: HR=1.27 (0.77-2.11)           
p(MCS)=0.3461                             
p(Education0)=0.0408              
p(Education1)=0.1415               
p(Education2)=0.7046 
0: 2.21%           
1: 4.10% 
Crude 
MCS (restricted to those 
with tumor size) 
  
0: 113                 
1: 114                
2: 114  
n=341                    
d=99 
  
0: HR=1.38 (0.84-2.27)                
1: HR=1.26 (0.78-2.07) 
p=0.4244 
0: HR=1.38 (0.84-2.27)            
p(MCS)=0.1979                               
1: HR=1.26 (0.78-2.07)           
p(MCS)=0.3593 
-- 
16 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=99 
10 
0: HR=1.00                                     
1: HR=1.21 (0.66-2.21) 
p=0.5424 
0: HR=1.38 (0.84-2.26)           
p(MCS)=0.2021                            
1: HR=1.27 (0.77-2.08)           
p(MCS)=0.3527                            
p(Size)=0.5424 
0: 0.00%           
1: 0.79% 
Crude 
MCS (restricted to those 
with lymph node 
involvement) 
  
0: 112                 
1: 114                
2: 115  
n=341                    
d=92 
  
0: HR=1.18 (0.71-1.96)                
1: HR=1.19 (0.72-1.97) 
p=0.7579 
0: HR=1.18 (0.71-1.96)               
p(MCS)=0.5337                               
1: HR=1.19 (0.72-1.97)          
p(MCS)=0.4980 
-- 










Missing Univariate-Cox HR (95% CI) p-values* 








0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=92 
10 
0: HR=1.00                                 
1: HR=1.25 (0.78-1.99) 
p=0.3564 
0: HR=1.19 (0.71-1.99)           
p(MCS)=0.5050                             
1: HR=1.19 (0.72-1.98)           
p(MCS)=0.4916                             
p(Lymph node)=0.3564 
0: 0.85%           
1: 0.00% 
Crude 
MCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 110                 
1: 109                
2: 111  
n=330                    
d=91 
  
0: HR=1.42 (0.85-2.36)                
1: HR=1.21 (0.72-2.03) 
p=0.4106 
0: HR=1.42 (0.85-2.36)           
p(MCS)=0.1824                            
1: HR=1.21 (0.72-2.03)          
p(MCS)=0.4824 
-- 
18 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=91 
21 
0: HR=1.13 (0.75-1.70)                                    
1: HR=1.00 
p=0.5755 
0: HR=1.41 (0.84-2.35)           
p(MCS)=0.1916                             
1: HR=1.19 (0.71-2.01)           
p(MCS)=0.5088                             
p(Tamoxifen)=0.5755 
0: 0.70%           
1: 1.65% 
19 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=91 
21 
0: HR=1.00                                     
1: HR=0.98 (0.62-1.51)                                  
2: HR=1.27 (0.68-2.40)                    
p=0.6859 
0: HR=1.39 (0.83-2.33)           
p(MCS)=0.2090                            
1: HR=1.20 (0.71-2.03)           
p(MCS)=0.1671                              
p(Smoker1)=0.8821            
p(Smoker2)=0.4551                
0: 2.11%           
1: 0.83% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





20 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=91 
21 
0: HR=1.99 (1.16-3.41)                                    
1: HR=1.05 (0.50-2.19)                                 
2: HR=1.00     
p=0.0132 
0: HR=1.54 (0.92-2.57)           
p(MCS)=0.0995                            
1: HR=1.34 (0.79-2.27)           
p(MCS)=0.2729                              
p(PA0)=0.0130            
p(PA1)=0.9068           
0: 8.45%           
1: 10.74% 
Crude 
MCS (restricted to those 
with BMI) 
  
0: 110                 
1: 108                
2: 106  
n=324                    
d=85 
  
0: HR=1.42 (0.83-2.43)                
1: HR=1.27 (0.74-2.18) 
p=0.4304 
0: HR=1.42 (0.83-2.43)            
p(MCS)=0.1963                                
1: HR=1.27 (0.74-2.18)          
p(MCS)=0.3968 
-- 
21 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=85 
27 
0: HR=1.00                                     
1: HR=0.91 (0.54-1.52)                   
2: HR=1.52 (0.89-2.59)                    
p=0.1846 
0: HR=1.42 (0.83-2.42)           
p(MCS)=0.2046                            
1: HR=1.35 (0.78-2.33)           
p(MCS)=0.2913                             
p(BMI1)=0.7102             
p(BMI2)=0.1235               
0: 0.00%           
1: 6.30% 
Crude 
MCS (restricted to those 
tumor subtype) 
  
0: 99                      
1: 99                      
2: 102  
n=300                    
d=87 
  
0: HR=1.16 (0.69-1.94)                
1: HR=1.06 (0.63-1.78) 
p=0.8474 
0: HR=1.16 (0.69-1.94)             
p(MCS)=0.5696                             














Missing Univariate-Cox HR (95% CI) p-values* 





22 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=87
51 
0: HR=1.00                                     
1: HR=1.17 (0.68-2.02)      
p=0.5712 
0: HR=1.16 (0.69-1.94)           
p(MCS)=0.5832                            
1: HR=1.05 (0.62-1.76)           
p(MCS)=0.8604                             
p(Subtype)=0.5712                           
0: 0.00%           
1: 0.94% 












Appendix F. Percent Change from Crude Model and Model 1 with Each Potential Confounder (MCS & All-Cause Mortality) 
(N = 351) 
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Dataset restricted to those with full HRQOL data and baseline covariates 
Crude Mental Component Summary Score (MCS) 
0: HR=1.36 (0.83-2.23)                
1: HR=1.25 (0.76-2.06)                             
2: HR=1.00 (REF)                      
p=0.4590 
0 
n=351                    
d=99 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.67 (1.01-2.75)               
1: HR=1.32 (0.80-2.18)                               
2: HR=1.00 (REF)                   
p=0.1319 
0 
n=351                    
d=99 
0: 22.79%                      
1: 5.60% 
-- 
2 Model 1 + Race/Ethnicity 
0: HR=1.69 (1.03-2.79)               
1: HR=1.33 (0.81-2.19)                               
2: HR=1.00 (REF)                   
p=0.1208 
0 
n=351                    
d=99 
0: 24.26%                      
1: 6.40% 
0: 1.20%           
1: 0.76% 
3 Model 1 + Treatment Type 
0: HR=1.63 (0.99-2.68)               
1: HR=1.27 (0.77-2.09)                               
2: HR=1.00 (REF)                   
p=0.1560 
0 
n=351                    
d=99 
0: 19.85%                      
1: 1.60% 
0: 2.40%           
1: 3.79% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
4 Model 1 + Comorbidities 
0: HR=1.56 (0.93-2.59)               
1: HR=1.33 (0.81-2.19)                               
2: HR=1.00 (REF)                   
p=0.2308 
0 
n=351                    
d=99 
0: 14.71%                      
1: 2.21% 
0: 6.59%           
1: 0.76% 
5 Model 1 + Current Lymphedema 
0: HR=1.71 (1.03-2.82)               
1: HR=1.33 (0.81-2.19)                               
2: HR=1.00 (REF)                   
p=0.1137 
0 
n=351                    
d=99 
0: 25.74%                      
1: 6.40% 
0: 2.40%           
1: 0.76% 
6 Model 1 + Optimism 
0: HR=1.57 (0.94-2.62)               
1: HR=1.26 (0.76-2.09)                               
2: HR=1.00 (REF)                   
p=0.2271 
0 
n=351                    
d=99 
0: 15.44%                      
1: 0.80% 
0: 5.99%           
1: 4.55% 
7 Model 1 + Pessimism 
0: HR=1.47 (0.88-2.45)               
1: HR=1.25 (0.75-2.06)                               
2: HR=1.00 (REF)                   
p=0.3316 
0 
n=351                    
d=99 
0: 8.09%                      
1: 0.00% 
0: 11.98%           
1: 5.30% 
8 Model 1 + Current Fatigue 
0: HR=1.78 (1.01-3.14)               
1: HR=1.35 (0.81-2.25)                               
2: HR=1.00 (REF)                   
p=0.1358 
0 
n=351                    
d=99 
0: 30.88%                      
1: 8.00% 
0: 6.59%           
1: 2.27% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
9 Model 1 + Fear of Recurrence 
0: HR=1.71 (1.04-2.83)               
1: HR=1.35 (0.82-2.22)                               
2: HR=1.00 (REF)                   
p=0.1111 
0 
n=351                    
d=99 
0: 25.74%                      
1: 8.00% 
0: 2.40%           
1: 2.27% 
10 Model 1 + Number of Types of Confidants 
0: HR=1.67 (1.02-2.76)               
1: HR=1.34 (0.81-2.21)                               
2: HR=1.00 (REF)                   
p=0.1295 
0 
n=351                    
d=99 
0: 22.79%                      
1: 7.20% 
0: 0.00%                      
1: 1.52% 
11 Model 1 + Bodily Pain 
0: HR=1.58 (0.96-2.62)               
1: HR=1.28 (0.78-2.11)                               
2: HR=1.00 (REF)                   
p=0.2053 
0 
n=351                    
d=99 
0: 16.18%                      
1: 2.40% 
0: 5.39%           
1: 3.03% 
12 Model 1 + Perceived General Health 
0: HR=1.41 (0.83-2.37)               
1: HR=1.31 (0.80-2.16)                               
2: HR=1.00 (REF)                   
p=0.5532 
0 
n=351                    
d=99 
0: 3.68%                      
1: 4.80% 
0: 15.57%           
1: 0.76% 
Subset--Restricted to participants with Education variable 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Crude Mental Component Summary Score (MCS) 
0: HR=1.36 (0.83-2.23)                
1: HR=1.22 (0.74-2.01)                              
2: HR=1.00 (REF)                      
p=0.4628 
1 
n=350                    
d=98 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.62 (0.99-2.65)               
1: HR=1.31 (0.80-2.16)                              
2: HR=1.00 (REF)                    
p=0.1645 
1 
n=350                    
d=98 
0: 19.12%                      
1: 7.38% 
-- 
13 Model 1 + Education 
0: HR=1.64 (0.99-2.70)               
1: HR=1.37 (0.83-2.28)                              
2: HR=1.00 (REF)                    
p=0.1498 
1 
n=350                    
d=98 
0: 20.59%                      
1: 12.30% 
0: 1.23%           
1: 4.58% 
Subset--Restricted to participants with the Tumor Size variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.38 (0.84-2.27)                
1: HR=1.26 (0.77-2.07)                             
2: HR=1.00 (REF)                      
p=0.4244 
10 
n=341                  
d=99 
-- -- 
 Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.66 (1.01-2.73)               
1: HR=1.32 (0.80-2.17)                               
2: HR=1.00 (REF)                   
p=0.1392 
10 
n=341                  
d=99 
0: 20.29%                      
1: 4.76% 
-- 
14 Model 1 + Tumor Size 
0: HR=1.64 (1.00-2.70)               
1: HR=1.36 (0.82-2.24)                               
2: HR=1.00 (REF)                   
p=0.1496 
10 
n=341                  
d=99 
0: 18.84%                      
1: 7.94% 
0: 1.20%           
1: 3.03% 
Subset--Restricted to participants with Lymph Node Involvement variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.18 (0.71-1.96)                
1: HR=1.19 (0.72-1.97)                              
2: HR=1.00 (REF)                     
p=0.7579 
10 
n=341                  
d=92 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.49 (0.89-2.49)               
1: HR=1.33 (0.80-2.21)                               
2: HR=1.00 (REF)                   
p=0.2946 
10 
n=341                  
d=92 
0: 26.27%                      
1: 11.76% 
-- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
15 Model 1 + Lymph Node Involvement 
0: HR=1.48 (0.88-2.48)               
1: HR=1.32 (0.80-2.20)                               
2: HR=1.00 (REF)                   
p=0.3132 
10 
n=341                  
d=92 
0: 25.42%                      
1: 10.92% 
0: 0.67%           
1: 0.75% 
Subset--Restricted to participants with Tamoxifen Use, Smoking Status, & Physical Activity variables (24-month follow-up) 
Crude Mental Component Summary Score (MCS) 
0: HR=1.42 (0.85-2.36)                
1: HR=1.21 (0.72-2.03)                              
2: HR=1.00 (REF)                     
p=0.4071 
21 
n=330                    
d=91 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.69 (1.01-2.83)               
1: HR=1.32 (0.78-2.23)                               
2: HR=1.00 (REF)                   
p=0.1360 
21 
n=330                    
d=91 
0: 19.01%                      
1: 9.09% 
-- 
16 Model 1 + Tamoxifen Use 
0: HR=1.74 (1.04-2.92)               
1: HR=1.28 (0.76-2.17)                               
2: HR=1.00 (REF)                   
p=0.1046 
21 
n=330                    
d=91 
0: 22.54%                      
1: 5.79% 
0: 2.96%           
1: 3.03% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
17 Model 1 + Smoking Status 
0: HR=1.64 (0.98-2.75)               
1: HR=1.32 (0.78-2.22)                               
2: HR=1.00 (REF)                   
p=0.1753 
21 
n=330                    
d=91 
0: 15.49%                      
1: 9.09% 
0: 2.96%           
1: 0.00% 
18 Model 1 + Physical Activity 
0: HR=1.71 (1.02-2.87)               
1: HR=1.41 (0.83-2.39)                               
2: HR=1.00 (REF)                   
p=0.1230 
21 
n=330                    
d=91 
0: 20.42%                      
1: 16.53% 
0: 1.18%           
1: 6.82% 
Subset--Restricted to participants with BMI variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.42 (0.83-2.43)                
1: HR=1.27 (0.74-2.18)                              
2: HR=1.00 (REF)                     
p=0.4304 
27 
n=324                    
d=85 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.73 (1.01-2.97)               
1: HR=1.27 (0.74-2.20)                               
2: HR=1.00 (REF)                   
p=0.1335 
27 
n=324                    
d=85 
0: 21.83%                      
1: 0.00% 
-- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
19 Model 1 + BMI 
0: HR=1.72 (1.00-2.96)               
1: HR=1.32 (0.76-2.28)                               
2: HR=1.00 (REF)                   
p=0.1492 
27 
n=324                    
d=85 
0: 21.13%                      
1: 3.94% 
0: 0.58%           
1: 3.94% 
Subset--Restricted to participants with Tumor Subtype variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.16 (0.69-1.94)                
1: HR=1.06 (0.63-1.78)                              
2: HR=1.00 (REF)                     
p=0.8481 
51 
n=300                    
d=87 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.39 (0.83-2.34)               
1: HR=1.12 (0.67-1.89)                               
2: HR=1.00 (REF)                   
p=0.4426 
51 
n=300                    
d=87 
0: 19.83%                      
1: 5.66% 
-- 
20 Model 1 + Tumor Subtype 
0: HR=1.42 (0.85-2.39)               
1: HR=1.12 (0.66-1.88)                               
2: HR=1.00 (REF)                   
p=0.3926 
51 
n=300                    
d=87 
0: 22.41%                      
1: 5.66% 
0: 2.16%           
1: 0.00% 




Appendix G. Multivariable Modeling with Mental Component Summary Score as the Predictor and All-Cause Mortality as 
the Outcome (N = 351) 
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Crude Mental Component Summary Score (MCS) 
0: HR=1.36 (0.83-2.23)                
1: HR=1.25 (0.76-2.06)                              
2: HR=1.00 (REF)                     
p=0.4590 
0 
n=351                    
d=99 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.67 (1.01-2.75)               
1: HR=1.32 (0.80-2.18)                               
2: HR=1.00 (REF)                   
p=0.1319 
0 
n=351                    
d=99 
0: 22.79%                      
1: 5.60% 
-- -- 
2 Model 1 + Race/Ethnicity 
0: HR=1.69 (1.03-2.79)               
1: HR=1.33 (0.81-2.19)                               
2: HR=1.00 (REF)                   
p=0.1208 
0 
n=351                    
d=99 
0: 24.26%                      
1: 6.40% 
0: 1.20%           
1: 0.76% 
-- 
3 Model 1 + Race/Ethnicity + Treatment Type 
0: HR=1.64 (1.00-2.71)               
1: HR=1.27 (0.77-2.10)                               
2: HR=1.00 (REF)                   
p=0.1468 
0 
n=351                    
d=99 
0: 20.59%                      
1: 1.60% 
0: 1.80%           
1: 3.79% 
0: 2.96%           
1: 4.51% 
4 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities 
0: HR=1.51 (0.90-2.53)               
1: HR=1.27 (0.77-2.10)                               
2: HR=1.00 (REF)                   
p=0.2871 
0 
n=351                    
d=99 
0: 11.03%                      
1: 1.60% 
0: 9.58%           
1: 3.79% 
0: 7.93%           
1: 0.00% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema 
0: HR=1.56 (0.93-2.61)               
1: HR=1.30 (0.79-2.14)                               
2: HR=1.00 (REF)                   
p=0.2397 
0 
n=351                    
d=99 
0: 14.71%                      
1: 4.00% 
0: 6.59%           
1: 1.52% 
0: 3.31%           
1: 2.36% 
6 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism 
0: HR=1.41 (0.83-2.37)               
1: HR=1.24 (0.75-2.06)                               
2: HR=1.00 (REF)                   
p=0.4326 
0 
n=351                    
d=99 
0: 3.68%                      
1: 0.80% 
0: 15.57%           
1: 6.06% 
0: 9.62%           
1: 4.62% 
7 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence 
0: HR=1.44 (0.85-2.42)               
1: HR=1.27 (0.76-2.11)                               
2: HR=1.00 (REF)                   
p=0.3898 
0 
n=351                    
d=99 
0: 5.88%                      
1: 1.60% 
0: 13.77%           
1: 3.79% 
0: 2.13%           
1: 2.42% 
8 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Number of Types of Confidants 
(Confide) 
0: HR=1.45 (0.86-2.46)               
1: HR=1.29 (0.78-2.15)                               
2: HR=1.00 (REF)                   
p=0.3664 
0 
n=351                    
d=99 
0: 6.62%                      
1: 3.20% 
0: 13.17%           
1: 2.27% 
0: 0.69%           
1: 1.57% 
9 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.40 (0.82-2.38)               
1: HR=1.26 (0.76-2.11)                               
2: HR=1.00 (REF)                   
p=0.4499 
0 
n=351                    
d=99 
0: 2.94%                      
1: 0.80% 
0: 16.17%           
1: 4.55% 
0: 3.45%           
1: 2.33% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Confide + Bodily Pain + Perceived 
General Health 
0: HR=1.24 (0.72-2.15)               
1: HR=1.26 (0.76-2.10)                               
2: HR=1.00 (REF)                   
p=0.6340 
0 
n=351                    
d=99 
0: 8.82%                      
1: 0.80% 
0: 25.75%           
1: 4.55% 
0: 11.43%           
1: 0.00% 
Subset--Restricted to participants with Education variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.36 (0.83-2.23)                
1: HR=1.22 (0.74-2.01)                                
2: HR=1.00 (REF)                   
p=0.4628 
1 
n=350                  
d=98 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.66 (1.01-2.74)               
1: HR=1.30 (0.79-2.14)                                  
2: HR=1.00 (REF)                
p=0.1352 
1 
n=350                  
d=98 
0: 22.06%                      
1: 6.56% 
-- -- 
11 Model 1 + Education 
0: HR=1.64 (1.00-2.70)               
1: HR=1.37 (0.83-2.28)                               
2: HR=1.00 (REF)                   
p=0.1498 
1 
n=350                  
d=98 
0: 20.59%                      
1: 12.30% 




Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











12 Model 1 + Education + Race/Ethnicity 
0: HR=1.66 (1.01-4.04)               
1: HR=1.40 (0.84-2.34)                               
2: HR=1.00 (REF)                   
p=0.1333 
1 
n=350                  
d=98 
0: 22.06%                      
1: 14.75% 
0: 0.00%           
1: 7.69% 
0: 1.22%           
1: 2.19% 
13 Model 1 + Education + Race/Ethnicity + Treatment Type 
0: HR=1.61 (0.98-2.65)               
1: HR=1.35 (0.81-2.25)                               
2: HR=1.00 (REF)                   
p=0.1714 
1 
n=350                  
d=98 
0: 18.38%                      
1: 10.66% 
0: 3.01%           
1: 3.85% 
0: 3.01%           
1: 3.57% 
14 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities 
0: HR=1.50 (0.90-2.51)               
1: HR=1.33 (0.80-2.22)                               
2: HR=1.00 (REF)                   
p=0.2847 
1 
n=350                  
d=98 
0: 10.29%                      
1: 9.02% 
0: 9.64%           
1: 2.31% 
0: 6.83%           
1: 1.48% 
15 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema 
0: HR=1.54 (0.92-2.58)               
1: HR=1.34 (0.81-2.24)                               
2: HR=1.00 (REF)                   
p=0.2447 
1 
n=350                  
d=98 
0: 13.24%                      
1: 9.84% 
0: 18.46%           
1: 3.08% 
0: 2.67%           
1: 0.75% 
16 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism 
0: HR=1.39 (0.83-2.35)               
1: HR=1.28 (0.76-2.13)                               
2: HR=1.00 (REF)                   
p=0.4368 
1 
n=350                  
d=98 
0: 2.21%                      
1: 4.92% 
0: 16.27%           
1: 1.54% 
0: 9.74%           
1: 4.48% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence 
0: HR=1.43 (0.85-2.41)               
1: HR=1.31 (0.78-2.20)                               
2: HR=1.00 (REF)                   
p=0.3834 
1 
n=350                  
d=98 
0: 5.15%                      
1: 7.38% 
0: 13.86%           
1: 0.77% 
0: 2.88%           
1: 2.34% 
18 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Confide 
0: HR=1.44 (0.85-2.44)               
1: HR=1.33 (0.79-2.24)                               
2: HR=1.00 (REF)                   
p=0.3641 
1 
n=350                  
d=98 
0: 5.88%                      
1: 9.02% 
0: 13.25%           
1: 2.31% 
0: 0.70%           
1: 1.53% 
19 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.39 (0.82-2.36)               
1: HR=1.31 (0.78-2.21)                               
2: HR=1.00 (REF)                   
p=0.4419 
1 
n=350                  
d=98 
0: 2.21%                      
1: 7.38% 
0: 16.27%           
1: 0.77% 
0: 3.47%           
1: 1.50% 
20 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Current Lymphedema + Pessimism + 
Fear of Recurrence + Confide+ Bodily Pain + Perceived 
General Health 
0: HR=1.25 (0.72-2.15)               
1: HR=1.30 (0.77-2.19)                               
2: HR=1.00 (REF)                   
p=0.5877 
1 
n=350                  
d=98 
0: 8.09%                      
1: 6.56% 
0: 24.70%           
1: 0.00% 
0: 10.07%           
1: 0.76% 
Subset--Restricted to participants with Physical Activity variable (24-month follow-up) 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Crude Mental Component Summary Score (MCS) 
0: HR=1.42 (0.85-2.36)                
1: HR=1.21 (0.72-2.03)                              
2: HR=1.00 (REF)                     
p=0.4106 
21 
n=330                 
d=91 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.69 (1.01-2.83)               
1: HR=1.32 (0.78-2.23)                                
2: HR=1.00 (REF)                  
p=0.1360 
21 
n=330                 
d=91 
0: 19.01%                      
1: 9.09% 
-- -- 
21 Model 1 + Physical Activity 
0: HR=1.71 (1.02-2.87)               
1: HR=1.41 (0.83-2.39)                                
2: HR=1.00 (REF)                  
p=0.1230 
21 
n=330                 
d=91 
0: 20.42%                      
1: 16.53% 
0: 1.18%           
1: 6.82% 
-- 
22 Model 1 + Physical Activity + Race/Ethnicity 
0: HR=1.74 (1.04-2.93)               
1: HR=1.41 (0.83-2.40)                                
2: HR=1.00 (REF)                  
p=0.1084 
21 
n=330                 
d=91 
0: 22.54%                      
1: 16.53% 
0: 2.96%           
1: 6.82% 
0: 1.75%           
1: 0.00% 
23 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type 
0: HR=1.72 (1.03-2.88)               
1: HR=1.37 (0.80-2.33)                                
2: HR=1.00 (REF)                  
p=0.1216 
21 
n=330                 
d=91 
0: 21.13%                      
1: 13.22% 
0: 1.78%           
1: 3.79% 
0: 1.15%           
1: 2.84% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities 
0: HR=1.59 (0.94-2.70)               
1: HR=1.37 (0.80-2.34)                                
2: HR=1.00 (REF)                  
p=0.2217 
21 
n=330                 
d=91 
0: 46.48%                      
1: 25.00% 
0: 12.84%           
1: 5.65% 
0: 6.40%           
1: 1.68% 
25 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema 
0: HR=1.60 (0.94-2.73)               
1: HR=1.40 (0.82-2.39)                                
2: HR=1.00 (REF)                  
p=0.2048 
21 
n=330                 
d=91 
0: 12.68%                      
1: 15.70% 
0: 5.33%           
1: 6.06% 
0: 0.63%           
1: 2.19% 
26 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism 
0: HR=1.50 (0.88-2.57)               
1: HR=1.38 (0.81-2.37)                                
2: HR=1.00 (REF)                  
p=0.3011 
21 
n=330                 
d=91 
0: 5.63%                      
1: 14.05% 
0: 11.24%           
1: 4.55% 
0: 6.25%           
1: 1.43% 
27 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence 
0: HR=1.51 (0.88-2.59)               
1: HR=1.39 (0.81-2.38)                                
2: HR=1.00 (REF)                  
p=0.2958 
21 
n=330                 
d=91 
0: 6.34%                      
1: 14.88% 
0: 10.65%           
1: 5.30% 
0: 0.67%           
1: 0.72% 
28 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide 
0: HR=1.55 (0.89-2.68)               
1: HR=1.41 (0.82-2.42)                                
2: HR=1.00 (REF)                  
p=0.2686 
21 
n=330                 
d=91 
0: 9.15%                      
1: 16.53% 
0: 8.28%           
1: 6.82% 
0: 2.65%           
1: 1.44% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.48 (0.85-2.59)               
1: HR=1.38 (0.80-2.38)                                
2: HR=1.00 (REF)                  
p=0.3478 
21 
n=330                 
d=91 
0: 4.23%                      
1: 14.05% 
0: 12.43%           
1: 4.55% 
0: 4.52%           
1: 2.13% 
30 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide + Bodily Pain 
+ Perceived General Health 
0: HR=1.31 (0.73-2.33)               
1: HR=1.34 (0.78-2.31)                                
2: HR=1.00 (REF)                  
p=0.5299 
21 
n=330                 
d=91 
0: 7.75%                      
1: 10.74% 
0: 22.49%           
1: 1.52% 
0: 11.49%           
1: 2.90% 
Subset--Restricted to participants with Education and Physical Activity variables  
Crude Mental Component Summary Score (MCS) 
0: HR=1.42 (0.85-2.36)                
1: HR=1.17 (0.69-1.98)                               
2: HR=1.00 (REF)                    
p=0.4045 
22 
n=329                   
d=90 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.68 (1.01-2.82)               
1: HR=1.29 (0.76-2.18)                                
2: HR=1.00 (REF)                  
p=0.1388 
22 
n=329                   
d=90 




Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











31 Model 1 + Education + Physical Activity 
0: HR=1.66 (0.99-2.78)               
1: HR=1.40 (0.82-2.39)                                
2: HR=1.00 (REF)                  
p=0.1535 
22 
n=329                   
d=90 
0: 16.90%                      
1: 19.66% 




Model 1 + Education +  Physical Activity + 
Race/Ethnicity 
0: HR=1.69 (1.01-2.83)               
1: HR=1.42 (0.83-2.43)                                
2: HR=1.00 (REF)                  
p=0.1362 
22 
n=329                   
d=90 
0: 19.01%                      
1: 21.37% 
0: 0.60%           
1: 10.08% 
0: 1.81%           
1: 1.43% 
33 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type 
0: HR=1.66 (0.99-2.78)               
1: HR=1.38 (0.80-2.38)                                
2: HR=1.00 (REF)                  
p=0.1584 
22 
n=329                   
d=90 
0: 16.90%                      
1: 17.95% 
0: 1.19%           
1: 6.98% 
0: 1.78%           
1: 2.82% 
34 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities 
0: HR=1.54 (0.91-2.62)               
1: HR=1.37 (0.80-2.36)                                
2: HR=1.00 (REF)                  
p=0.2578 
22 
n=329                   
d=90 
0: 8.45%                      
1: 17.09% 
0: 8.33%           
1: 6.20% 
0: 7.23%           
1: 0.72% 
35 
Model 1 + Education + Physical Activity + Race/Ethnicity 
+ Treatment Type + Comorbidities + Current 
Lymphedema 
0: HR=1.56 (0.92-2.65)               
1: HR=1.39 (0.81-2.39)                                
2: HR=1.00 (REF)                  
p=0.2404 
22 
n=329                   
d=90 
0: 9.86%                      
1: 18.80% 
0: 7.14%           
1: 7.75% 
0: 1.30%           
1: 1.46% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Physical Activity + Race/Ethnicity 
+ Treatment Type + Comorbidities + Current 
Lymphedema + Pessimism 
0: HR=1.46 (0.85-2.50)               
1: HR=1.37 (0.79-2.36)                                
2: HR=1.00 (REF)                  
p=0.3446 
22 
n=329                   
d=90 
0: 2.82%                      
1: 17.09% 
0: 13.1%           
1: 6.20% 
0: 6.41%           
1: 1.44% 
37 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
0: HR=1.47 (0.86-2.52)               
1: HR=1.37 (0.80-2.37)                                
2: HR=1.00 (REF)                  
p=0.3356 
22 
n=329                   
d=90 
0: 3.52%                      
1: 17.09% 
0: 12.50%           
1: 6.20% 
0: 0.68%           
1: 0.00% 
38 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide 
0: HR=1.50 (0.86-2.59)               
1: HR=1.39 (0.80-2.40)                                
2: HR=1.00 (REF)                  
p=0.3178 
22 
n=329                   
d=90 
0: 5.63%                      
1: 18.80% 
0: 10.71%           
1: 7.75% 
0: 2.04%           
1: 1.46% 
39 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide + Bodily Pain 
0: HR=1.43 (0.82-2.51)               
1: HR=1.37 (0.79-2.37)                                
2: HR=1.00 (REF)                  
p=0.3985 
22 
n=329                   
d=90 
0: 0.70%                      
1: 17.09% 
0: 14.88%           
1: 6.20% 
0: 4.67%           
1: 1.44% 
40 
Model 1 + Education +  Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide + Bodily Pain + Perceived General Health 
0: HR=1.28 (0.72-2.29)               
1: HR=1.33 (0.76-2.31)                                
2: HR=1.00 (REF)                  
p=0.5655 
22 
n=329                   
d=90 
0: 9.86%                      
1: 13.68% 
0: 23.81%           
1: 3.10% 
0: 10.49%           
1: 2.92% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Subset--Restricted to participants with BMI variable  
Crude Mental Component Summary Score (MCS) 
0: HR=1.42 (0.83-2.43)                
1: HR=1.27 (0.74-2.18)                               
2: HR=1.00 (REF)                    
p=0.4304 
27 
n=324                    
d=85 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.73 (1.01-2.97)               
1: HR=1.27 (0.74-2.20)                                
2: HR=1.00 (REF)                  
p=0.1335 
27 
n=324                    
d=85 
0: 21.83%                      
1: 0.00% 
-- -- 
41 Model 1 + Education + BMI 
0: HR=1.72 (1.00-2.96)               
1: HR=1.32 (0.76-2.28)                                
2: HR=1.00 (REF)                  
p=0.1492 
27 
n=324                    
d=85 
0: 21.13%                      
1: 3.94% 
0: 0.58%           
1: 3.94% 
-- 
42 Model 1 + Education + BMI + Race/Ethnicity 
0: HR=1.75 (1.01-3.02)               
1: HR=1.33 (0.77-2.32)                                
2: HR=1.00 (REF)                  
p=0.1360 
27 
n=324                    
d=85 
0: 23.24%                      
1: 4.72% 
0: 1.16%           
1: 4.72% 
0: 1.74%           
1: 0.76% 
43 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type 
0: HR=1.67 (0.97-2.89)               
1: HR=1.23 (0.70-2.15)                                
2: HR=1.00 (REF)                  
p=0.1739 
27 
n=324                    
d=85 
0: 17.61%                      
1: 3.15% 
0: 31.50%           
1: 3.15% 
0: 4.57%           
1: 7.52% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities 
0: HR=1.61 (0.92-2.82)               
1: HR=1.22 (0.70-2.14)                                
2: HR=1.00 (REF)                  
p=0.2370 
27 
n=324                    
d=85 
0: 13.38%                      
1: 3.94% 
0: 6.94%           
1: 3.94% 
0: 3.59%           
1: 0.81% 
45 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema 
0: HR=1.69 (0.96-2.95)               
1: HR=1.25 (0.71-2.20)                                
2: HR=1.00 (REF)                  
p=0.1838 
27 
n=324                    
d=85 
0: 19.01%                      
1: 1.57% 
0: 2.31%           
1: 1.57% 
0: 4.97%           
1: 2.46% 
46 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism 
0: HR=1.52 (0.86-2.67)               
1: HR=1.19 (0.68-2.08)                                
2: HR=1.00 (REF)                  
p=0.3423 
27 
n=324                    
d=85 
0: 7.04%                      
1: 6.30% 
0: 12.14%           
1: 6.30% 
0: 10.06%           
1: 4.80% 
47 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence 
0: HR=1.54 (0.88-2.71)               
1: HR=1.21 (0.69-2.14)                                
2: HR=1.00 (REF)                  
p=0.3206 
27 
n=324                    
d=85 
0: 8.45%                      
1: 4.72% 
0: 10.98%           
1: 4.72% 
0: 1.32%           
1: 1.68% 
48 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide 
0: HR=1.56 (0.88-2.74)               
1: HR=1.22 (0.69-2.14)                                
2: HR=1.00 (REF)                  
p=0.3061 
27 
n=324                    
d=85 
0: 9.86%                      
1: 3.94% 
0: 9.83%           
1: 3.94% 
0: 1.30%           
1: 0.83% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.54 (0.87-2.71)               
1: HR=1.20 (0.68-2.12)                                
2: HR=1.00 (REF)                  
p=0.3289 
27 
n=324                    
d=85 
0: 8.45%                      
1: 5.51% 
0: 10.98%           
1: 5.51% 
0: 1.28%           
1: 1.64% 
50 
Model 1 + Education + BMI + Race/Ethnicity + Treatment 
Type + Comorbidities + Current Lymphedema + 
Pessimism + Fear of Recurrence + Confide + Bodily Pain 
+ Perceived General Health 
0: HR=1.37 (0.76-2.46)               
1: HR=1.18 (0.67-2.08)                                
2: HR=1.00 (REF)                  
p=0.5805 
27 
n=324                    
d=85 
0: 3.52%                      
1: 7.09% 
0: 20.81%           
1: 7.09% 
0: 11.04%           
1: 1.67% 
Subset--Restricted to participants with Education, Physical Activity, and BMI variables  
Crude Mental Component Summary Score (MCS) 
0: HR=1.51 (0.87-2.64)                
1: HR=1.21 (0.68-2.15)                               
2: HR=1.00 (REF)                    
p=0.3415 
46 
n=305                      
d=77 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.84 (1.05-3.22)               
1: HR=1.31 (0.74-2.33)                                
2: HR=1.00 (REF)                  
p=0.1006 
46 
n=305                      
d=77 
0: 21.85%                      
1: 8.26% 
-- -- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











51 Model 1 + Education + Physical Activity + BMI 
0: HR=1.78 (1.01-3.14)               
1: HR=1.46 (0.81-2.64)                                
2: HR=1.00 (REF)                  
p=0.1317 
46 
n=305                      
d=77 
0: 17.88%                      
1: 20.66% 




Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity 
0: HR=1.84 (1.04-3.26)               
1: HR=1.51 (0.83-2.73)                                
2: HR=1.00 (REF)                  
p=0.1064 
46 
n=305                      
d=77 
0: 21.85%                      
1: 24.79% 
0: 0.00%           
1: 15.27% 
0: 3.37%           
1: 3.42% 
53 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type 
0: HR=1.81 (1.02-3.19)               
1: HR=1.46 (0.80-2.66)                                
2: HR=1.00 (REF)                  
p=0.1246 
46 
n=305                      
d=77 
0: 19.87%                      
1: 20.66% 
0: 1.63%           
1: 11.45% 
0: 1.63%           
1: 3.31% 
54 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities 
0: HR=1.75 (0.98-3.12)               
1: HR=1.44 (0.79-2.64)                                
2: HR=1.00 (REF)                  
p=0.1618 
46 
n=305                      
d=77 
0: 15.89%                      
1: 19.01% 
0: 4.89%           
1: 9.92% 
0: 3.31%           
1: 1.37% 
55 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema 
0: HR=1.78 (1.00-3.17)               
1: HR=1.46 (0.80-2.67)                                
2: HR=1.00 (REF)                  
p=0.1471 
46 
n=305                      
d=77 
0: 17.88%                      
1: 20.66% 
0: 3.26%           
1: 11.45% 
0: 1.71%           
1: 1.39% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism 
0: HR=1.65 (0.92-2.96)               
1: HR=1.43 (0.78-2.62)                                
2: HR=1.00 (REF)                  
p=0.2391 
46 
n=305                      
d=77 
0: 9.27%                      
1: 18.18% 
0: 10.33%           
1: 9.16% 
0: 7.30%           
1: 2.05% 
57 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
0: HR=1.65 (0.92-2.97)               
1: HR=1.43 (0.78-2.63)                                
2: HR=1.00 (REF)                  
p=0.2384 
46 
n=305                      
d=77 
0: 9.27%                      
1: 18.18% 
0: 10.33%           
1: 9.16% 
0: 0.00%           
1: 0.00% 
58 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide 
0: HR=1.68 (0.93-3.05)               
1: HR=1.44 (0.78-2.64)                                
2: HR=1.00 (REF)                  
p=0.2213 
46 
n=305                      
d=77 
0: 11.26%                      
1: 19.01% 
0: 8.70%           
1: 9.92% 
0: 1.82%           
1: 0.70% 
59 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide + Bodily Pain 
0: HR=1.66 (0.91-3.03)               
1: HR=1.43 (0.78-2.63)                                
2: HR=1.00 (REF)                  
p=0.2449 
46 
n=305                      
d=77 
0: 9.93%                      
1: 18.18% 
0: 9.78%           
1: 9.16% 
0: 1.19%           
1: 0.69% 
60 
Model 1 + Education + Physical Activity + BMI + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Current Lymphedema + Pessimism + Fear of Recurrence 
+ Confide + Bodily Pain + Perceived General Health 
0: HR=1.46 (0.79-2.71)               
1: HR=1.35 (0.73-2.50)                                
2: HR=1.00 (REF)                  
p=0.4553 
46 
n=305                      
d=77 
0: 3.31%                      
1: 11.57% 
0: 20.65%           
1: 3.05% 
0: 12.05%           
1: 5.59% 
 
 Appendix H. Physical Component Summary Score Univariate HR Analysis and Percent Change for Breast Cancer-Specific 
Mortality when Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (PCS) 
0: ≤ 50.28                                      
1: > 50.28 (REF) 
0: 176                 
1: 175 
n=351                    
d=26 
0 0: HR=1.09 (0.51-2.36) p=0.8239 
0: HR=1.09 (0.51-2.36)             
p(PCS)=0.8239                       
-- 
1 Age Continuous -- 
n=351                    
d=26 
0 HR=1.00 (0.97-1.04) p=0.8950 
0: HR=1.08 (0.49-2.37)           
p(PCS)=0.8473                                                          
p(Age)=0.8950 
0: 0.92%            
2 Race/Ethnicity 
0: Non-Hispanic 
White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=26 
0 
0: HR=1.00                                    
1: HR=0.84 (0.32-2.23) 
p=0.7292 
0: HR=1.09 (0.51-2.36)           
p(PCS)=0.8230                                                       
p(Ethnicity)=0.7292 
0: 0.00%        
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=26 
0 
0: HR=1.10 (0.51-2.40)                                    
1: HR=1.00 
p=0.8040 
0: HR=1.08 (0.50-2.34)           
p(PCS)=0.8454                                                            
p(Marital)=0.8040 
0: 0.92%        
   










Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=2.75 (1.26-5.99)         
p=0.0110 
0: HR=1.14 (0.53-2.46)           
p(PCS)=0.7388                                                          
p(Stage)=0.0110                                       
0: 4.59%        
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=26 
0 
0: HR=1.00                                  
1: HR=6.83 (1.56-29.79)                                  
2: HR=2.56 (0.54-12.04)                    
p=0.0076 
0: HR=1.24 (0.57-2.68)           
p(PCS)=0.5852                                                          
p(Treatment1)=0.0106              
p(Treatment2)=0.2354                
0: 13.76%        
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=26 
0 
0: HR=1.00                                    
1: HR=1.49 (0.55-4.01) 
p=0.4335 
0: HR=1.04 (0.47-2.27)           
p(PCS)=0.9274                                                           
p(Comorbidities)=0.4335 
0: 4.59%        
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307           
1: 44             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=0.83 (0.25-2.81) 
p=0.7685 
0: HR=1.11 (0.51-2.42)           
p(PCS)=0.7910                                                          
p(Lymphedema)=0.7685 
0: 1.83%        
   










Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                     
1: 268            
n=351                    
d=26 
0 
0: HR=0.62 (0.21-1.81)                                    
1: HR=1.00 
p=0.3819 
0: HR=1.15 (0.53-2.49)           
p(PCS)=0.7299                                                        
p(Optimism)=0.3819 
0: 5.50%        
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255                    
1: 96             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=1.55 (0.68-3.54) 
p=0.2970 
0: HR=1.01 (0.46-2.21)           
p(PCS)=0.9825                                            
p(Pessimism)=0.2970 
0: 7.34%        
10 
Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                  
1: 172            
2: 113                 
n=351                    
d=26 
0 
0: HR=0.30 (0.07-1.35)                                     
1: HR=0.67 (0.30-1.49)                                  
2: HR=1.00 
p=0.2463 
0: HR=1.07 (0.49-2.31)           
p(PCS)=0.8670                                                        
p(Confidant0)=0.1174            
p(Confidant1)=0.3220                
0: 1.83%        
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154           
1: 197             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=1.43 (0.64-3.21) 
p=0.3862 
0: HR=1.10 (0.51-2.38)           
p(PCS)=0.8047                                                 
p(Fear)=0.3862 
0: 0.92%        
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with education) 
  
0: 175                 
1: 175                 
n=350                    
d=26 
  0: HR=1.09 (0.51-2.36)                 p=0.8183 
0: HR=1.09 (0.51-2.36)           
p(PCS)=0.8183                                 
-- 
12 Education 
0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=26 
1 
0: HR=1.36 (0.48-3.85)                                     
1: HR=1.10 (0.39-3.05)                   
2: HR=0.17 (0.02-1.44)                   
3: HR=1.00 
p=0.2800 
0: HR=0.99 (0.45-2.15)           
p(PCS)=0.9735                                                         
p(Education0)=0.5647              
p(Education1)=0.8616               
p(Education2)=0.1047 
0: 9.17%        
Crude 
PCS (restricted to those 
with tumor size) 
  
0: 173                 
1: 168                 
n=341                    
d=26 
  0: HR=1.07 (0.50-2.31)                 p=0.8631 
0: HR=1.07 (0.50-2.31)               
p(PCS)=0.8631                        
-- 
13 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=26 
10 
0: HR=1.00                                     
1: HR=3.88 (1.69-8.94) 
p=0.0014 
0: HR=1.11 (0.51-2.39)           
p(PCS)=0.7997                                                           
p(Size)=0.0014 
0: 3.74%        
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with lymph node 
involvement) 
  
0: 170                 
1: 171                 
n=341                    
d=24 
  0: HR=0.94 (0.42-2.09)             p=0.8715 






0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=24 
10 
0: HR=1.00                                 
1: HR=2.97 (0.83-2.10) 
p=0.0080 
0: HR=0.99 (0.44-2.22)           
p(PCS)=0.9865                                                           
p(Lymph node)=0.0080 
0: 5.32%        
Crude 
PCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 165                 
1: 165                 
n=330                    
d=24 
  0: HR=1.31 (0.59-2.93)                 p=0.5088 
0: HR=1.31 (0.59-2.93)                      
p(PCS)=0.5088 
-- 
15 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=24 
21 
0: HR=0.88 (0.39-1.97)                                    
1: HR=1.00 
p=0.7580 
0: HR=1.32 (0.59-2.95)           
p(PCS)=0.4990                                                           
p(Tamoxifen)=0.7580 
0: 0.76%        
   










Missing Univariate-Cox HR (95% CI) p-values* 





16 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=24 
21 
0: HR=1.00                                     
1: HR=0.91 (0.37-2.23)                                  
2: HR=1.86 (0.63-5.44)                    
p=0.4113 
0: HR=1.24 (0.55-2.79)           
p(PCS)=0.6020                                                           
p(Smoker1)=0.8280              
p(Smoker2)=0.2600                
0: 5.34%        
17 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=24 
21 
0: HR=1.27 (0.44-3.60)                                    
1: HR=1.64 (0.49-5.44)                                 
2: HR=1.00     
p=0.7216 
0: HR=1.25 (0.55-2.82)           
p(PCS)=0.5970                                                           
p(PA0)=0.6600             
p(PA1)=0.4222            
0: 4.58%        
Crude 
PCS (restricted to those 
with BMI) 
  
0: 161                 
1: 163                 
n=324                    
d=24 
  0: HR=1.09 (0.49-2.42)                 p=0.8385 
0: HR=1.09 (0.49-2.42)             
p(PCS)=0.8385                              
-- 
18 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=24 
27 
0: HR=1.00                                     
1: HR=1.77 (0.72-4.39)                   
2: HR=1.48 (0.49-4.45)                    
p=0.4574 
0: HR=1.02 (0.45-2.28)           
p(PCS)=0.9684                                                           
p(BMI1)=0.2149              
p(BMI2)=0.4887                
0: 6.42%        
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
tumor subtype) 
  
0: 155                 
1: 145                
n=300                    
d=22 
  0: HR=1.02 (0.44-2.35)                 p=0.9667 
0: HR=1.02 (0.44-2.35)             
p(PCS)=0.9667                                 
-- 
19 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=22
51 
0: HR=1.00                                     
1: HR=1.55 (0.57-4.19)      
p=0.3926 
0: HR=1.02 (0.44-2.35)           
p(PCS)=0.9659                                                          
p(Subtype)=0.3926                           
0: 0.00%        







 Appendix I. Mental Component Summary Score Univariate HR Analysis and Percent Change for Breast Cancer-Specific 
Mortality when Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (MCS) 
0: ≤ 50.70                                     
1: > 50.70 (REF) 
0: 176                
1: 175 
n=351                    
d=26 
0 0: HR=1.22 (0.57-2.65)                 p=0.6082 
0: HR=1.22 (0.57-2.65)              
p(MCS)=0.6082                                
-- 
1 Age Continuous -- 
n=351                    
d=26 
0 HR=1.00 (0.97-1.04) p=0.8186 
0: HR=1.24 (0.57-2.68)           





White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=26 
0 
0: HR=1.00                                    
1: HR=0.83 (0.31-2.20) 
p=0.7047 
0: HR=1.24 (0.57-2.68)           
p(MCS)=0.5910                                                         
p(Ethnicity)=0.7047 
0: 1.64%
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=26 
0 
0: HR=1.11 (0.51-2.40)                                    
1: HR=1.00 
p=0.7902 
0: HR=1.22 (0.57-2.64)           














Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=2.77 (1.27-6.05)         
p=0.0104 
0: HR=1.29 (0.60-2.80)           
p(MCS)=0.5165                                                          
p(Stage)=0.0104                                          
0: 5.74%
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=26 
0 
0: HR=1.00                                  
1: HR=6.61 (1.52-28.74)                                  
2: HR=2.54 (0.54-11.97)                    
p=0.0092 
0: HR=1.14 (0.53-2.47)           
p(MCS)=0.2111                                                          
p(Treatment1)=0.0119              
p(Treatment2)=0.2383                
0: 6.56%       
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=26 
0 
0: HR=1.00                                    
1: HR=1.45 (0.54-3.90) 
p=0.4574 
0: HR=1.18 (0.54-2.57)           
p(MCS)=0.6824                                                           
p(Comorbidities)=0.4574 
0: 3.28%
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307           
1: 44             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=0.84 (0.25-2.79) 
p=0.7688 
0: HR=1.23 (0.57-2.67)           














Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                     
1: 268            
n=351                    
d=26 
0 
0: HR=0.60 (0.20-1.75)                                    
1: HR=1.00 
p=0.3460 
0: HR=1.32 (0.60-2.88)           
p(MCS)=0.4909                                                        
p(Optimism)=0.3460 
0: 8.20%
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255                    
1: 96             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=1.51 (0.66-3.46) 
p=0.3280 
0: HR=1.13 (0.51-2.49)           
p(MCS)=0.7593                                                          
p(Pessimism)=0.3280 
0: 7.38%
10 Current Fatigue 
0: No (REF)                                           
1: Yes  
0: 136           
1: 215             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=0.75 (0.55-1.35) 
p=0.5085 
0: HR=1.36 (0.59-3.12)           
p(MCS)=0.4728                                                 
p(Fatigue)=0.5085 
0: 11.48%     
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154           
1: 197             
n=351                    
d=26 
0 
0: HR=1.00                                     
1: HR=1.39 (0.61-3.15) 
p=0.4284 
0: HR=1.16 (0.53-2.54)           
p(MCS)=0.7029                                                
p(Fear)=0.4284 
0: 4.92%   










Missing Univariate-Cox HR (95% CI) p-values* 






Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                  
1: 172            
2: 113                 
n=351                    
d=26 
0 
0: HR=0.30 (0.07-1.32)                                     
1: HR=0.65 (0.29-1.46)                                  
2: HR=1.00 
p=0.2284 
0: HR=1.28 (0.59-2.78)           
p(MCS)=0.5283                                                        
p(Confidant0)=0.1105            
p(Confidant1)=0.2964                
0: 4.92%       
13 Bodily Pain 
0: No Pain                                      
1: Experienced Pain 
(REF) 
0: 180                        
1: 171             
n=351                   
d=26 
0 
0: HR=1.00                                   
1: HR=1.20 (0.48-3.02) 
p=0.6965 
0: HR=1.20 (0.55-2.61)           
p(MCS)=0.6517                                             
p(Pain)=0.6965 




0: "Poor" & "Fair"                                          
1: "Good", "Very 
Good", & "Excellent" 
(REF) 
0: 54                   
1: 297            
n=351                    
d=26 
0 
0: HR=1.42 (0.52-3.83)                                     
1: HR=1.00 
p=0.4930 
0: HR=1.17 (0.53-2.56)              
p(MCS)=0.7027                                                
p(Health)=0.4930              
0: 4.10%   
Crude 
MCS (restricted to those 
with education) 
  
0: 176                 
1: 174                 
n=350                    
d=26 
  0: HR=1.22 (0.56-2.64)                 p=0.6131 














Missing Univariate-Cox HR (95% CI) p-values* 






0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=26 
1 
0: HR=1.37 (0.49-3.85)                                     
1: HR=1.09 (0.40-3.01)                   
2: HR=0.18 (0.02-1.48)                   
3: HR=1.00 
p=0.2833 
0: HR=1.12 (0.52-2.42)           
p(MCS)=0.7803                                                        
p(Education0)=0.5539              
p(Education1)=0.8640               
p(Education2)=0.1095 
0: 8.20%       
Crude 
MCS (restricted to those 
with tumor size) 
  
0: 170                 
1: 171                 
n=341                    
d=26 
  0: HR=1.24 (0.58-2.69) p=0.5804 
0: HR=1.24 (0.58-2.69)            
p(MCS)=0.5804                               
-- 
16 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=26 
10 
0: HR=1.00                                     
1: HR=3.88 (1.69-8.93) 
p=0.0014 
0: HR=1.26 (0.58-2.72)           
p(MCS)=0.5608                                          
p(Size)=0.0014 
0: 1.61%       
Crude 
MCS (restricted to those 
with lymph node 
involvement) 
  
0: 170                 
1: 171                 
n=341                    
d=24 
  0: HR=1.05 (0.47-2.33)                 p=0.9126 
0: HR=1.05 (0.47-2.33)                  
p(MCS)=0.9126                              
-- 
  










Missing Univariate-Cox HR (95% CI) p-values* 








0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=24 
10 
0: HR=1.00                                 
1: HR=2.98 (1.34-6.66) 
p=0.0077 
0: HR=1.09 (0.49-2.44)           




MCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 165                 
1: 165                 
n=330                    
d=24 
  0: HR=1.26 (0.56-2.81)                 p=0.5772 
0: HR=1.26 (0.56-2.81)              
p(MCS)=0.5772                             
-- 
18 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=24 
21 
0: HR=0.89 (0.40-1.99)                                    
1: HR=1.00 
p=0.7758 
0: HR=1.26 (0.56-2.81)           
p(MCS)=0.5732                                                         
p(Tamoxifen)=0.7758 
0: 0.00%
19 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=24 
21 
0: HR=1.00                                     
1: HR=0.88 (0.36-2.17)                                  
2: HR=1.84 (0.62-5.42)                    
p=0.3991 
0: HR=1.21 (0.54-2.71)           
p(MCS)=0.6497                                                         
p(Smoker1)=0.7795            
p(Smoker2)=0.2698                
0: 3.97%       
  










Missing Univariate-Cox HR (95% CI) p-values* 





20 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=24 
21 
0: HR=1.37 (0.49-3.87)                                    
1: HR=1.76 (0.54-5.78)                                 
2: HR=1.00     
p=0.6484 
0: HR=1.29 (0.58-2.90)           
p(MCS)=0.5332                                                        
p(PA0)=0.5499            
p(PA1)=0.3520           
0: 2.38%       
Crude 
MCS (restricted to those 
with BMI) 
  
0: 167                 
1: 157                
n=324                    
d=24 
  0: HR=1.40 (0.62-3.16)                 p=0.4144 
0: HR=1.40 (0.62-3.16)               
p(MCS)=0.4144                            
-- 
21 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=24 
27 
0: HR=1.00                                     
1: HR=1.75 (0.71-4.31)                   
2: HR=1.46 (0.49-4.35)                    
p=0.4729 
0: HR=1.36 (0.61-3.08)           
p(MCS)=0.4539                                                         
p(BMI1)=0.2250             
p(BMI2)=0.5021               
0: 2.86%       
Crude 
MCS (restricted to those 
tumor subtype) 
  
0: 150                      
1: 150                       
n=300                    
d=22
  0: HR=1.05 (0.45-2.42)                 p=0.9132 
0: HR=1.05 (0.45-2.42)              
p(MCS)=0.9132                              
-- 
  










Missing Univariate-Cox HR (95% CI) p-values* 





22 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=22
51 
0: HR=1.00                                     
1: HR=1.54 (0.57-4.18)      
p=0.3945 
0: HR=1.04 (0.45-2.39)           
p(MCS)=0.9342                                                        
p(Subtype)=0.3945                           
0: 0.95%




 Appendix J. Physical Component Summary Score Univariate HR Analysis and Percent Change for Non-Cancer Mortality 
when Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (PCS) 
0: ≤ 44.75                                      
1: > 44.75 & ≤ 54.39                       
2: > 54.39 (REF) 
0: 117                
1: 117            
2: 117  
n=351                    
d=64 
0 
0: HR=5.63 (2.74-11.55)                
1: HR=1.41 (0.59-3.35) 
p=<0.0001 
0: HR=5.63 (2.74-11.55)             
p(PCS)=<0.0001                                
1: HR=1.41 (0.59-3.35)           
p(PCS)=0.4366 
-- 
1 Age Continuous -- 
n=351                    
d=64 
0 HR=1.10 (1.07-1.13) p=<0.0001 
0: HR=2.71 (1.28-5.74)           
p(PCS)=0.0090                              
1: HR=0.92 (0.38-2.27)           
p(PCS)=0.8539                              
p(Age)=<0.0001 




White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=64 
0 
0: HR=1.00                                    
1: HR=0.55 (0.27-1.11) 
p=0.0941 
0: HR=5.63 (2.74-11.57)           
p(PCS)=<0.0001                              
1: HR=1.41 (0.59-3.34)           
p(PCS)=0.0944                             
p(Ethnicity)=0.0941 
0: 0.00%           
1: 0.00% 
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=64 
0 
0: HR=2.23 (1.32-3.77)                                    
1: HR=1.00 
p=0.0028 
0: HR=5.10 (2.48-10.49)           
p(PCS)=<0.0001                              
1: HR=1.39 (0.59-3.31)           
p(PCS)=0.4514                              
p(Marital)=0.0028 
0: 9.41%           
1: 1.42% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.81 (0.42-1.55)         
p=0.5227 
0: HR=5.58 (2.72-11.45)           
p(PCS)=<0.0001                              
1: HR=1.40 (0.59-3.32)           
p(PCS)=0.4485                            
p(Stage)=0.5227                                         
0: 0.89%           
1: 0.71% 
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=64 
0 
0: HR=1.00                                  
1: HR=0.43 (0.21-0.87)                                  
2: HR=0.69 (0.40-1.19)                    
p=0.0556 
0: HR=5.31 (2.58-10.92)           
p(PCS)=<0.0001                             
1: HR=1.39 (0.58-3.29)           
p(PCS)=0.4594                             
p(Treatment1)=0.0181              
p(Treatment2)=0.1819                
0: 5.68%           
1: 1.42% 
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=64 
0 
0: HR=1.00                                    
1: HR=1.31 (0.72-2.40) 
p=0.3799 
0: HR=5.36 (2.58-11.11)           
p(PCS)=<0.0001                              
1: HR=1.38 (0.58-3.27)           
p(PCS)=0.4704                             
p(Comorbidities)=0.3799 
0: 4.80%           
1: 2.13% 
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307                     
1: 44             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.48 (0.21-1.12) 
p=0.0875 
0: HR=6.09 (2.96-12.54)           
p(PCS)=<0.0001                              
1: HR=1.47 (0.62-3.49)           
p(PCS)=0.3823                             
p(Lymphedema)=0.0875 
0: 8.17%           
1: 4.26% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                   
1: 268            
n=351                    
d=64 
0 
0: HR=1.50 (0.90-2.53)                                    
1: HR=1.00 
p=0.1227 
0: HR=5.09 (2.44-10.58)           
p(PCS)=<0.0001                              
1: HR=1.36 (0.57-3.23)           
p(PCS)=0.4895                           
p(Optimism)=0.1227 
0: 9.59%           
1: 3.55% 
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255             
1: 96             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=1.39 (0.83-2.33) 
p=0.2062 
0: HR=5.26 (2.54-10.89)           
p(PCS)=<0.0001                              
1: HR=1.38 (0.58-3.28)           
p(PCS)=0.4664                             
p(Pessimism)=0.2062 
0: 6.57%           
1: 2.13% 
10 
Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                 
1: 172            
2: 113                 
n=351                    
d=64 
0 
0: HR=2.85 (1.41-5.74)                                     
1: HR=1.67 (0.87-3.20)                                  
2: HR=1.00 
p=0.0123 
0: HR=5.77 (2.81-11.86)           
p(PCS)=<0.0001                             
1: HR=1.50 (0.63-3.57)           
p(PCS)=0.3575                            
p(Confidant0)=0.0034            
p(Confidant1)=0.1212                
0: 2.49%           
1: 6.38% 
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154                     
1: 197             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.49 (0.30-0.81) 
p=0.0053 
0: HR=5.63 (2.74-11.56)           
p(PCS)=<0.0001                            
1: HR=1.43 (0.60-3.39)           
p(PCS)=0.4191                      
p(Fear)=0.0053 
0: 0.00%           
1: 1.42% 
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with education) 
  
0: 116                 
1: 117                
2: 117  
n=350                    
d=63 
  
0: HR=5.51 (2.68-11.33)                
1: HR=1.41 (0.59-3.35) 
p=<0.0001 
0: HR=5.51 (2.68-11.33)           
p(PCS)=<0.0001                                




0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=63 
1 
0: HR=2.50 (1.05-5.94)                                     
1: HR=1.73 (0.74-4.04)                   
2: HR=2.05 (0.81-5.22)                   
3: HR=1.00 
p=0.2047 
0: HR=5.34 (2.56-11.12)           
p(PCS)=<0.0001                             
1: HR=1.33 (0.56-3.17)           
p(PCS)=0.5231                              
p(Education0)=0.0386              
p(Education1)=0.2037               
p(Education2)=0.1319 
0: 3.09%           
1: 5.67% 
Crude 
PCS (restricted to those 
with tumor size) 
  
0: 116                 
1: 114                
2: 111  
n=341                    
d=64 
  
0: HR=5.43 (2.64-11.14)                
1: HR=1.39 (0.59-3.30) 
p=<0.0001 
0: HR=5.43 (2.64-11.14)            
p(PCS)=<0.0001                                
1: HR=1.39 (0.59-3.30)           
p(PCS)=0.4544 
-- 
13 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=64 
10 
0: HR=1.00                                     
1: HR=0.45 (0.14-1.45) 
p=0.1828 
0: HR=5.44 (2.65-11.16)           
p(PCS)=<0.0001                              
1: HR=1.42 (0.60-3.38)           
p(PCS)=0.4238                             
p(Size)=0.1828 
0: 0.18%           
1: 4.51% 
  










Missing Univariate-Cox HR (95% CI) p-values* 






PCS (restricted to those 
with lymph node 
involvement) 
  
0: 113                 
1: 112                
2: 116  
n=341                    
d=59 
  
0: HR=6.29 (2.95-13.41)                
1: HR=1.36 (0.54-3.45) 
p=<0.0001 
0: HR=6.29 (2.95-13.41)            
p(PCS)=<0.0001                                 






0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=59 
10 
0: HR=1.00                                 
1: HR=0.86 (0.45-1.66) 
p=0.6606 
0: HR=6.25 (2.93-13.34)           
p(PCS)=<0.0001                              
1: HR=1.36 (0.53-3.43)           
p(PCS)=0.5225                             
p(Lymph node)=0.6606 
0: 0.64%           
1: 0.00% 
Crude 
PCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 107                 
1: 110                
2: 113  
n=330                    
d=59 
  
0: HR=5.19 (2.51-10.74)                
1: HR=1.42 (0.60-3.37) 
p=<0.0001 
0: HR=5.19 (2.51-10.74)           
p(PCS)=<0.0001                                
1: HR=1.42 (0.60-3.37)           
p(PCS)=0.4276 
-- 
15 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=59 
21 
0: HR=1.36 (0.81-2.26)                                    
1: HR=1.00 
p=0.2465 
0: HR=5.22 (2.52-10.81)           
p(PCS)=<0.0001                              
1: HR=1.39 (0.59-3.31)           
p(PCS)=0.4522                             
p(Tamoxifen)=0.2465 
0: 0.58%           
1: 2.11% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





16 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=59 
21 
0: HR=1.00                                     
1: HR=1.07 (0.62-1.86)                                  
2: HR=1.20 (0.54-2.67)                    
p=0.8981 
0: HR=5.16 (2.49-10.70)           
p(PCS)=<0.0001                             
1: HR=1.41 (0.59-3.34)           
p(PCS)=0.4393                             
p(Smoker1)=0.7983              
p(Smoker2)=0.6515                
0: 0.58%           
1: 0.70% 
17 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=59 
21 
0: HR=1.51 (0.77-2.97)                                    
1: HR=0.37 (0.12-1.81)                                 
2: HR=1.00     
p=0.0191 
0: HR=4.99 (2.38-10.48)           
p(PCS)=<0.0001                             
1: HR=1.35 (0.57-3.23)           
p(PCS)=0.4965                              
p(PA0)=0.2314             
p(PA1)=0.0936            
0: 3.85%           
1: 4.93% 
Crude 
PCS (restricted to those 
with BMI) 
  
0: 106                 
1: 110                
2: 108  
n=324                    
d=54 
  
0: HR=5.09 (2.36-10.99)                
1: HR=1.41 (0.57-3.51) 
p=<0.0001 
0: HR=5.09 (2.36-10.99)              
p(PCS)=<0.0001                                
1: HR=1.41 (0.57-3.51)         
p(PCS)=0.4585 
-- 
   










Missing Univariate-Cox HR (95% CI) p-values* 





18 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=54 
27 
0: HR=1.00                                     
1: HR=0.51 (0.25-1.04)                   
2: HR=1.03 (0.54-1.95)                    
p=0.1354 
0: HR=5.25 (2.40-11.49)           
p(PCS)=<0.0001                             
1: HR=1.46 (0.58-3.64)           
p(PCS)=0.4199                              
p(BMI1)=0.0622              
p(BMI2)=0.9382                
0: 3.14%           
1: 3.55% 
Crude 
PCS (restricted to those 
tumor subtype) 
  
0: 102                 
1: 101                
2: 97  
n=300                    
d=56 
  
0: HR=4.43 (2.13-9.20)                
1: HR=1.27 (0.53-3.07) 
p=<0.0001 
0: HR=4.43 (2.13-9.20)               
p(PCS)=<0.0001                                
1: HR=1.27 (0.53-3.07)         
p(PCS)=0.5912 
-- 
19 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=56
51 
0: HR=1.00                                     
1: HR=1.47 (0.76-2.85)      
p=0.2578 
0: HR=4.53 (2.18-9.43)           
p(PCS)=<0.0001                             
1: HR=1.27 (0.53-3.06)           
p(PCS)=0.5963                              
p(Subtype)=0.2578                           
0: 2.26%           
1: 0.00% 




 Appendix K. Percent Change from Crude and Model 1 with Each Potential Confounder (PCS & Non-Cancer Mortality) (N = 
351) 
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Dataset restricted to those diagnosed with invasive breast cancer who have HRQOL and baseline covariates data 
Crude Physical Component Summary Score (PCS) 
0: HR=5.63 (2.74-11.55)                
1: HR=1.41 (0.59-3.35)                            
2: HR=1.00 (REF)                     
p=<0.0001 
0 
n=351                    
d=64 
-- -- 
1 Age, Marital Status, & Tumor Size 
0: HR=2.53 (1.19-5.40)               
1: HR=0.91 (0.38-2.19)                            
2: HR=1.00 (REF)                       
p=0.0016 
0 
n=351                    
d=64 
0: 55.06%                      
1: 35.46% 
-- 
2 Model 1 + Race/Ethnicity 
0: HR=2.53 (1.18-5.39)               
1: HR=0.90 (0.37-2.18)                            
2: HR=1.00 (REF)                       
p=0.0016 
0 
n=351                    
d=64 
0: 55.06%                      
1: 36.17% 
0: 0.00%                      
1: 1.10% 
3 Model 1 + Treatment Type 
0: HR=2.51 (1.18-5.35)               
1: HR=0.87 (0.36-2.11)                            
2: HR=1.00 (REF)                       
p=0.0013 
0 
n=351                    
d=64 
0: 55.42%                      
1: 38.30% 
0: 0.79%                      
1: 4.40% 
  
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
4 Model 1 + Comorbidities 
0: HR=2.50 (1.16-5.37)               
1: HR=0.90 (0.37-2.18)                            
2: HR=1.00 (REF)                       
p=0.0024 
0 
n=351                    
d=64 
0: 55.60%                      
1: 36.17% 
0: 1.19%                      
1: 1.10% 
5 Model 1 + Current Lymphedema 
0: HR=2.62 (1.22-5.64)               
1: HR=0.92 (0.38-2.23)                            
2: HR=1.00 (REF)                       
p=0.0014 
0 
n=351                    
d=64 
0: 53.46%                      
1: 34.75% 
0: 3.56%                      
1: 1.10% 
6 Model 1 + Optimism 
0: HR=2.40 (1.20-5.14)               
1: HR=0.88 (0.36-2.14)                            
2: HR=1.00 (REF)                       
p=0.0028 
0 
n=351                    
d=64 
0: 57.37%                      
1: 37.59% 
0: 5.14%                      
1: 3.30% 
7 Model 1 + Pessimism 
0: HR=2.48 (1.17-5.26)               
1: HR=0.97 (0.40-2.35)                            
2: HR=1.00 (REF)                       
p=0.0042 
0 
n=351                    
d=64 
0: 55.95%                      
1: 31.21% 
0: 1.98%                      
1: 6.59% 
8 Model 1 + Number of Types of Confidants 
0: HR=2.62 (1.23-5.59)               
1: HR=0.96 (0.40-2.32)                            
2: HR=1.00 (REF)                       
p=0.0017 
0 
n=351                    
d=64 
0: 53.46%                      
1: 31.91% 
0: 3.56%                      
1: 5.49% 
  
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
9 Model 1 + Fear of Recurrence 
0: HR=2.58 (1.21-5.51)               
1: HR=0.91 (0.38-2.20)                            
2: HR=1.00 (REF)                       
p=0.0013 
0 
n=351                    
d=64 
0: 54.17%                      
1: 35.46% 
0: 1.98%                      
1: 0.00% 
Subset--Restricted to participants with Education variable 
Crude Physical Component Summary Score (PCS) 
0: HR=5.51 (2.68-11.33)                
1: HR=1.41 (0.59-3.35)                             
2: HR=1.00 (REF)                       
p=<0.0001 
1 
n=350                    
d=63 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.48 (1.16-5.29)               
1: HR=0.90 (0.37-2.17)                            
2: HR=1.00 (REF)                       
p=0.0022 
1 
n=350                    
d=63 
0: 54.99%                      
1: 36.17% 
-- 
10 Model 1 + Education 
0: HR=2.59 (1.21-5.54)               
1: HR=0.90 (0.37-2.17)                             
2: HR=1.00 (REF)                      
p=0.0016 
1 
n=350                    
d=63 
0: 52.99%                      
1: 36.17% 
0: 4.44%                      
1: 0.00% 
Subset--Restricted to participants with the Tumor Size variable 
  
Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Crude Physical Component Summary Score (PCS) 
0: HR=5.43 (2.64-11.14)                
1: HR=1.39 (0.59-3.30)                            
2: HR=1.00 (REF)                        
p=<0.0001 
10 
n=341                  
d=64 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.53 (1.19-5.39)               
1: HR=0.92 (0.38-2.22)                            
2: HR=1.00 (REF)                       
p=0.0018 
10 
n=341                  
d=64 
0: 53.41%                      
1: 33.81% 
-- 
11 Model 1 + Tumor Size 
0: HR=2.53 (1.19-5.39)               
1: HR=0.91 (0.38-2.21)                            
2: HR=1.00 (REF)                       
p=0.0018 
10 
n=341                  
d=64 
0: 53.41%                      
1: 34.53% 
0: 0.00%                      
1: 1.09% 
Subset--Restricted to participants with Lymph Node Involvement variable 
Crude Physical Component Summary Score (PCS) 
0: HR=6.29 (2.95-13.41)                
1: HR=1.36 (0.54-3.45)                            
2: HR=1.00 (REF)                        
p=<0.0001 
10 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.71 (1.22-6.02)               
1: HR=0.96 (0.38-2.46)                             
2: HR=1.00 (REF)                      
p=0.0029 
10 
n=341                    
d=59 
0: 56.92%                      
1: 29.41% 
-- 
12 Model 1 + Lymph Node Involvement 
0: HR=2.69 (1.21-5.97)               
1: HR=0.95 (0.37-2.45)                             
2: HR=1.00 (REF)                      
p=0.0030 
10 
n=341                    
d=59 
0: 57.23%                      
1: 30.15% 
0: 0.74%                      
1: 1.04% 
Subset--Restricted to participants with Tamoxifen Use, Smoking Status, & Physical Activity variables (24-month follow-up) 
Crude Physical Component Summary Score (PCS) 
0: HR=5.19 (2.51-10.74)                
1: HR=1.42 (0.60-3.37)                             
2: HR=1.00 (REF)                       
p=<0.0001 
21 
n=330                    
d=59 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.40 (1.12-5.16)               
1: HR=0.94 (0.39-2.27)                              
2: HR=1.00 (REF)                     
p=0.0054 
21 
n=330                    
d=59 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
13 Model 1 + Tamoxifen Use 
0: HR=2.51 (1.18-5.37)               
1: HR=0.93 (0.38-2.24)                              
2: HR=1.00 (REF)                     
p=0.0027 
21 
n=330                    
d=59 
0: 51.64%                      
1: 34.51% 
0: 4.58%                      
1: 1.06% 
14 Model 1 + Smoking Status 
0: HR=2.38 (1.11-5.09)               
1: HR=0.93 (0.38-2.25)                              
2: HR=1.00 (REF)                     
p=0.0057 
21 
n=330                    
d=59 
0: 54.14%                      
1: 34.51% 
0: 0.83%                      
1: 1.06% 
15 Model 1 + Physical Activity 
0: HR=2.45 (1.13-5.28)               
1: HR=0.94 (0.39-2.27)                              
2: HR=1.00 (REF)                     
p=0.0049 
21 
n=330                    
d=59 
0: 52.79%                      
1: 33.80% 
0: 2.08%                      
1: 0.00% 
Subset--Restricted to participants with BMI variable 
Crude Physical Component Summary Score (PCS) 
0: HR=5.09 (2.36-10.99)                
1: HR=1.41 (0.57-3.51)                             
2: HR=1.00 (REF)                       
p=<0.0001 
27 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.41 (1.07-5.41)               
1: HR=1.00 (0.39-2.52)                              
2: HR=1.00 (REF)                     
p=0.0129 
27 
n=324                    
d=54 
0: 52.65%                      
1: 29.08% 
-- 
16 Model 1 + BMI 
0: HR=2.54 (1.11-5.83)               
1: HR=1.07 (0.42-2.72)                              
2: HR=1.00 (REF)                     
p=0.0147 
27 
n=324                    
d=54 
0: 50.10%                      
1: 24.11% 
0: 5.12%                      
1: 7.00% 
Subset--Restricted to participants with Tumor Subtype variable 
Crude Physical Component Summary Score (PCS) 
0: HR=4.43 (2.13-9.20)                
1: HR=1.27 (0.53-3.07)                             
2: HR=1.00 (REF)                       
p=<0.0001 
51 
n=300                    
d=56 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.09 (0.97-4.52)               
1: HR=0.86 (0.35-2.13)                              
2: HR=1.00 (REF)                     
p=0.0172 
51 
n=300                    
d=56 




Model Variable(s) in model 
Physical Component Summary 
Score (PCS) HR (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
17 Model 1 + Tumor Subtype 
0: HR=2.17 (1.01-4.71)               
1: HR=0.88 (0.36-2.16)                              
2: HR=1.00 (REF)                     
p=0.0132 
51 
n=300                    
d=56 
0: 51.02%                      
1: 30.71% 
0: 3.83%                      
1: 2.33% 











 Appendix L. Multivariable Modeling with Physical Component Summary Score as the Predictor and Non-Cancer Mortality as 
the Outcome (N = 351) 
Model Variable(s) in model 
Physical Component 




Total in model 











Crude Physical Component Summary Score (PCS) 
0: HR=5.63 (2.74-11.55)                
1: HR=1.41 (0.59-3.35)                             
2: HR=1.00 (REF)                       
p=<0.0001 
0 
n=351                    
d=64 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.53 (1.19-5.40)               
1: HR=0.91 (0.38-2.19)                             
2: HR=1.00 (REF)                      
p=0.0016 
0 
n=351                    
d=64 
0: 55.06%                      
1: 35.46% 
-- -- 
2 Model 1 + Race/Ethnicity 
0: HR=2.53 (1.18-5.39)               
1: HR=0.90 (0.37-2.18)                             
2: HR=1.00 (REF)                      
p=0.0016 
0 
n=351                    
d=64 
0: 55.06%                      
1: 36.17% 
0: 0.00%                      
1: 1.10% 
-- 
3 Model 1 + Race/Ethnicity + Treatment Type 
0: HR=2.50 (1.17-5.32)               
1: HR=0.86 (0.35-2.09)                            
2: HR=1.00 (REF)                       
p=0.0013 
0 
n=351                    
d=64 
0: 55.60%                      
1: 39.01% 
0: 1.19%                      
1: 5.49% 
0: 1.19%                      
1: 4.44% 
4 
Model 1 + Race/Ethnicity + Treatment Type + Current 
Lymphedema 
0: HR=2.60 (1.21-5.60)               
1: HR=0.88 (0.36-2.15)                            
2: HR=1.00 (REF)                       
p=0.0010 
0 
n=351                    
d=64 
0: 53.82%                      
1: 37.59% 
0: 2.77%                      
1: 3.30% 
0: 4.00%                      
1: 2.33% 
   
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Race/Ethnicity + Treatment Type + Current 
Lymphedema + Optimism 
0: HR=2.49 (1.16-5.38)               
1: HR=0.86 (0.35-2.10)                            
2: HR=1.00 (REF)                       
p=0.0015 
0 
n=351                    
d=64 
0: 55.77%                      
1: 39.01% 
0: 1.58%                      
1: 5.49% 
0: 4.23%                      
1: 2.27% 
6 
Model 1 + Race/Ethnicity + Treatment Type + Current 
Lymphedema + Optimism + Number of Types of 
Confidants (Confide) 
0: HR=2.67 (1.23-5.77)               
1: HR=0.94 (0.38-2.31)                            
2: HR=1.00 (REF)                       
p=0.0014 
0 
n=351                    
d=64 
0: 52.58%                      
1: 33.33% 
0: 5.53%                      
1: 3.30% 
0: 7.23%                      
1: 9.30% 
7 
Model 1 + Race/Ethnicity + Treatment Type + Current 
Lymphedema + Optimism + Confide + Fear of Recurrence 
0: HR=2.65 (1.22-5.74)               
1: HR=0.95 (0.38-2.33)                              
2: HR=1.00 (REF)                     
p=0.0015 
0 
n=351                    
d=64 
0: 52.93%                      
1: 32.62% 
0: 4.74%                      
1: 4.40% 
0: 0.75%                      
1: 1.06% 
Subset--Restricted to participants with Education variable 
Crude Physical Component Summary Score (PCS) 
0: HR=5.51 (2.68-11.33)                
1: HR=1.41 (0.59-3.35)                             
2: HR=1.00 (REF)                       
p=<0.0001 
1 
n=350                  
d=63 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.48 (1.16-5.29)               
1: HR=0.90 (0.37-2.17)                              
2: HR=1.00 (REF)                     
p=0.0022 
1 
n=350                  
d=63 
0: 54.99%                      
1: 36.17% 
-- -- 
   
Model Variable(s) in model 
Physical Component 




Total in model 











8 Model 1 + Education 
0: HR=2.59 (1.21-5.54)               
1: HR=0.90 (0.37-2.17)                              
2: HR=1.00 (REF)                     
p=0.0016 
1 
n=350                  
d=63 
0: 52.99%                      
1: 36.17% 
0: 4.44%                      
1: 0.00% 
-- 
9 Model 1 + Education + Race/Ethnicity 
0: HR=2.57 (1.20-5.52)               
1: HR=0.90 (0.37-2.15)                              
2: HR=1.00 (REF)                     
p=0.0016 
1 
n=350                  
d=63 
0: 53.36%                      
1: 36.17% 
0: 3.63%                      
1: 0.00% 
0: 0.77%                      
1: 0.00% 
10 Model 1 + Education + Race/Ethnicity + Treatment Type 
0: HR=2.51 (1.17-5.37)               
1: HR=0.85 (0.35-2.07)                              
2: HR=1.00 (REF)                     
p=0.0014 
1 
n=350                  
d=63 
0: 54.45%                      
1: 39.72% 
0: 1.21%                      
1: 5.56% 
0: 2.33%                      
1: 5.56% 
11 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Current Lymphedema 
0: HR=2.71 (1.25-5.84)               
1: HR=0.88 (0.36-2.15)                              
2: HR=1.00 (REF)                     
p=0.0008 
1 
n=350                  
d=63 
0: 50.82%                      
1: 37.59% 
0: 9.27%                      
1: 2.22% 
0: 7.97%                      
1: 3.53% 
12 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism 
0: HR=2.61 (1.20-5.65)               
1: HR=0.87 (0.36-2.11)                              
2: HR=1.00 (REF)                     
p=0.0012 
1 
n=350                  
d=63 
0: 52.63%                      
1: 38.30% 
0: 5.24%                      
1: 3.33% 
0: 3.69%                      
1: 1.14% 
   
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism + Confide 
0: HR=2.71 (1.25-5.89)               
1: HR=0.93 (0.38-2.28)                              
2: HR=1.00 (REF)                     
p=0.0013 
1 
n=350                  
d=63 
0: 50.82%                      
1: 34.04% 
0: 9.27%                      
1: 3.33% 
0: 3.83%                      
1: 6.90% 
14 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism + Confide + Fear of 
Recurrence 
0: HR=2.69 (1.24-5.84)               
1: HR=0.93 (0.38-2.30)                              
2: HR=1.00 (REF)                     
p=0.0014 
1 
n=350                  
d=63 
0: 51.18%                      
1: 34.04% 
0: 8.47%                      
1: 3.33% 
0: 0.74%                      
1: 0.00% 
Subset--Restricted to participants with Tumor Size variable 
Crude Physical Component Summary Score (PCS) 
0: HR=5.43 (2.64-11.14)                
1: HR=1.39 (0.59-3.30)                              
2: HR=1.00 (REF)                       
p=<0.0001 
10 
n=341                
d=64 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.53 (1.19-5.39)               
1: HR=0.92 (0.38-2.22)                              
2: HR=1.00 (REF)                     
p=0.0018 
10 
n=341                
d=64 
0: 53.41%                      
1: 33.81% 
-- -- 
15 Model 1 + Tumor Size 
0: HR=2.53 (1.19-5.39)               
1: HR=0.91 (0.38-2.21)                              
2: HR=1.00 (REF)                     
p=0.0018 
10 
n=341                
d=64 
0: 53.41%                      
1: 34.53% 




Model Variable(s) in model 
Physical Component 




Total in model 











16 Model 1 + Tumor Size + Race/Ethnicity 
0: HR=2.52 (1.19-5.38)               
1: HR=0.91 (0.38-2.20)                              
2: HR=1.00 (REF)                     
p=0.0018 
10 
n=341                
d=64 
0: 53.59%                      
1: 34.53% 
0: 0.40%                      
1: 1.09% 
0: 0.40%                      
1: 0.00% 
17 Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
0: HR=2.50 (1.17-5.32)               
1: HR=0.87 (0.36-2.11)                              
2: HR=1.00 (REF)                     
p=0.0013 
10 
n=341                
d=64 
0: 53.96%                      
1: 37.41% 
0: 1.19%                      
1: 5.43% 
0: 0.79%                      
1: 4.40% 
18 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Current Lymphedema 
0: HR=2.61 (1.22-5.61)               
1: HR=0.89 (0.36-2.17)                              
2: HR=1.00 (REF)                     
p=0.0011 
10 
n=341                
d=64 
0: 51.93%                      
1: 35.97% 
0: 3.16%                      
1: 3.26% 
0: 4.40%                      
1: 2.30% 
19 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism 
0: HR=2.50 (1.16-5.39)               
1: HR=0.86 (0.35-2.11)                              
2: HR=1.00 (REF)                     
p=0.0016 
10 
n=341                
d=64 
0: 53.96%                      
1: 38.13% 
0: 1.19%                      
1: 6.52% 
0: 4.21%                      
1: 3.37% 
20 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism + Confide 
0: HR=2.67 (1.23-5.78)               
1: HR=0.95 (0.39-2.34)                              
2: HR=1.00 (REF)                     
p=0.0016 
10 
n=341                
d=64 
0: 50.83%                      
1: 31.65% 
0: 5.53%                      
1: 3.26% 
0: 6.80%                      
1: 10.47% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Current Lymphedema + Optimism + Confide + Fear of 
Recurrence 
0: HR=2.66 (1.23-5.76)               
1: HR=0.96 (0.39-2.36)                              
2: HR=1.00 (REF)                     
p=0.0016 
10 
n=341                
d=64 
0: 51.01%                      
1: 30.94% 
0: 5.14%                      
1: 4.35% 
0: 0.37%                      
1: 1.05% 
Subset--Restricted to participants with Education and Tumor Size variables (24-month follow-up) 
Crude Physical Component Summary Score (PCS) 
0: HR=5.31 (2.59-10.92)                
1: HR=1.39 (0.59-3.30)                             
2: HR=1.00 (REF)                       
p=<0.0001 
11 
n=340               
d=63 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.48 (1.16-5.28)               
1: HR=0.91 (0.38-2.20)                              
2: HR=1.00 (REF)                     
p=0.0024 
11 
n=340               
d=63 
0: 53.30%                      
1: 34.53% 
-- -- 
22 Model 1 + Education + Tumor Size 
0: HR=2.57 (1.20-5.50)               
1: HR=0.91 (0.69-2.49)                              
2: HR=1.00 (REF)                     
p=0.0018 
11 
n=340               
d=63 
0: 51.60%                      
1: 34.53% 
0: 3.63%                      
1: 0.00% 
-- 
23 Model 1 Education + Tumor Size + Race/Ethnicity 
0: HR=2.56 (1.20-5.48)               
1: HR=0.90 (0.37-2.18)                              
2: HR=1.00 (REF)                     
p=0.0018 
11 
n=340               
d=63 
0: 51.79%                      
1: 35.25% 
0: 3.23%                      
1: 1.10% 
0: 0.39%                      
1: 1.10% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type 
0: HR=2.49 (1.18-5.33)               
1: HR=0.86 (0.36-2.10)                              
2: HR=1.00 (REF)                     
p=0.0016 
11 
n=340               
d=63 
0: 53.11%                      
1: 38.13% 
0: 0.40%                      
1: 5.49% 
0: 2.73%                      
1: 4.44% 
25 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Current Lymphedema 
0: HR=2.70 (1.25-5.83)               
1: HR=0.89 (0.37-2.18)                              
2: HR=1.00 (REF)                     
p=0.0009 
11 
n=340               
d=63 
0: 49.15%                      
1: 35.97% 
0: 8.87%                      
1: 2.20% 
0: 8.43%                      
1: 3.49% 
26 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Current Lymphedema + Optimism 
0: HR=2.60 (1.20-5.64)               
1: HR=0.88 (0.36-2.14)                              
2: HR=1.00 (REF)                     
p=0.0014 
11 
n=340               
d=63 
0: 51.04%                      
1: 36.69% 
0: 4.84%                      
1: 3.30% 
0: 3.70%                      
1: 1.12% 
27 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Current Lymphedema + Optimism + 
Confide 
0: HR=2.72 (1.25-5.91)               
1: HR=0.95 (0.39-2.33)                              
2: HR=1.00 (REF)                     
p=0.0015 
11 
n=340               
d=63 
0: 48.78%                      
1: 31.65% 
0: 9.68%                      
1: 4.40% 
0: 4.62%                      
1: 7.95% 
28 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Current Lymphedema + Optimism + 
Confide + Fear of Recurrence 
0: HR=2.69 (1.24-5.85)               
1: HR=0.95 (0.38-2.35)                              
2: HR=1.00 (REF)                     
p=0.0016 
11 
n=340               
d=63 
0: 49.34%                      
1: 31.65% 
0: 8.47%                      
1: 4.40% 
0: 1.10%                      
1: 0.00% 
Subset--Restricted to participants with Tamoxifen Use & Physical Activity variable (24-month follow-up) 
   
Model Variable(s) in model 
Physical Component 




Total in model 











Crude Physical Component Summary Score (PCS) 
0: HR=5.19 (2.51-10.74)                
1: HR=1.42 (0.60-3.37)                             
2: HR=1.00 (REF)                       
p=<0.0001 
21 
n=330                    
d=59 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.40 (1.12-5.16)               
1: HR=0.94 (0.39-2.27)                              
2: HR=1.00 (REF)                     
p=0.0054 
21 
n=330                    
d=59 
0: 53.76%                      
1: 33.80% 
-- -- 
29 Model 1 + Tamoxifen Use + Physical Activity 
0: HR=2.56 (1.19-5.48)               
1: HR=0.93 (0.39-2.24)                              
2: HR=1.00 (REF)                     
p=0.0025 
21 
n=330                    
d=59 
0: 50.67%                      
1: 34.51% 




Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity 
0: HR=2.55 (1.19-5.47)               
1: HR=0.92 (0.38-2.23)                              
2: HR=1.00 (REF)                     
p=0.0025 
21 
n=330                    
d=59 
0: 50.87%                      
1: 35.21% 
0: 6.25%                      
1: 2.13% 
0: 0.39%                      
1: 1.08% 
31 
Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity + Treatment Type 
0: HR=2.47 (1.15-5.30)               
1: HR=0.89 (0.37-2.16)                              
2: HR=1.00 (REF)                     
p=0.0029 
21 
n=330                    
d=59 
0: 52.41%                      
1: 37.32% 
0: 2.92%                      
1: 5.32% 
0: 3.14%                      
1: 3.26% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity + Treatment Type + Current Lymphedema 
0: HR=2.44 (1.12-5.31)               
1: HR=0.90 (0.37-2.19)                              
2: HR=1.00 (REF)                     
p=0.0050 
21 
n=330                    
d=59 
0: 52.99%                      
1: 36.62% 
0: 1.67%                      
1: 4.26% 
0: 1.21%                      
1: 1.12% 
33 
Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity + Treatment Type + Current Lymphedema 
+ Optimism 
0: HR=2.45 (1.14-5.29)               
1: HR=0.88 (0.36-2.15)                              
2: HR=1.00 (REF)                     
p=0.0031 
21 
n=330                    
d=59 
0: 52.79%                      
1: 38.03% 
0: 2.08%                      
1: 6.38% 
0: 0.41%                      
1: 2.22% 
34 
Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity + Treatment Type + Current Lymphedema 
+ Optimism + Confide 
0: HR=2.60 (1.19-5.68)               
1: HR=0.94 (0.38-2.33)                              
2: HR=1.00 (REF)                     
p=0.0027 
21 
n=330                    
d=59 
0: 49.90%                      
1: 33.80% 
0: 8.33%                      
1: 0.00% 
0: 6.12%                      
1: 6.82% 
35 
Model 1 + Tamoxifen Use + Physical Activity + 
Race/Ethnicity + Treatment Type + Current Lymphedema 
+ Optimism + Confide + Fear of Recurrence 
0: HR=2.60 (1.19-5.69)               
1: HR=0.96 (0.39-2.38)                              
2: HR=1.00 (REF)                     
p=0.0029 
21 
n=330                    
d=59 
0: 49.90%                      
1: 32.39% 
0: 8.33%                      
1: 2.13% 
0: 0.00%                      
1: 2.13% 
Subset--Restricted to participants with Education, Tumor Size, Tamoxifen Use, and Physical Activity variables  
Crude Physical Component Summary Score (PCS) 
0: HR=4.88 (2.35-10.12)                
1: HR=1.40 (0.59-3.33)                             
2: HR=1.00 (REF)                       
p=<0.0001 
32 
n=319                 
d=58 
-- -- -- 
  
Model Variable(s) in model 
Physical Component 




Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=2.35 (1.09-5.05)               
1: HR=0.95 (0.39-2.29)                              
2: HR=1.00 (REF)                     
p=0.0078 
32 
n=319                 
d=58 




Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity 
0: HR=2.65 (1.22-5.72)               
1: HR=0.94 (0.39-2.27)                              
2: HR=1.00 (REF)                     
p=0.0024 
32 
n=319                 
d=58 
0: 45.70%                      
1: 32.86% 




Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity 
0: HR=2.64 (1.22-5.71)               
1: HR=0.94 (0.39-2.26)                              
2: HR=1.00 (REF)                     
p=0.0025 
32 
n=319                 
d=58 
0: 45.90%                      
1: 32.86% 
0: 12.34%                      
1: 1.05% 
0: 0.38%                      
1: 0.00% 
38 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity + Treatment Type 
0: HR=2.52 (1.17-5.44)               
1: HR=0.89 (0.37-2.17)                              
2: HR=1.00 (REF)                     
p=0.0029 
32 
n=319                 
d=58 
0: 48.36%                      
1: 36.43% 
0: 7.23%                      
1: 6.32% 
0: 4.55%                      
1: 5.32% 
39 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity + Treatment Type + 
Current Lymphedema 
0: HR=2.61 (1.20-5.67)               
1: HR=0.91 (0.37-2.21)                              
2: HR=1.00 (REF)                     
p=0.0024 
32 
n=319                 
d=58 
0: 46.52%                      
1: 35.00% 
0: 11.06%                      
1: 4.21% 
0: 3.57%                      
1: 2.25% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism 
0: HR=2.58 (1.18-5.60)               
1: HR=0.89 (0.36-2.19)                              
2: HR=1.00 (REF)                     
p=0.0026 
32 
n=319                 
d=58 
0: 47.13%                      
1: 36.43% 
0: 9.79%                      
1: 6.32% 
0: 1.15%                      
1: 2.20% 
41 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism + Confide 
0: HR=2.67 (1.21-5.87)               
1: HR=0.94 (0.38-2.34)                              
2: HR=1.00 (REF)                     
p=0.0024 
32 
n=319                 
d=58 
0: 45.29%                      
1: 32.86% 
0: 13.62%                      
1: 1.05% 
0: 3.49%                      
1: 5.62% 
42 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism + Confide + Fear of 
Recurrence 
0: HR=2.66 (1.21-5.85)               
1: HR=0.95 (0.38-2.38)                              
2: HR=1.00 (REF)                     
p=0.0027 
32 
n=319                 
d=58 
0: 45.49%                      
1: 32.14% 
0: 13.19%                      
1: 0.00% 
0: 0.37%                      
1: 1.06% 
Subset--Restricted to participants with BMI variable 
Crude Physical Component Summary Score (PCS) 
0: HR=5.09 (2.36-10.99)                
1: HR=1.41 (0.57-3.51)                             
2: HR=1.00 (REF)                       
p=<0.0001 
27 
n=324                 
d=54 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.41 (1.07-5.41)               
1: HR=1.00 (0.39-2.52)                              
2: HR=1.00 (REF)                     
p=0.0129 
27 
n=324                 
d=54 
0: 52.65%                      
1: 29.08% 
-- -- 
   
Model Variable(s) in model 
Physical Component 




Total in model 











43 Model 1 + BMI 
0: HR=2.54 (1.11-5.83)               
1: HR=1.07 (0.42-2.72)                              
2: HR=1.00 (REF)                     
p=0.0147 
27 
n=324                 
d=54 
0: 50.10%                      
1: 24.11% 
0: 5.39%                      
1: 7.00% 
-- 
44 Model 1 + BMI + Race/Ethnicity 
0: HR=2.54 (1.11-5.82)               
1: HR=1.07 (0.42-2.71)                              
2: HR=1.00 (REF)                     
p=0.0150 
27 
n=324                 
d=54 
0: 50.10%                      
1: 24.11% 
0: 5.39%                      
1: 7.00% 
0: 0.00%                      
1: 0.00% 
45 Model 1 + BMI + Race/Ethnicity + Treatment Type 
0: HR=2.42 (1.05-5.57)               
1: HR=1.03 (0.41-2.63)                              
2: HR=1.00 (REF)                     
p=0.0184 
27 
n=324                 
d=54 
0: 52.46%                      
1: 26.95% 
0: 0.41%                      
1: 3.00% 
0: 4.72%                      
1: 3.74% 
46 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Current Lymphedema 
0: HR=2.50 (1.08-5.78)               
1: HR=1.06 (0.41-2.70)                              
2: HR=1.00 (REF)                     
p=0.0160 
27 
n=324                 
d=54 
0: 50.88%                      
1: 24.82% 
0: 3.73%                      
1: 6.00% 
0: 3.31%                      
1: 2.91% 
47 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism 
0: HR=2.37 (1.03-5.50)               
1: HR=0.99 (0.39-2.56)                              
2: HR=1.00 (REF)                     
p=0.0187 
27 
n=324                 
d=54 
0: 53.44%                      
1: 29.79% 
0: 1.66%                      
1: 1.00% 
0: 5.20%                      
1: 6.60% 
  
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism + Confide 
0: HR=2.59 (1.11-6.02)               
1: HR=1.08 (0.42-2.78)                              
2: HR=1.00 (REF)                     
p=0.0150 
27 
n=324                 
d=54 
0: 49.12%                      
1: 23.40% 
0: 7.47%                      
1: 8.00% 
0: 9.28%                      
1: 9.09% 
49 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Current Lymphedema + Optimism + Confide + Fear of 
Recurrence 
0: HR=2.54 (1.09-5.89)               
1: HR=1.08 (0.42-2.78)                              
2: HR=1.00 (REF)                     
p=0.0174 
27 
n=324                 
d=54 
0: 50.10%                      
1: 23.40% 
0: 5.39%                      
1: 8.00% 
0: 1.93%                      
1: 0.00% 
Subset--Restricted to participants with Education, Tumor Size, Tamoxifen Use, Physical Activity, & BMI variables 
Crude Physical Component Summary Score (PCS) 
0: HR=4.42 (2.03-9.65)                
1: HR=1.40 (0.56-3.47)                             
2: HR=1.00 (REF)                       
p=<0.0001 
56 
n=295                 
d=49 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=2.32 (1.02-5.25)               
1: HR=1.01 (0.40-2.56)                              
2: HR=1.00 (REF)                     
p=0.0231 
56 
n=295                 
d=49 




Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI 
0: HR=2.88 (1.23-6.72)               
1: HR=1.06 (0.42-2.68)                              
2: HR=1.00 (REF)                     
p=0.0068 
56 
n=295                 
d=49 
0: 34.84%                      
1: 24.29% 




Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity 
0: HR=2.87 (1.23-6.70)               
1: HR=1.05 (0.42-2.67)                              
2: HR=1.00 (REF)                     
p=0.0069 
56 
n=295                 
d=49 
0: 35.07%                      
1: 25.00% 
0: 23.71%                      
1: 3.96% 
0: 0.35%                      
1: 0.94% 
52 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity + Treatment 
Type 
0: HR=2.63 (1.13-6.14)               
1: HR=1.02 (0.40-2.61)                              
2: HR=1.00 (REF)                     
p=0.0139 
56 
n=295                 
d=49 
0: 40.50%                      
1: 27.14% 
0: 13.36%                      
1: 0.99% 
0: 8.36%                      
1: 2.86% 
53 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity + Treatment 
Type + Current Lymphedema 
0: HR=2.60 (1.10-6.11)               
1: HR=1.03 (0.40-2.63)                              
2: HR=1.00 (REF)                     
p=0.0178 
56 
n=295                 
d=49 
0: 41.18%                      
1: 26.43% 
0: 12.07%                      
1: 1.98% 
0: 1.14%                      
1: 0.98% 
54 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity + Treatment 
Type + Current Lymphedema + Optimism 
0: HR=2.55 (1.08-6.02)               
1: HR=0.99 (0.38-2.57)                              
2: HR=1.00 (REF)                     
p=0.0169 
56 
n=295                 
d=49 
0: 42.31%                      
1: 29.29% 
0: 9.91%                      
1: 1.98% 
0: 1.92%                      
1: 3.88% 
55 
Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity + Treatment 
Type + Current Lymphedema + Optimism + Confide 
0: HR=2.65 (1.11-6.29)               
1: HR=1.04 (0.40-2.74)                              
2: HR=1.00 (REF)                     
p=0.0158 
56 
n=295                 
d=49 
0: 40.06%                      
1: 25.71% 
0: 14.22%                      
1: 2.97% 
0: 3.92%                      
1: 5.05% 
   
Model Variable(s) in model 
Physical Component 




Total in model 












Model 1 + Education + Tumor Size + Tamoxifen Use + 
Physical Activity + BMI + Race/Ethnicity + Treatment 
Type + Current Lymphedema + Optimism + Confide + 
Fear of Recurrence 
0: HR=2.56 (1.07-6.11)               
1: HR=1.05 (0.40-2.76)                              
2: HR=1.00 (REF)                     
p=0.0226 
56 
n=295                 
d=49 
0: 42.08%                      
1: 25.00% 
0: 10.34%                      
1: 3.96% 













 Appendix M. Mental Component Summary Score Univariate HR Analysis and Percent Change for Non-Cancer Mortality 
when Assessing for Potential Confounders (N = 351) 










Missing Univariate-Cox HR (95% CI) p-values* 







Summary Score (MCS) 
0: ≤ 45.12                                      
1: > 45.12 & ≤ 54.40                       
2: > 54.40 (REF) 
0: 117                 
1: 117            
2: 117  
n=351                    
d=64 
0 
0: HR=1.45 (0.78-2.72)                
1: HR=1.42 (0.76-2.64) 
p=0.4424 
0: HR=1.45 (0.78-2.72)            
p(MCS)=0.2439                               
1: HR=1.42 (0.76-2.64)           
p(MCS)=0.2705 
-- 
1 Age Continuous -- 
n=351                    
d=64 
0 HR=1.11 (1.08-1.14) p=<0.0001 
0: HR=1.83 (0.98-3.44)           
p(MCS)=0.0596                              
1: HR=1.44 (0.77-2.69)           
p(MCS)=0.2576                              
p(Age)=<0.0001 




White (REF)            1: 
Hispanic 
0: 273                      
1: 78 
n=351                    
d=64 
0 
0: HR=1.00                                    
1: HR=0.53 (0.26-1.07) 
p=0.0774 
0: HR=1.52 (0.81-2.85)           
p(MCS)=0.1917                              
1: HR=1.46 (0.78-2.72)           
p(MCS)=0.2331                             
p(Ethnicity)=0.0774 
0: 4.83%           
1: 2.82% 
3 Marital Status 
0: Single                                      
1: Married (REF)                 
0: 160                     
1: 191                 
n=351                    
d=64 
0 
0: HR=2.65 (1.57-4.48)                                    
1: HR=1.00 
p=0.0003 
0: HR=1.44 (0.77-2.69)           
p(MCS)=0.2574                              
1: HR=1.48 (0.79-2.75)           
p(MCS)=0.2207                              
p(Marital)=0.0003 
0: 0.69%           
1: 4.23% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





4 Tumor Stage 
0: Localized (I)                                    
1: Regional (II-IIIa)               
0: 276             
1: 75    
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.77 (0.40-1.48)         
p=0.4351 
0: HR=1.43 (0.76-2.68)           
p(MCS)=0.2630                              
1: HR=1.41 (0.76-2.63)           
p(MCS)=0.2781                            
p(Stage)=0.4351                                          
0: 1.38%           
1: 0.70% 
5 
Breast Cancer Treatment 
Type 
0: Surgery only (REF)                               
1: Any chemotherapy                                      
2: Surgery and 
radiation 
0: 98                     
1: 109                   
2: 144                  
n=351                    
d=64 
0 
0: HR=1.00                                  
1: HR=0.36 (0.18-0.72)                                  
2: HR=0.66 (0.39-1.13)                    
p=0.0154 
0: HR=1.51 (0.81-2.84)           
p(MCS)=0.1956                             
1: HR=1.45 (0.78-2.70)           
p(MCS)=0.2441                             
p(Treatment1)=0.0043              
p(Treatment2)=0.1312                
0: 4.14%           
1: 2.11% 
6 Comorbidities 
0: Zero (REF)                                     
1: One or more           
0: 298              
1: 53              
n=351                    
d=64 
0 
0: HR=1.00                                    
1: HR=1.86 (1.02-3.39) 
p=0.0442 
0: HR=1.34 (0.71-2.53)           
p(MCS)=0.3636                              
1: HR=1.40 (0.75-2.60)           
p(MCS)=0.2903                             
p(Comorbidities)=0.0442 
0: 7.59%           
1: 1.41% 
7 Current Lymphedema 
0: No (REF)                                           
1: Yes  
0: 307           
1: 44             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.62 (0.26-1.44) 
p=0.2624 
0: HR=1.53 (0.81-2.87)           
p(MCS)=0.1902                             
1: HR=1.45 (0.78-2.69)           
p(MCS)=0.2465                             
p(Lymphedema)=0.2624 
0: 5.52%           
1: 2.11% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





8 Perceived Optimism 
0: ≤ 10                                          
1: > 10 (REF)              
0: 83                     
1: 268            
n=351                    
d=64 
0 
0: HR=2.08 (1.23-3.53)                                    
1: HR=1.00 
p=0.0066 
0: HR=1.16 (0.60-2.23)           
p(MCS)=0.6636                              
1: HR=1.26 (0.67-2.36)           
p(MCS)=0.4759                           
p(Optimism)=0.0066 
0: 20.00%           
1: 11.27% 
9 Perceived Pessimism 
0: ≤ 10 (REF)                                          
1: > 10      
0: 255                    
1: 96             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=1.80 (1.07-3.04) 
p=0.0264 
0: HR=1.25 (0.66-2.38)           
p(MCS)=0.5018                              
1: HR=1.32 (0.71-2.47)           
p(MCS)=0.3831                             
p(Pessimism)=0.0264 
0: 13.79%           
1: 7.04% 
10 Current Fatigue 
0: No (REF)                                           
1: Yes  
0: 136           
1: 215             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=1.03 (0.58-1.82) 
p=0.9171 
0: HR=1.43 (0.72-2.85)           
p(MCS)=0.3081                             
1: HR=1.41 (0.75-2.65)           
p(MCS)=0.2870                      
p(Fatigue)=0.9171 
0: 1.38%           
1: 0.70% 
11 Fear of Recurrence 
0: No (REF)                                           
1: Yes  
0: 154           
1: 197             
n=351                    
d=64 
0 
0: HR=1.00                                     
1: HR=0.45 (0.27-0.74) 
p=0.0019 
0: HR=1.72 (0.91-3.24)           
p(MCS)=0.0961                           
1: HR=1.60 (0.86-3.00)           
p(MCS)=0.1396                     
p(Fear)=0.0019 
0: 18.62%           
1: 12.68% 
   










Missing Univariate-Cox HR (95% CI) p-values* 






Number of Types of 
Confidants 
0: < 3                                           
1: 4-5                                                  
2: > 5 (REF) 
0: 66                  
1: 172            
2: 113                 
n=351                    
d=64 
0 
0: HR=2.86 (1.42-5.75)                                     
1: HR=1.60 (0.84-3.06)                                  
2: HR=1.00 
p=0.0105 
0: HR=1.44 (0.77-2.69)           
p(MCS)=0.2591                            
1: HR=1.44 (0.77-2.68)           
p(MCS)=0.2529                           
p(Confidant0)=0.0032            
p(Confidant1)=0.1565                
0: 0.69%           
1: 1.41% 
13 Bodily Pain 
0: No Pain                                      
1: Experienced Pain 
(REF) 
0: 180                        
1: 171             
n=351                   
d=64 
0 
0: HR=1.00                                   
1: HR=1.51 (0.80-2.85) 
p=0.2006 
0: HR=1.37 (0.73-2.58)           
p(MCS)=0.3285                          
1: HR=1.39 (0.74-2.58)           
p(MCS)=0.3053                     
p(Pain)=0.2006 





0: "Poor" & "Fair"                                          
1: "Good", "Very 
Good", & "Excellent" 
(REF) 
0: 54                   
1: 297            
n=351                    
d=64 
0 
0: HR=2.84 (1.62-4.97)                                     
1: HR=1.00 
p=0.0003 
0: HR=1.08 (0.56-2.09)              
p(MCS)=0.8160                          
1: HR=1.36 (0.73-2.53)                   
p(MCS)=0.3391                           
p(Health)=0.0003               
0: 25.52%           
1: 4.23% 
Crude 
MCS (restricted to those 
with education) 
  
0: 117                 
1: 116                
2: 117  
n=350                    
d=63 
  
0: HR=1.45 (0.78-2.72)                
1: HR=1.36 (0.73-2.55) 
p=0.4697 
0: HR=1.45 (0.78-2.72)           
p(MCS)=0.2438                                
1: HR=1.36 (0.73-2.55)           
p(MCS)=0.3346 
-- 
   










Missing Univariate-Cox HR (95% CI) p-values* 






0: High school or less                  
1: Some college                         
2: College graduate                       
3: Graduate school 
(REF) 
0: 92                     
1: 114                   
2: 70                   
3: 74 
n=350                    
d=63 
1 
0: HR=2.88 (1.22-6.85)                                     
1: HR=2.24 (0.96-5.19)                   
2: HR=1.85 (0.73-4.70)                   
3: HR=1.00 
p=0.1075 
0: HR=1.46 (0.78-2.75)           
p(MCS)=0.2356                             
1: HR=1.44 (0.77-2.71)           
p(MCS)=0.2356                             
p(Education0)=0.0163              
p(Education1)=0.0612               
p(Education2)=0.1989 
0: 0.69%           
1: 5.88% 
Crude 
MCS (restricted to those 
with tumor size) 
  
0: 113                 
1: 114                
2: 114  
n=341                    
d=64 
  
0: HR=1.48 (0.79-2.77)                
1: HR=1.43 (0.77-2.67) 
p=0.4136 
0: HR=1.48 (0.79-2.77)            
p(MCS)=0.2216                               
1: HR=1.43 (0.77-2.67)           
p(MCS)=0.2569 
-- 
16 Tumor Size 
0: < 3 cm (REF)                                          
1: ≥ 3 cm              
0: 304                     
1: 37                 
n=341                    
d=64 
10 
0: HR=1.00                                     
1: HR=0.43 (0.14-1.38) 
p=0.1574 
0: HR=1.50 (0.80-2.80)           
p(MCS)=0.2095                            
1: HR=1.42 (0.76-2.64)           
p(MCS)=0.2702                            
p(Size)=0.1574 
0: 1.35%           
1: 0.70% 
Crude 
MCS (restricted to those 
with lymph node 
involvement) 
  
0: 112                 
1: 114                
2: 115  
n=341                    
d=59 
  
0: HR=1.26 (0.66-2.41)                
1: HR=1.31 (0.70-2.47) 
p=0.6737 
0: HR=1.26 (0.66-2.41)               
p(MCS)=0.4803                               
1: HR=1.31 (0.70-2.47)          
p(MCS)=0.4008 
-- 










Missing Univariate-Cox HR (95% CI) p-values* 








0: None (REF)                                            
1: ≥ 1 lymph node 
involved  
0: 264                     
1: 77              
n=341                    
d=59 
10 
0: HR=1.00                                 
1: HR=0.81 (0.42-1.56) 
p=0.5276 
0: HR=1.25 (0.65-2.39)           
p(MCS)=0.4997                             
1: HR=1.31 (0.70-2.47)           
p(MCS)=0.4055                             
p(Lymph node)=0.5276 
0: 0.79%           
1: 0.00% 
Crude 
MCS (restricted to those 
with Tamoxifen use, 
smoking status, and 
physical activity) 
  
0: 110                 
1: 109                
2: 111  
n=330                    
d=59 
  
0: HR=1.52 (0.80-2.89)                
1: HR=1.33 (0.70-2.56) 
p=0.4430 
0: HR=1.52 (0.80-2.89)           
p(MCS)=0.2060                            
1: HR=1.33 (0.70-2.56)          
p(MCS)=0.3870 
-- 
18 Tamoxifen Use 
0: No                                            
1: Yes (REF)  
0: 160                     
1: 170              
n=330                    
d=59 
21 
0: HR=1.25 (0.75-2.09)                                    
1: HR=1.00 
p=0.3983 
0: HR=1.49 (0.78-2.85)           
p(MCS)=0.2227                             
1: HR=1.31 (0.68-2.51)           
p(MCS)=0.4239                             
p(Tamoxifen)=0.3983 
0: 1.49%           
1: 1.50% 
19 Smoking Status 
0: Never (REF)                              
1: Former                                     
2: Current 
0: 145                 
1: 144                   
2: 41                 
n=330                    
d=59 
21 
0: HR=1.00                                     
1: HR=1.00 (0.58-1.73)                                  
2: HR=1.25 (0.56-2.78)                    
p=0.8476 
0: HR=1.49 (0.78-2.85)           
p(MCS)=0.2289                            
1: HR=1.33 (0.69-2.55)           
p(MCS)=0.3925                              
p(Smoker1)=0.9984            
p(Smoker2)=0.5901                
0: 1.49%           
1: 0.00% 
  










Missing Univariate-Cox HR (95% CI) p-values* 





20 Physical Activity 
0: None                                       
1: Low                                            
2: Moderate/Vigorous 
(REF) 
0: 185                     
1: 59                   
2: 86                 
n=330                    
d=59 
21 
0: HR=2.24 (1.15-4.36)                                    
1: HR=0.54 (0.17-1.71)                                 
2: HR=1.00     
p=0.0033 
0: HR=1.70 (0.89-3.25)           
p(MCS)=0.1089                            
1: HR=1.54 (0.80-2.97)           
p(MCS)=0.1966                              
p(PA0)=0.0176            
p(PA1)=0.2974           
0: 11.84%           
1: 15.79% 
Crude 
MCS (restricted to those 
with BMI) 
  
0: 110                 
1: 108                
2: 106  
n=324                    
d=54 
  
0: HR=1.31 (0.67-2.58)                
1: HR=1.29 (0.66-2.52) 
p=0.6886 
0: HR=1.31 (0.67-2.58)             
p(MCS)=0.1963                                
1: HR=1.29 (0.66-2.52)          
p(MCS)=0.4547 
-- 
21 Body Mass Index (BMI) 
0: <25 (REF)                               
1: 25-29                                        
2: ≥30 
0: 161                     
1: 99                
2: 64                    
n=324                    
d=54 
27 
0: HR=1.00                                     
1: HR=0.61 (0.31-1.24)                   
2: HR=1.53 (0.80-2.91)                    
p=0.0755 
0: HR=1.31 (0.66-2.57)           
p(MCS)=0.4383                            
1: HR=1.38 (0.70-2.72)           
p(MCS)=0.3556                             
p(BMI1)=0.1727             
p(BMI2)=0.1972               
0: 0.00%           
1: 6.98% 
Crude 
MCS (restricted to those 
tumor subtype) 
  
0: 99                      
1: 99                      
2: 102  
n=300                    
d=56 
  
0: HR=1.16 (0.60-2.26)                
1: HR=1.27 (0.67-2.40) 
p=0.7681 
0: HR=1.16 (0.60-2.26)              
p(MCS)=0.6573                              
1: HR=1.27 (0.67-2.40)         
p(MCS)=0.4695 
-- 
   










Missing Univariate-Cox HR (95% CI) p-values* 





22 Tumor Subtype 
0: ER+ (REF)                              
1: ER-             
0: 251                     
1: 49                                    
n=300                    
d=56
51 
0: HR=1.00                                     
1: HR=1.24 (0.64-2.41)      
p=0.5186 
0: HR=1.15 (0.59-2.24)           
p(MCS)=0.6747                            
1: HR=1.25 (0.66-2.37)           
p(MCS)=0.5025                             
p(Subtype)=0.5186                         
0: 0.86%           
1: 1.57% 










 Appendix N. Percent Change from Crude and Model 1 with Each Potential Confounder (MCS & Non-Cancer Mortality) (N = 
351) 
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Dataset restricted to those with full HRQOL data and baseline covariates 
Crude Mental Component Summary Score (MCS) 
0: HR=1.45 (0.78-2.72)                
1: HR=1.42 (0.76-2.64)                             
2: HR=1.00 (REF)                      
p=0.4424 
0 
n=351                    
d=64 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.73 (0.92-3.25)               
1: HR=1.46 (0.78-2.72)                               
2: HR=1.00 (REF)                   
p=0.2327 
0 
n=351                    
d=64 
0: 19.31%                      
1: 2.82% 
-- 
2 Model 1 + Race/Ethnicity 
0: HR=1.73 (0.92-3.27)               
1: HR=1.45 (0.78-2.72)                               
2: HR=1.00 (REF)                   
p=0.2293 
0 
n=351                    
d=64 
0: 19.31%                      
1: 2.11% 
0: 0.00%                      
1: 0.68% 
3 Model 1 + Treatment Type 
0: HR=1.73 (0.92-3.26)               
1: HR=1.40 (0.74-2.64)                               
2: HR=1.00 (REF)                   
p=0.2395 
0 
n=351                    
d=64 
0: 19.31%                      
1: 1.41% 
0: 0.00%                      
1: 4.11% 
 Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
4 Model 1 + Comorbidities 
0: HR=1.64 (0.85-3.15)               
1: HR=1.47 (0.78-2.74)                               
2: HR=1.00 (REF)                   
p=0.3020 
0 
n=351                    
d=64 
0: 13.10%                      
1: 3.52% 
0: 5.20%                      
1: 0.68% 
5 Model 1 + Current Lymphedema 
0: HR=1.74 (0.92-3.30)               
1: HR=1.46 (0.78-2.73)                               
2: HR=1.00 (REF)                   
p=0.2310 
0 
n=351                    
d=64 
0: 20.00%                      
1: 2.82% 
0: 0.58%                      
1: 0.00% 
6 Model 1 + Optimism 
0: HR=1.60 (0.83-3.06)               
1: HR=1.35 (0.71-2.56)                               
2: HR=1.00 (REF)                   
p=0.3678 
0 
n=351                    
d=64 
0: 10.34%                      
1: 4.93% 
0: 7.51%                      
1: 7.53% 
7 Model 1 + Pessimism 
0: HR=1.52 (0.79-2.91)               
1: HR=1.39 (0.74-2.61)                               
2: HR=1.00 (REF)                   
p=0.4252 
0 
n=351                    
d=64 
0: 4.83%                      
1: 2.11% 
0: 12.14%                      
1: 4.79% 
9 Model 1 + Current Fatigue 
0: HR=1.58 (0.76-3.29)               
1: HR=1.41 (0.74-2.67)                               
2: HR=1.00 (REF)                   
p=0.4371 
0 
n=351                    
d=64 
0: 8.97%                      
1: 0.70% 
0: 8.67%                      
1: 3.42% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
10 Model 1 + Fear of Recurrence 
0: HR=1.83 (0.96-3.46)               
1: HR=1.52 (0.81-2.84)                               
2: HR=1.00 (REF)                   
p=0.1739 
0 
n=351                    
d=64 
0: 26.21%                      
1: 7.04% 
0: 5.78%                      
1: 4.11% 
11 Model 1 + Number of Types of Confidants 
0: HR=1.75 (0.93-3.31)               
1: HR=1.53 (0.82-2.88)                               
2: HR=1.00 (REF)                   
p=0.2085 
0 
n=351                    
d=64 
0: 20.69%                      
1: 7.75% 
0: 1.16%                      
1: 4.79% 
12 Model 1 + Bodily Pain 
0: HR=1.69 (0.89-3.21)               
1: HR=1.44 (0.77-2.70)                               
2: HR=1.00 (REF)                   
p=0.2679 
0 
n=351                    
d=64 
0: 16.55%                      
1: 1.41% 
0: 2.31%                      
1: 1.37% 
13 Model 1 + Perceived General Health 
0: HR=1.41 (0.72-2.74)               
1: HR=1.49 (0.79-2.79)                               
2: HR=1.00 (REF)                   
p=0.4240 
0 
n=351                    
d=64 
0: 2.76%                      
1: 4.93% 
0: 18.50%                      
1: 2.05% 
Subset--Restricted to participants with Education variable 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
Crude Mental Component Summary Score (MCS) 
0: HR=1.45 (0.78-2.72)                
1: HR=1.36 (0.73-2.55)                              
2: HR=1.00 (REF)                      
p=0.4751 
1 
n=350                    
d=63 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.76 (0.94-3.30)               
1: HR=1.39 (0.74-2.61)                              
2: HR=1.00 (REF)                    
p=0.2145 
1 
n=350                    
d=63 
0: 21.38%                      
1: 2.21% 
-- 
14 Model 1 + Education 
0: HR=1.72 (0.91-3.25)               
1: HR=1.54 (0.81-2.94)                              
2: HR=1.00 (REF)                    
p=0.2187 
1 
n=350                    
d=63 
0: 18.62%                      
1: 13.24% 
0: 2.27%                      
1: 10.79% 
Subset--Restricted to participants with the Tumor Size variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.48 (0.79-2.77)                
1: HR=1.43 (0.77-2.67)                             
2: HR=1.00 (REF)                      
p=0.4136 
10 
n=341                  
d=64 
-- -- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.71 (0.91-3.22)               
1: HR=1.45 (0.78-2.72)                               
2: HR=1.00 (REF)                   
p=0.2438 
10 
n=341                  
d=64 
0: 15.54%                      
1: 1.40% 
-- 
15 Model 1 + Tumor Size 
0: HR=1.71 (0.91-3.22)               
1: HR=1.46 (0.78-2.74)                               
2: HR=1.00 (REF)                   
p=0.2433 
10 
n=341                  
d=64 
0: 15.54%                      
1: 2.10% 
0: 0.00%                      
1: 0.69% 
Subset--Restricted to participants with Lymph Node Involvement variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.26 (0.66-2.41)                
1: HR=1.31 (0.70-2.47)                              
2: HR=1.00 (REF)                     
p=0.6737 
10 
n=341                  
d=59 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.55 (0.81-2.98)               
1: HR=1.53 (0.81-2.91)                               
2: HR=1.00 (REF)                   
p=0.3260 
10 
n=341                  
d=59 
0: 23.02%                      
1: 16.79% 
-- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
16 Model 1 + Lymph Node Involvement 
0: HR=1.53 (0.80-2.96)               
1: HR=1.52 (0.80-2.89)                               
2: HR=1.00 (REF)                   
p=0.3480 
10 
n=341                  
d=59 
0: 21.43%                      
1: 16.03% 
0: 1.29%                      
1: 0.65% 
Subset--Restricted to participants with Tamoxifen Use, Smoking Status, & Physical Activity variables (24-month follow-up) 
Crude Mental Component Summary Score (MCS) 
0: HR=1.52 (0.80-2.89)                
1: HR=1.33 (0.70-2.56)                              
2: HR=1.00 (REF)                     
p=0.4430 
21 
n=330                    
d=59 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.75 (0.91-3.37)               
1: HR=1.39 (0.72-2.68)                               
2: HR=1.00 (REF)                   
p=0.2429 
21 
n=330                    
d=59 
0: 15.13%                      
1: 4.51% 
-- 
17 Model 1 + Tamoxifen Use 
0: HR=1.89 (0.98-3.64)               
1: HR=1.32 (0.68-2.55)                               
2: HR=1.00 (REF)                   
p=0.1597 
21 
n=330                    
d=59 
0: 24.34%                      
1: 0.75% 
0: 8.00%                      
1: 5.04% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
18 Model 1 + Smoking Status 
0: HR=1.69 (0.87-3.26)               
1: HR=1.40 (0.72-2.69)                               
2: HR=1.00 (REF)                   
p=0.2992 
21 
n=330                    
d=59 
0: 11.18%                      
1: 5.26% 
0: 3.43%                      
1: 0.72% 
19 Model 1 + Physical Activity 
0: HR=1.75 (0.91-3.38)               
1: HR=1.48 (0.76-2.89)                               
2: HR=1.00 (REF)                   
p=0.2387 
21 
n=330                    
d=59 
0: 15.13%                      
1: 11.28% 
0: 0.00%                      
1: 6.47% 
Subset--Restricted to participants with BMI variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.31 (0.67-2.58)                
1: HR=1.29 (0.66-2.52)                              
2: HR=1.00 (REF)                     
p=0.6886 
27 
n=324                    
d=54 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.46 (0.74-2.90)               
1: HR=1.19 (0.60-2.35)                               
2: HR=1.00 (REF)                   
p=0.5524 
27 
n=324                    
d=54 




Model Variable(s) in model 
Mental Component Summary 
Score (MCS) (95% CI) 
Difference in 
'N' 
Total in model (n) 
and total dead (d) 
% change from 
Crude 
% change from 
model 1 
20 Model 1 + BMI 
0: HR=1.49 (0.74-2.97)               
1: HR=1.24 (0.63-2.45)                               
2: HR=1.00 (REF)                   
p=0.5325 
27 
n=324                    
d=54 
0: 13.74%                      
1: 3.88% 
0: 2.05%                      
1: 4.20% 
Subset--Restricted to participants with Tumor Subtype variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.16 (0.60-2.26)                
1: HR=1.27 (0.67-2.40)                              
2: HR=1.00 (REF)                     
p=0.7681 
51 
n=300                    
d=56 
-- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.36 (0.70-2.65)               
1: HR=1.34 (0.70-2.55)                               
2: HR=1.00 (REF)                   
p=0.5966 
51 
n=300                    
d=56 
0: 17.24%                      
1: 5.51% 
-- 
21 Model 1 + Tumor Subtype 
0: HR=1.47 (0.75-2.89)               
1: HR=1.37 (0.72-2.62)                               
2: HR=1.00 (REF)                   
p=0.4811 
51 
n=300                    
d=56 
0: 26.72%                      
1: 7.87% 
0: 8.09%                      
1: 2.24% 




 Appendix O. Multivariable Modeling with Mental Component Score as the Predictor and Non-Cancer Mortality as the 
Outcome (N = 351) 
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Crude Mental Component Summary Score (MCS) 
0: HR=1.45 (0.78-2.72)                
1: HR=1.42 (0.76-2.64)                              
2: HR=1.00 (REF)                     
p=0.4424 
0 
n=351                    
d=64 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.73 (0.92-3.25)               
1: HR=1.46 (0.78-2.72)                               
2: HR=1.00 (REF)                   
p=0.2327 
0 
n=351                    
d=64 
0: 19.31%                      
1: 2.82% 
-- -- 
2 Model 1 + Race/Ethnicity 
0: HR=1.73 (0.92-3.27)               
1: HR=1.45 (0.78-2.72)                               
2: HR=1.00 (REF)                   
p=0.2293 
0 
n=351                    
d=64 
0: 19.31%                      
1: 2.11% 
0: 0.00%                      
1: 0.68% 
-- 
3 Model 1 + Race/Ethnicity + Treatment Type 
0: HR=1.73 (0.92-3.26)               
1: HR=1.39 (0.74-2.63)                               
2: HR=1.00 (REF)                   
p=0.2377 
0 
n=351                    
d=64 
0: 19.31%                      
1: 2.11% 
0: 0.00%                      
1: 4.79% 
0: 0.00%                      
1: 4.14% 
4 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities 
0: HR=1.63 (0.84-3.14)               
1: HR=1.40 (0.74-2.64)                               
2: HR=1.00 (REF)                   
p=0.3328 
0 
n=351                    
d=64 
0: 12.41%                      
1: 1.41% 
0: 5.78%                      
1: 4.11% 
0: 5.78%                      
1: 0.72% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism 
0: HR=1.51 (0.77-2.96)               
1: HR=1.31 (0.69-2.49)                               
2: HR=1.00 (REF)                   
p=0.4828 
0 
n=351                    
d=64 
0: 4.14%                      
1: 7.75% 
0: 12.72%                      
1: 10.27% 
0: 7.36%                      
1: 6.43% 
6 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence 
0: HR=1.58 (0.80-3.10)               
1: HR=1.37 (0.72-2.61)                               
2: HR=1.00 (REF)                   
p=0.4022 
0 
n=351                    
d=64 
0: 8.97%                      
1: 3.52% 
0: 8.67%                      
1: 6.16% 
0: 4.64%                      
1: 4.58% 
7 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Number of Types of Confidants (Confide) 
0: HR=1.62 (0.82-3.20)               
1: HR=1.46 (0.76-2.80)                               
2: HR=1.00 (REF)                   
p=0.3513 
0 
n=351                    
d=64 
0: 11.72%                      
1: 2.82% 
0: 6.36%                      
1: 0.00% 
0: 2.53%                      
1: 6.57% 
8 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain 
0: HR=1.58 (0.79-3.14)               
1: HR=1.44 (0.75-2.78)                               
2: HR=1.00 (REF)                   
p=0.3822 
0 
n=351                    
d=64 
0: 8.97%                      
1: 1.41% 
0: 8.67%                      
1: 1.37% 
0: 2.47%                      
1: 1.37% 
9 
Model 1 + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain + Perceived General Health 
0: HR=1.40 (0.69-2.85)               
1: HR=1.47 (0.76-2.83)                               
2: HR=1.00 (REF)                   
p=0.4814 
0 
n=351                    
d=64 
0: 3.45%                      
1: 3.52% 
0: 19.08%                      
1: 0.68% 
0: 11.39%                      
1: 2.08% 
 Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Subset--Restricted to participants with Education variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.45 (0.78-2.72)                
1: HR=1.36 (0.73-2.55)                                
2: HR=1.00 (REF)                   
p=0.4751 
1 
n=350                  
d=63 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.72 (0.91-3.23)               
1: HR=1.41 (0.75-2.65)                                  
2: HR=1.00 (REF)                
p=0.2464 
1 
n=350                  
d=63 
0: 18.62%                      
1: 3.68% 
-- -- 
10 Model 1 + Education 
0: HR=1.72 (0.91-3.25)               
1: HR=1.54 (0.81-2.94)                               
2: HR=1.00 (REF)                   
p=0.2187 
1 
n=350                  
d=63 
0: 18.62%                      
1: 13.24% 
0: 0.00%                      
1: 9.22% 
-- 
11 Model 1 + Education + Race/Ethnicity 
0: HR=1.73 (0.92-3.26)               
1: HR=1.55 (0.81-2.97)                               
2: HR=1.00 (REF)                   
p=0.2119 
1 
n=350                  
d=63 
0: 19.31%                      
1: 13.97% 
0: 0.58%                      
1: 9.93% 
0: 0.58%                      
1: 0.65% 
12 Model 1 + Education + Race/Ethnicity + Treatment Type 
0: HR=1.72 (0.91-3.25)               
1: HR=1.48 (0.77-2.85)                               
2: HR=1.00 (REF)                   
p=0.2310 
1 
n=350                  
d=63 
0: 18.62%                      
1: 8.82% 
0: 0.00%                      
1: 4.96% 
0: 0.58%                      
1: 4.52% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities 
0: HR=1.64 (0.85-3.17)               
1: HR=1.47 (0.76-2.84)                               
2: HR=1.00 (REF)                   
p=0.3079 
1 
n=350                  
d=63 
0: 13.10%                      
1: 8.09% 
0: 4.56%                      
1: 4.26% 
0: 4.65%                      
1: 0.68% 
14 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism 
0: HR=1.54 (0.78-3.02)               
1: HR=1.39 (0.71-2.71)                               
2: HR=1.00 (REF)                   
p=0.4303 
1 
n=350                  
d=63 
0: 6.21%                      
1: 2.21% 
0: 10.47%                      
1: 1.42% 
0: 6.10%                      
1: 5.44% 
15 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence 
0: HR=1.63 (0.83-3.20)               
1: HR=1.49 (0.76-2.93)                               
2: HR=1.00 (REF)                   
p=0.3310 
1 
n=350                  
d=63 
0: 12.41%                      
1: 9.56% 
0: 5.23%                      
1: 5.67% 
0: 5.84%                      
1: 7.19% 
16 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide 
0: HR=1.66 (0.84-3.27)               
1: HR=1.57 (0.80-3.09)                               
2: HR=1.00 (REF)                   
p=0.2923 
1 
n=350                  
d=63 
0: 14.48%                      
1: 15.44% 
0: 3.49%                      
1: 11.35% 
0: 1.84%                      
1: 5.37% 
17 
Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain 
0: HR=1.62 (0.81-3.21)               
1: HR=1.56 (0.79-3.07)                               
2: HR=1.00 (REF)                   
p=0.3205 
1 
n=350                  
d=63 
0: 11.72%                      
1: 14.71% 
0: 5.81%                      
1: 10.64% 
0: 2.41%                      
1: 0.64% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide+ Bodily Pain + Perceived General Health 
0: HR=1.46 (0.72-2.96)               
1: HR=1.58 (0.80-3.13)                               
2: HR=1.00 (REF)                   
p=0.3839 
1 
n=350                  
d=63 
0: 0.69%                      
1: 16.18% 
0: 15.12%                      
1: 12.06% 
0: 9.88%                      
1: 1.28% 
Subset--Restricted to participants with Tumor Size variable 
Crude Mental Component Summary Score (MCS) 
0: HR=1.48 (0.79-2.77)                
1: HR=1.43 (0.77-2.67)                                
2: HR=1.00 (REF)                   
p=0.4136 
10 
n=341                  
d=64 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.71 (0.91-3.22)               
1: HR=1.45 (0.78-2.72)                                  
2: HR=1.00 (REF)                
p=0.2438 
10 
n=341                  
d=64 
0: 15.54%                      
1: 1.40% 
-- -- 
19 Model 1 + Tumor Size 
0: HR=1.71 (0.91-3.22)               
1: HR=1.46 (0.78-2.74)                               
2: HR=1.00 (REF)                   
p=0.2433 
10 
n=341                  
d=64 
0: 15.54%                      
1: 2.10% 
0: 0.00%                      
1: 0.69% 
-- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











20 Model 1 + Tumor Size + Race/Ethnicity 
0: HR=1.72 (0.91-3.24)               
1: HR=1.46 (0.78-2.74)                               
2: HR=1.00 (REF)                   
p=0.2394 
10 
n=341                  
d=64 
0: 16.22%                      
1: 2.10% 
0: 0.58%                      
1: 0.69% 
0: 0.58%                      
1: 0.00% 
21 Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
0: HR=1.72 (0.91-3.24)               
1: HR=1.40 (0.74-2.63)                               
2: HR=1.00 (REF)                   
p=0.2476 
10 
n=341                  
d=64 
0: 16.22%                      
1: 2.10% 
0: 0.58%                      
1: 3.45% 
0: 0.00%                      
1: 4.11% 
22 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities 
0: HR=1.62 (0.84-3.12)               
1: HR=1.40 (0.74-2.65)                               
2: HR=1.00 (REF)                   
p=0.3409 
10 
n=341                  
d=64 
0: 9.46%                      
1: 2.10% 
0: 5.26%                      
1: 3.45% 
0: 5.81%                      
1: 0.00% 
23 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism 
0: HR=1.50 (0.77-2.95)               
1: HR=1.31 (0.68-2.50)                               
2: HR=1.00 (REF)                   
p=0.4875 
10 
n=341                  
d=64 
0: 1.35%                      
1: 8.39% 
0: 12.28%                      
1: 9.66% 
0: 7.41%                      
1: 6.43% 
24 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence 
0: HR=1.58 (0.80-3.10)               
1: HR=1.38 (0.72-2.64)                               
2: HR=1.00 (REF)                   
p=0.3992 
10 
n=341                  
d=64 
0: 6.76%                      
1: 3.50% 
0: 7.60%                      
1: 4.83% 
0: 5.33%                      
1: 5.34% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide 
0: HR=1.62 (0.82-3.20)               
1: HR=1.48 (0.77-2.85)                               
2: HR=1.00 (REF)                   
p=0.3443 
10 
n=341                  
d=64 
0: 9.46%                      
1: 3.50% 
0: 5.26%                      
1: 2.07% 
0: 2.53%                      
1: 7.25% 
26 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain 
0: HR=1.58 (0.80-3.15)               
1: HR=1.47 (0.76-2.84)                               
2: HR=1.00 (REF)                   
p=0.3747 
10 
n=341                  
d=64 
0: 6.76%                      
1: 2.80% 
0: 7.60%                      
1: 1.38% 
0: 2.47%                      
1: 0.68% 
27 
Model 1 + Tumor Size + Race/Ethnicity + Treatment Type 
+ Comorbidities + Optimism + Fear of Recurrence + 
Confide+ Bodily Pain + Perceived General Health 
0: HR=1.40 (0.69-2.85)               
1: HR=1.49 (0.77-2.88)                               
2: HR=1.00 (REF)                   
p=0.4631 
10 
n=341                  
d=64 
0: 5.41%                      
1: 4.20% 
0: 18.13%                      
1: 2.76% 
0: 11.39%                      
1: 1.36% 
Subset--Restricted to participants with Education and Tumor Size variables  
Crude Mental Component Summary Score (MCS) 
0: HR=1.48 (0.79-2.77)                
1: HR=1.38 (0.74-2.78)                               
2: HR=1.00 (REF)                    
p=0.4439 
11 
n=340                   
d=63 
-- -- -- 
 Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=1.70 (0.90-3.20)               
1: HR=1.41 (0.75-2.65)                                
2: HR=1.00 (REF)                  
p=0.2587 
11 
n=340                   
d=63 
0: 14.86%                      
1: 2.17% 
-- -- 
28 Model 1 + Education + Tumor Size 
0: HR=1.70 (0.90-3.21)               
1: HR=1.52 (0.80-2.90)                                
2: HR=1.00 (REF)                  
p=0.2355 
11 
n=340                   
d=63 
0: 14.86%                      
1: 10.14% 
0: 0.00%                      
1: 7.80% 
-- 
29 Model 1 + Education + Tumor Size + Race/Ethnicity 
0: HR=1.71 (0.91-3.23)               
1: HR=1.54 (0.80-2.94)                                
2: HR=1.00 (REF)                  
p=0.2259 
11 
n=340                   
d=63 
0: 15.54%                      
1: 11.59% 
0: 0.59%                      
1: 9.22% 
0: 0.59%                      
1: 1.32% 
30 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type 
0: HR=1.71 (0.91-3.22)               
1: HR=1.46 (0.76-2.81)                                
2: HR=1.00 (REF)                  
p=0.2449 
11 
n=340                   
d=63 
0: 15.54%                      
1: 5.80% 
0: 0.59%                      
1: 3.55% 
0: 0.00%                      
1: 5.19% 
31 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities 
0: HR=1.63 (0.84-3.14)               
1: HR=1.44 (0.74-2.78)                                
2: HR=1.00 (REF)                  
p=0.3266 
11 
n=340                   
d=63 
0: 10.14%                      
1: 4.35% 
0: 4.12%                      
1: 2.13% 
0: 4.68%                      
1: 1.37% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities + Optimism 
0: HR=1.53 (0.78-3.01)               
1: HR=1.36 (0.70-2.66)                                
2: HR=1.00 (REF)                  
p=0.4431 
11 
n=340                   
d=63 
0: 3.38%                      
1: 1.45% 
0: 10.00%                      
1: 3.55% 
0: 6.13%                      
1: 5.56% 
33 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities + Optimism + Fear of 
Recurrence 
0: HR=1.63 (0.83-3.19)               
1: HR=1.47 (0.75-2.91)                                
2: HR=1.00 (REF)                  
p=0.3372 
11 
n=340                   
d=63 
0: 10.14%                      
1: 6.52% 
0: 4.12%                      
1: 4.26% 
0: 6.54%                      
1: 8.09% 
34 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities + Optimism + Fear of 
Recurrence + Confide 
0: HR=1.66 (0.84-3.27)               
1: HR=1.56 (0.79-3.08)                                
2: HR=1.00 (REF)                  
p=0.2949 
11 
n=340                   
d=63 
0: 12.16%                      
1: 13.04% 
0: 2.35%                      
1: 10.64% 
0: 1.84%                      
1: 6.12% 
35 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities + Optimism + Fear of 
Recurrence + Confide + Bodily Pain 
0: HR=1.63 (0.82-3.24)               
1: HR=1.56 (0.79-3.09)                                
2: HR=1.00 (REF)                  
p=0.3136 
11 
n=340                   
d=63 
0: 10.14%                      
1: 13.04% 
0: 4.12%                      
1: 10.64% 
0: 1.81%                      
1: 0.00% 
36 
Model 1 + Education + Tumor Size + Race/Ethnicity + 
Treatment Type + Comorbidities + Optimism + Fear of 
Recurrence + Confide + Bodily Pain + Perceived General 
Health 
0: HR=1.47 (0.73-2.98)               
1: HR=1.57 (0.79-3.12)                                
2: HR=1.00 (REF)                  
p=0.3889 
11 
n=340                   
d=63 
0: 0.68%                      
1: 13.77% 
0: 13.53%                      
1: 11.35% 
0: 9.82%                      
1: 0.64% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Subset--Restricted to participants with Physical Activity variable (24-month follow-up) 
Crude Mental Component Summary Score (MCS) 
0: HR=1.52 (0.80-2.89)                
1: HR=1.33 (0.70-2.56)                              
2: HR=1.00 (REF)                     
p=0.4430 
21 
n=330                 
d=59 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.75 (0.91-3/37)               
1: HR=1.39 (0.72-2.68)                                
2: HR=1.00 (REF)                  
p=0.2429 
21 
n=330                 
d=59 
0: 15.13%                      
1: 4.51% 
-- -- 
37 Model 1 + Physical Activity 
0: HR=1.75 (0.91-3.38)               
1: HR=1.48 (0.76-2.89)                                
2: HR=1.00 (REF)                  
p=0.2387 
21 
n=330                 
d=59 
0: 15.13%                      
1: 11.28% 
0: 0.00%                      
1: 6.47% 
-- 
38 Model 1 + Physical Activity + Race/Ethnicity 
0: HR=1.75 (0.91-3.39)               
1: HR=1.48 (0.76-2.88)                                
2: HR=1.00 (REF)                  
p=0.2369 
21 
n=330                 
d=59 
0: 15.13%                      
1: 11.28% 
0: 0.00%                      
1: 6.47% 
0: 0.00%                      
1: 0.00% 
39 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type 
0: HR=1.76 (0.91-3.39)               
1: HR=1.40 (0.71-2.76)                                
2: HR=1.00 (REF)                  
p=0.2434 
21 
n=330                 
d=59 
0: 15.79%                      
1: 5.26% 
0: 0.57%                      
1: 0.72% 
0: 0.57%                      
1: 5.41% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities 
0: HR=1.64 (0.83-3.22)               
1: HR=1.41 (0.72-2.78)                                
2: HR=1.00 (REF)                  
p=0.3495 
21 
n=330                 
d=59 
0: 7.89%                      
1: 6.02% 
0: 6.29%                      
1: 1.44% 
0: 6.82%                      
1: 0.72% 
41 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Optimism 
0: HR=1.49 (0.75-2.98)               
1: HR=1.34 (0.68-2.66)                                
2: HR=1.00 (REF)                  
p=0.5063 
21 
n=330                 
d=59 
0: 1.97%                      
1: 0.75% 
0: 14.86%                      
1: 3.60% 
0: 9.15%                      
1: 4.96% 
42 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Optimism + Fear of Recurrence 
0: HR=1.57 (0.78-3.13)               
1: HR=1.39 (0.70-2.76)                                
2: HR=1.00 (REF)                  
p=0.4278 
21 
n=330                 
d=59 
0: 3.29%                      
1: 4.51% 
0: 10.29%                      
1: 0.00% 
0: 5.37%                      
1: 3.73% 
43 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Optimism + Fear of Recurrence + 
Confide 
0: HR=1.64 (0.80-3.33)               
1: HR=1.44 (0.72-2.88)                                
2: HR=1.00 (REF)                  
p=0.3760 
21 
n=330                 
d=59 
0: 7.89%                      
1: 8.27% 
0: 6.29%                      
1: 3.60% 
0: 4.46%                      
1: 3.60% 
44 
Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain 
0: HR=1.57 (0.76-3.24)               
1: HR=1.42 (0.71-2.85)                                
2: HR=1.00 (REF)                  
p=0.4457 
21 
n=330                 
d=59 
0: 3.29%                      
1: 6.77% 
0: 10.29%                      
1: 2.16% 
0: 4.27%                      
1: 1.39% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Physical Activity + Race/Ethnicity + Treatment 
Type + Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain + Perceived General Health 
0: HR=1.36 (0.64-2.92)               
1: HR=1.40 (0.70-2.80)                                
2: HR=1.00 (REF)                  
p=0.6065 
21 
n=330                 
d=59 
0: 10.53%                      
1: 5.26% 
0: 22.29%                      
1: 0.72% 
0: 13.38%                      
1: 1.41% 
Subset--Restricted to participants with Education, Tumor Size, and Physical Activity variables  
Crude Mental Component Summary Score (MCS) 
0: HR=1.55 (0.81-2.95)                
1: HR=1.29 (0.67-2.48)                               
2: HR=1.00 (REF)                    
p=0.4139 
32 
n=319                   
d=58 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.72 (0.90-3.31)               
1: HR=1.34 (0.69-2.59)                                
2: HR=1.00 (REF)                  
p=0.2645 
32 
n=319                   
d=58 
0: 10.97%                      
1: 3.88% 
-- -- 
46 Model 1 + Education + Tumor Size + Physical Activity 
0: HR=1.69 (0.87-3.27)               
1: HR=1.47 (0.74-2.91)                                
2: HR=1.00 (REF)                  
p=0.2818 
32 
n=319                   
d=58 
0: 9.03%                      
1: 13.95% 
0: 1.74%                      
1: 9.70% 
-- 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity 
0: HR=1.69 (0.88-3.28)               
1: HR=1.47 (0.74-2.91)                                
2: HR=1.00 (REF)                  
p=0.2787 
32 
n=319                   
d=58 
0: 9.03%                      
1: 13.95% 
0: 1.74%                      
1: 9.70% 
0: 0.00%                      
1: 0.00% 
48 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type 
0: HR=1.68 (0.87-3.24)               
1: HR=1.37 (0.68-2.76)                                
2: HR=1.00 (REF)                  
p=0.3048 
32 
n=319                   
d=58 
0: 8.39%                      
1: 6.20% 
0: 2.33%                      
1: 2.24% 
0: 0.59%                      
1: 6.80% 
49 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities 
0: HR=1.59 (0.81-3.15)               
1: HR=1.36 (0.67-2.73)                                
2: HR=1.00 (REF)                  
p=0.3975 
32 
n=319                   
d=58 
0: 2.58%                      
1: 5.43% 
0: 7.56%                      
1: 1.49% 
0: 5.36%                      
1: 0.73% 
50 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Optimism 
0: HR=1.49 (0.74-2.98)               
1: HR=1.29 (0.64-2.61)                                
2: HR=1.00 (REF)                  
p=0.5232 
32 
n=319                   
d=58 
0: 3.87%                      
1: 0.00% 
0: 13.37%                      
1: 3.73% 
0: 6.29%                      
1: 5.15% 
51 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Optimism + Fear of Recurrence 
0: HR=1.59 (0.79-3.19)               
1: HR=1.37 (0.67-2.77)                                
2: HR=1.00 (REF)                  
p=0.4176 
32 
n=319                   
d=58 
0: 2.58%                      
1: 6.20% 
0: 7.56%                      
1: 2.24% 
0: 6.71%                      
1: 6.20% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Optimism + Fear of Recurrence + Confide 
0: HR=1.64 (0.81-3.36)               
1: HR=1.41 (0.69-2.88)                                
2: HR=1.00 (REF)                  
p=0.3824 
32 
n=319                   
d=58 
0: 5.81%                      
1: 9.30% 
0: 4.65%                      
1: 5.22% 
0: 3.14%                      
1: 2.92% 
53 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Optimism + Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.61 (0.77-3.35)               
1: HR=1.40 (0.68-2.87)                                
2: HR=1.00 (REF)                  
p=0.4303 
32 
n=319                   
d=58 
0: 3.87%                      
1: 8.53% 
0: 6.40%                      
1: 4.48% 
0: 1.83%                      
1: 0.71% 
54 
Model 1 + Education + Tumor Size + Physical Activity + 
Race/Ethnicity + Treatment Type + Comorbidities + 
Optimism + Fear of Recurrence + Confide + Bodily Pain + 
Perceived General Health 
0: HR=1.44 (0.67-3.09)               
1: HR=1.73 (0.67-2.83)                                
2: HR=1.00 (REF)                  
p=0.5886 
32 
n=319                   
d=58 
0: 7.10%                      
1: 34.11% 
0: 16.28%                      
1: 29.10% 
0: 10.56%                      
1: 23.57% 
Subset--Restricted to participants with BMI variable  
Crude Mental Component Summary Score (MCS) 
0: HR=1.31 (0.67-2.58)                
1: HR=1.29 (0.66-2.52)                               
2: HR=1.00 (REF)                    
p=0.6886 
27 
n=324                    
d=54 
-- -- -- 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











1 Age, Marital Status, & Tumor Stage 
0: HR=1.46 (0.74-2.90)               
1: HR=1.19 (0.60-2.35)                                
2: HR=1.00 (REF)                  
p=0.5524 
27 
n=324                    
d=54 
0: 11.45%                      
1: 7.75% 
-- -- 
55 Model 1 + BMI 
0: HR=1.49 (0.74-2.97)               
1: HR=1.24 (0.63-2.45)                                
2: HR=1.00 (REF)                  
p=0.5325 
27 
n=324                    
d=54 
0: 13.74%                      
1: 3.88% 
0: 2.05%                      
1: 4.20% 
-- 
56 Model 1 + BMI + Race/Ethnicity 
0: HR=1.48 (0.74-2.97)               
1: HR=1.24 (0.62-2.45)                                
2: HR=1.00 (REF)                  
p=0.5416 
27 
n=324                    
d=54 
0: 12.98%                      
1: 3.88% 
0: 1.37%                      
1: 4.20% 
0: 0.67%                      
1: 0.00% 
57 Model 1 + BMI + Race/Ethnicity + Treatment Type 
0: HR=1.45 (0.72-2.91)               
1: HR=1.14 (0.57-2.29)                                
2: HR=1.00 (REF)                  
p=0.5686 
27 
n=324                    
d=54 
0: 10.69%                      
1: 11.63% 
0: 0.68%                      
1: 0.00% 
0: 2.03%                      
1: 8.06% 
58 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities 
0: HR=1.43 (0.70-2.92)               
1: HR=1.14 (0.57-2.28)                                
2: HR=1.00 (REF)                  
p=0.6182 
27 
n=324                    
d=54 
0: 9.16%                      
1: 11.63% 
0: 2.05%                      
1: 4.20% 
0: 1.38%                      
1: 0.00% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism 
0: HR=1.30 (0.63-2.71)               
1: HR=1.03 (0.51-2.09)                                
2: HR=1.00 (REF)                  
p=0.7401 
27 
n=324                    
d=54 
0: 0.76%                      
1: 20.16% 
0: 10.96%                      
1: 13.45% 
0: 9.09%                      
1: 9.65% 
60 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence 
0: HR=1.38 (0.66-2.87)               
1: HR=1.13 (0.56-2.28)                                
2: HR=1.00 (REF)                  
p=0.6824 
27 
n=324                    
d=54 
0: 5.34%                      
1: 12.40% 
0: 5.48%                      
1: 5.04% 
0: 6.15%                      
1: 9.71% 
61 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Confide 
0: HR=1.39 (0.67-2.89)               
1: HR=1.14 (0.57-2.31)                                
2: HR=1.00 (REF)                  
p=0.6816 
27 
n=324                    
d=54 
0: 6.11%                      
1: 11.63% 
0: 4.79%                      
1: 6.72% 
0: 0.72%                      
1: 0.88% 
62 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain 
0: HR=1.35 (0.64-2.83)               
1: HR=1.12 (0.55-2.28)                                
2: HR=1.00 (REF)                  
p=0.7242 
27 
n=324                    
d=54 
0: 3.05%                      
1: 13.18% 
0: 7.53%                      
1: 5.88% 
0: 2.88%                      
1: 1.75\% 
63 
Model 1 + BMI + Race/Ethnicity + Treatment Type + 
Comorbidities + Optimism + Fear of Recurrence + 
Confide + Bodily Pain + Perceived General Health 
0: HR=1.17 (0.54-2.51)               
1: HR=1.10 (0.54-2.23)                                
2: HR=1.00 (REF)                  
p=0.9232 
27 
n=324                    
d=54 
0: 10.69%                      
1: 14.73% 
0: 19.86%                      
1: 7.56% 
0: 13.33%                      
1: 1.79% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 











Subset--Restricted to participants with Education, Tumor Size, Physical Activity, and BMI variables  
Crude Mental Component Summary Score (MCS) 
0: HR=1.41 (0.70-2.84)                
1: HR=1.20 (0.59-2.43)                               
2: HR=1.00 (REF)                    
p=0.6282 
56 
n=246                      
d=49 
-- -- -- 
1 Age, Marital Status, & Tumor Stage 
0: HR=1.59 (0.78-3.23)               
1: HR=1.20 (0.59-2.44)                                
2: HR=1.00 (REF)                  
p=0.4238 
56 
n=246                      
d=49 




Model 1 + Education + Tumor Size + Physical Activity + 
BMI 
0: HR=1.54 (0.75-3.17)               
1: HR=1.28 (0.61-2.68)                                
2: HR=1.00 (REF)                  
p=0.5037 
56 
n=246                      
d=49 
0: 9.22%                      
1: 6.67% 




Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity 
0: HR=1.54 (0.75-3.19)               
1: HR=1.28 (0.61-2.69)                                
2: HR=1.00 (REF)                  
p=0.5055 
56 
n=246                      
d=49 
0: 9.22%                      
1: 6.67% 
0: 3.14%                      
1: 6.67% 
0: 0.00%                      
1: 0.00% 
66 
Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type 
0: HR=1.52 (0.74-3.15)               
1: HR=1.15 (0.54-2.44)                                
2: HR=1.00 (REF)                  
p=0.5136 
56 
n=246                      
d=49 
0: 7.80%                      
1: 4.17% 
0: 4.40%                      
1: 4.17% 
0: 1.30%                      
1: 10.16% 
   
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
0: HR=1.46 (0.69-3.07)               
1: HR=1.17 (0.55-2.49)                                
2: HR=1.00 (REF)                  
p=0.6101 
56 
n=246                      
d=49 
0: 3.55%                      
1: 2.50% 
0: 8.18%                      
1: 2.50% 
0: 3.95%                      
1: 1.74% 
68 
Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
+ Optimism 
0: HR=1.30 (0.61-2.80)               
1: HR=1.09 (0.51-2.32)                                
2: HR=1.00 (REF)                  
p=0.7921 
56 
n=246                      
d=49 
0: 7.80%                      
1: 9.17% 
0: 18.24%                      
1: 9.17% 
0: 10.96%                      
1: 6.84% 
69 
Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
+ Optimism + Fear of Recurrence 
0: HR=1.39 (0.64-3.01)               
1: HR=1.17 (0.54-2.50)                                
2: HR=1.00 (REF)                  
p=0.7031 
56 
n=246                      
d=49 
0: 1.42%                      
1: 2.50% 
0: 12.58%                      
1: 2.50% 
0: 6.92%                      
1: 7.34% 
70 
Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
+ Optimism + Fear of Recurrence + Confide 
0: HR=1.41 (0.65-3.06)               
1: HR=1.17 (0.55-2.51)                                
2: HR=1.00 (REF)                  
p=0.6880 
56 
n=246                      
d=49 
0: 0.00%                      
1: 2.50% 
0: 11.32%                      
1: 2.50% 
0: 1.44%                      
1: 0.00% 
71 
Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
+ Optimism + Fear of Recurrence + Confide + Bodily Pain 
0: HR=1.36 (0.61-2.99)               
1: HR=1.17 (0.54-2.52)                                
2: HR=1.00 (REF)                  
p=0.7533 
56 
n=246                      
d=49 
0: 3.55%                      
1: 2.50% 
0: 14.47%                      
1: 2.50% 
0: 3.55%                      
1: 0.00% 
  
Model Variable(s) in model 
Mental Component Summary 
Score (MCS) HR (95% CI) 
Difference in 
'N' 
Total in model 












Model 1 + Education + Tumor Size + Physical Activity + 
BMI + Race/Ethnicity + Treatment Type + Comorbidities 
+ Optimism + Fear of Recurrence + Confide + Bodily Pain 
+ Perceived General Health 
0: HR=1.17 (0.52-2.67)               
1: HR=1.10 (0.51-2.38)                                
2: HR=1.00 (REF)                  
p=0.9274 
56 
n=246                      
d=49 
0: 17.02%                      
1: 8.33% 
0: 26.42%                      
1: 8.33% 






























































Appendix T: Kaplan-Meier Curves (Non-Cancer) Survival Probability Estimates 













Appendix U: Kaplan-Meier Curves: (Non-Cancer) Survival Probability Estimates 



























Appendix W: Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for 













Appendix X: Kaplan-Meier Curves: (All-Cause) Survival Probability Estimates for 












Appendix Y: Kaplan-Meier Curves: (Non-Cancer) Survival Probability Estimates 













Appendix Z: Kaplan-Meier Curves: (Non-Cancer) Survival Probability Estimates 
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